

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2	(3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-	(3s)-3-{4-[7-(Aminocarbonyl)-2	4/30/2010	Treatment of ovarian cancer	TESARO, Inc.
3	ascorbic acid	n/a	5/11/2009	Treatment of Charcot-Marie-Tooth disease type 1A.	Murigenetics SAS
4	budesonide	n/a	12/20/2006	Treatment of patients with eosinophilic esophagitis.	Meritage Pharma, Inc.
5	(-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester	n/a	10/12/2011	Treatment of Fragile X syndrome	Novartis Pharmaceuticals Corp.
6	(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-broethyl) diamidophosphate	n/a	6/5/2013	Treatment of pancreatic cancer	EMD Serono
7	(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate	n/a	3/9/2012	Treatment of soft tissue sarcoma	Threshold Pharmaceuticals, Inc.
8	(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-	n/a	2/17/2009	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	GlycoMimetics, Inc.
9	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	8/13/2004	Treatment of acute lymphoblastic leukemia	Mundipharma Research Limited

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
10	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribose hydrochloride	n/a	8/10/2004	Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia	Mundipharma Research Ltd.
11	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribose hydrochloride	n/a	1/29/2004	Treatment of T-cell non-Hodgkin's lymphoma	Mundipharma Research Limited
12	(1S,3S)-3-amino-4-(difluoromethylene)cyclopentanecarboxylic acid hydrochloride, (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride	n/a	9/15/2010	Treatment of infantile spasms.	Catalyst Pharmaceutical Partners
13	(2E, 4E, 6Z, 8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl) nona-2,4,6,8-tetraen-1-yl acetate	n/a	12/2/2010	Treatment of retinitis pigmentosa	QLT Inc.
14	(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenyl acetate 9-cis-retinyl acetate (API)	n/a	12/2/2010	Treatment of Leber congenital amaurosis (LCA) due to inherited mutations in RPE65 (encoding the protein retinal pigment epithelial protein 65) or LRAT (encoding the enzyme lecithin:retinol acyltransferase)genes.	QLT, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
15	(2S)-2-[[[(2R)-2-[[[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid	n/a	10/31/2012	Treatment of primary biliary cirrhosis	Albireo AB
16	(2S)-2-[[[(2R)-2-[[[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid	n/a	10/31/2012	Treatment of progressive familial intrahepatic cholestatis	Albireo AB
17	(2Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-hepten-6-ynamide	Fk778	1/10/2005	Prevention of acute rejection following kidney, heart, and liver transplantation	Fujisawa Healthcare, Inc.
18	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide	n/a	3/18/2011	Treatment of chronic myelogenous leukemia.	NATCO Pharma Limited
19	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide	n/a	3/18/2011	Treatment of pancreatic cancer	NATCO Pharma Limited

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
20	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide NRC-AN-019	n/a	3/18/2011	Treatment of Glioma	NATCO Pharma Limited
21	(3S)-3-(4-trifluoromethoxybenzyloxy)-6-nitro-2H-3,4-dihydroimidazo[2,1-b]oxazine	n/a	7/5/2007	Treatment of tuberculosis.	Global Alliance for TB Drug Development
22	(3S)-3-[(2S)-2-({N-[2-tert-butyl]phenyl}carbonyl)carboxylamino) propanoylamino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy) pentanoic acid	n/a	8/19/2003	Treatment of patients undergoing solid organ transplantation.	Pfizer Global Research and Development
23	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of progressive familial intrahepatic cholestasis	Lumena Pharmaceuticals. Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
24	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of primary biliary cirrhosis	Lumena Pharmaceuticals, Inc.
25	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of alagille syndrome	Lumena Pharmaceuticals, Inc.
26	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of primary sclerosing cholangitis	Lumena Pharmaceuticals' Inc.
27	(5R)-5-(4-{[2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, hydrochloride	n/a	7/24/2013	Treatment of trigeminal neuralgia	Convergence Pharmaceuticals Ltd.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
28	(6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl] amino-L-glyceroB-L-manno-heptopyranosyl]amino-9H-purine)	n/a	2/21/2014	Parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy that is refractory to conventional analgesics	DARA BioSciences, Inc.
29	(6-maleimidocaproyl)hydrazone of doxorubicin	n/a	6/29/2011	Treatment of soft tissue sarcoma	CytRx Corporation
30	(6R,S)5,10-methylene-tetrahydrofolic acid	Cofactor	8/13/2004	For use in combination with 5-fluorouracil for the treatment of patients with pancreatic cancer	Adventrx Pharmaceuticals, Inc.
31	(9-[N-(3-morpholinopropyl)-sulfonyl]-5,6-dihydro-5-oxo-11-H-indeno [1,2-c] isoquinoline methanesulfonic acid	n/a	12/8/2004	Prevention of post-operative complications of aortic aneurysm surgical repair	Inotek Pharmaceuticals Corporation
32	(E)-4-carboxystyryl-4-chlorobenzyl-sulfone, sodium salt	Ex-Rad(R)	9/4/2012	Treatment of acute radiation syndrome	Onconova Therapeutics, Inc.
33	(E)-4-carboxystyryl-4-chlorobenzyl-sulfone, sodium salt	Ex-Rad(R)	6/1/2012	Prevention of acute radiation toxicity, also known as Acute Radiation Syndrome (ARS)	Onconova Therapeutics, Inc.
34	(N-[2,6-bis(1-methylethyl)-pheyl-N'-[[1-4-dimethyl-amino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt	n/a	3/9/2012	Treatment of adrenocortical carcinoma	Atterocor, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
35	(R)-1-phenylethyl-5-(4-biphenyl-4-cyclopropanecarboxylic acid)-3-methylisoxazole-4-yl carbamate sodium salt	n/a	4/15/2011	Treatment of idiopathic pulmonary fibrosis	Bristol-Myers Squibb Company
36	(R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxy)methyl}-2,3-dihydroimidazo[2,1-b]oxazole	n/a	7/12/2007	Treatment of pulmonary tuberculosis.	Otsuka Pharmaceutical Company, Ltd
37	(R)-4-(3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride	n/a	12/19/2007	Treatment of small cell lung cancer.	AbbVie, Inc
38	(R)-N-[2-(6-Chloro-methoxy-1H-indol-3yl)propyl]acetamide	n/a	7/3/2003	Treatment of neuroleptic-induced tardive dyskinesia in schizophrenia patients	Phase 2 Discovery, Inc.
39	(R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide	n/a	10/3/2001	Treatment of circadian rhythm sleep disorders in blind people with no light perception	Phase 2 Discovery, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
40	(S)-10-[[dimethylamino)methyl]-4-ethyl-9hydroxy-4-O-[a-(2",4",5",7"-tetranitro-9"-fluorenylideneaminooxy)propionyl]-1H-pyrano[3',4',6',7',]indolizino [1,2-B]-quinoline-3,14-(4H, 12H)-dione, hydrochloride	Lipotecan	10/6/2010	Treatment of hepatocellular carcinoma	TLC Biopharmaceuticals, Inc.
41	(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one	n/a	4/15/2013	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Infinity Pharmaceuticals
42	(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one	n/a	8/1/2013	Treatment of follicular lymphoma	Infinity Pharmaceuticals, Inc.
43	(S)-4,5-dihydro-2[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiaxolecarboxylic acid	n/a	2/4/2009	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Ferrokin BioSciences, Inc.
44	(S)-4-(5-chloro-2-(isopropylamino)pyridin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-2-carboxamide hydrochloride	n/a	6/24/2013	Treatment of Stage IIb through Stage IV BRAF mutant melanoma	BioMed Valley Discoveries, Inc.
45	(UDU-stereoisomer of c-UJUun UNU-terminal UkUnhibitor)	n/a	3/28/2006	Treatment of acute sensorineural hearing loss	Auris Medical, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
46	(Z)-9-([2,2-bis-(hydroxymethyl)cyclopropylidene)methyl]guanine, cyclopropavir, ZSM-1-62 and NSC D745998	n/a	11/29/2010	Treatment of active cytomegalovirus infections.	Microbiotix, Inc.
47	1'-([5-(trifluoromethyl)-2-furyl]methyl)spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one	n/a	11/19/2012	Treatment of erythromelalgia	Teva Pharmaceuticals
48	1,2:5,6-Dianhydrogalactitol, NSC-132313	n/a	1/31/2012	Treatment of malignant gliomas	Del Mar Pharmaceuticals (BC),
49	1,5-(Butylimino)-1,5 dideoxy,D-glucitol	n/a	5/12/1998	Treatment of Fabry's disease.	Oxford GlycoSciences
50	1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine	Sapacitabine	6/24/2010	Treatment of myelodysplastic syndrome	Cyclacel Limited
51	1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine	Sapacitabine	6/24/2010	Treatment of acute myelogenous leukemia	Cyclacel Limited
52	1-(3-chloro-5-([4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbonyl)-2-pyridyl) piperidine-4-carboxylic acid Monomaleate	n/a	9/1/2011	Treatment of idiopathic thrombocytopenic purpura	Eisai, Inc.
53	1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one	n/a	9/26/2013	Management of postherpetic neuralgia	Zalicus Pharmaceuticals Ltd.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
54	1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridine-3-yl}phenyl)-3-(3-fluorophenyl)urea)	n/a	7/28/2011	Treatment of acute myelogenous leukemia	AbbVie, Inc.
55	1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]-urea	n/a	11/12/2009	Treatment of acute myeloid leukemia	Astex Therapeutics Ltd
56	1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy)methyl]benzene	n/a	1/9/2012	Treatment of poliovirus infection.	ViroDefense, Inc.
57	10 synthetic peptides targeting 5 tumor associated antigens	n/a	1/23/2013	Treatment of non-small cell lung cancer in patients expressing HLA-A2	Orphan Synergy Europe Pharma (OSE Pharma)
58	111Indium pentetreotide	Somatother	6/10/1999	Treatment of somatostatin receptor positive neuroendocrine tumors.	Louisiana State University Medical Center Foundation
59	12-A-p21 RAS(5-21). 12-C-p21 RAS(5-21). 12-D-p21 RAS(5-21). 12-Rp21 RAS(5-21). 12-S-p21 RAS(5-21). 12-V-p21 RAS(5-21). 13-D-p21 RAS(5-21)	n/a	6/7/2011	Treatment of pancreatic cancer	Targovax AS
60	14-amino acid peptide derived from wound growth factor	n/a	8/16/2010	Treatment of delayed graft function in renal transplant recipients	NephRx Corporation
61	14-amino acid peptide derived from wound growth factor	n/a	8/5/2010	Prevention of delayed graft function in renal transplant recipients	NephRx Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
62	16,16 dimethyl prostaglandin E2 (dmPGE2)	n/a	12/2/2010	Enhancement of stem cell engraftment through ex vivo treatment of human allogeneic hematopoietic stem cells (treatment of neutropenia, thrombocytopenia, lymphopenia, and anemia).	Fate Therapeutics, Inc.
63	17 amino acid peptide	n/a	1/29/2010	Prevention of ischemia reperfusion injury in the lung during lung transplantation	Apeptico
64	17-allylamino-17-demethoxygeldanamycin (17-AGG)	n/a	9/3/2004	Treatment of chronic myelogenous leukemia	Bristol-Myers Squibb Company
65	2 dimethylbutyrate	n/a	6/18/2008	Treatment of beta thalassemia	HemaQuest Pharmaceuticals, Inc.
66	2'-O-methyl phosphorothioate 5'-GCUAGGUUUACGGGACCUCU-3'	n/a	10/31/2012	Treatment of amyotrophic lateral sclerosis	LifeSplice Pharma LLC
67	2'-deoxycytidine	n/a	9/9/1996	As a host-protective agent in the treatment of acute myelogenous leukemia.	Grant, Steven M.D.
68	2,2'-(2-[1R]-1-((2,5-dichlorobenzoyl)amino)acetyl)amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl)diacetic acid (ixazomib citrate)	n/a	3/9/2012	Treatment of systemic light chain (AL) amyloidosis.	Millennium Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
69	2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione	n/a	9/21/2010	Treatment of idiopathic pulmonary fibrosis.	GenKyoTex S.A.
70	2-(2-phenylvinyl)-4-[-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	1/29/2010	Treatment of acute myeloid leukemia.	EntreMed, Inc.
71	2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	12/22/2008	Treatment of multiple myeloma.	EntreMed, Inc.
72	2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	3/18/2009	Treatment of ovarian carcinoma	EntreMed, Inc.
73	2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5]decane dimaleate	Atiprimod	9/18/2006	Treatment of carcinoid tumors	Callisto Pharmaceuticals, Inc.
74	2-(3-diethylaminopropyl)-8,8-dipropyl-2-azaspiro [4,5] decan dimaleate	Atiprimod	12/2/2003	Treatment of mulitple myeloma and associated bone resorption	Callisto Pharmaceuticals, Inc.
75	2-O-Butyryl-1-O-octyl-myo-inositol 3,4,5,6-tetrakisphosphate	n/a	8/15/2003	Treatment of cystic fibrosis	Inologic, Inc.
76	2-O-desulfated heparin	Aeropin	9/17/1993	Treatment of cystic fibrosis.	Kennedy & Hoidal,

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
77	2-Chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridinium sulfate	n/a	3/9/2012	Treatment of Fragile X Syndrome	Hoffmann-La Roche, Inc.
78	2-Chloro-N6--(3-iodobenzyl)adenosine-5'-N-methyluronamide	n/a	2/17/2012	Treatment of hepatocellular carcinoma	Can-Fite BioPharma Ltd.
79	2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol	Epidiolex(R)	11/14/2013	Treatment of Dravet syndrome.	GW Pharma Ltd.
80	2-[(3-methyl-4-(2,2,2-trifluoroethoxy) pyridin-2-yl)methylsulfanyl]-1H-benzimidazole	Prevonco (Tm)	8/27/2008	Treatment of hepatocellular carcinoma.	BioQuant, Inc.
81	2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide	n/a	12/18/2007	Treatment of malignant melanoma stages IIb through IV.	AbbVie, Inc.
82	2-[(R)-2methylpyrrolidin-2-yl]-1h-benzimidazole-4-carbozamide	n/a	9/3/2009	Treatment of epithelial ovarian cancer in combination with DNA-damaging agents	AbbVie, Inc.
83	2-[4-Methoxy-3-(2-m-tolylethoxy)-benzoylamino]-indian-2-carboxylic acid	n/a	5/14/2013	Treatment of patients with systemic sclerosis	Sanofi U. S., Inc.
84	2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}propyl)(ethyl)amino]ethyl dihydrogen phosphate trihydrate	n/a	1/19/2010	Treatment of acute myeloid leukemia	AstraZeneca Pharmaceuticals LP

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
85	2-chloroethyl-3-sarcosinamide-1-nitrosourea	Sarmustine	11/15/2001	Treatment for malignant glioma	Pangene Corporation
86	2-chloroethyl-3-sarcosinamide-1-nitrosourea	n/a	8/3/2001	Treatment for malignant gliomas	Lawrence Panasci, MD
87	2-hydroxypropyl-B-cyclodextrin	Kleptose	2/18/2013	Treatment of Niemann-Pick disease type C	National Institutes of Health
88	2-iminobiotin	n/a	2/24/2009	Treatment of perinatal asphyxia.	Neurophyxia B.V.
89	2-methoxyestradiol	Pulmolar	4/11/2005	Treatment of pulmonary arterial hypertension	PR Pharmaceuticals, Inc.
90	2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl) acetamide	n/a	4/30/2010	Treatment of pulmonary arterial hypertension	Actelion Ltd
91	20-mer complementary to Akt mRNA	n/a	12/10/2004	Treatment of stomach cancer	Rexahn Corporation
92	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/8/2004	Treatment of glioblastoma	Rexahn Corporation
93	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/1/2004	Treatment of renal cell carcinoma	Rexahn Corporation
94	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/1/2004	Treatment of ovarian cancer	Rexahn Corporation
95	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/8/2004	Treatment of pancreatic cancer	Rexahn Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
96	24,25 dihydroxycholecalciferol	n/a	2/27/1987	Treatment of uremic osteodystrophy.	Lemmon Company
97	2S,4R ketoconazole	n/a	3/9/2012	Treatment of endogenous Cushing's syndrome	Cortendo AB (HQ address)
98	3,4 diaminopyridine and choline bitartrate	n/a	4/30/2010	Treatment of Lambert-Eaton myasthenic syndrome	MS Therapeutics Limited
99	3,4-Diaminopyridine phosphate	n/a	11/12/2009	Treatment of Lambert-Eaton Myasthenic Syndrome	Catalyst Pharmaceutical
100	3,4-diaminopyridine	n/a	12/18/1990	Treatment of Lambert-Eaton myasthenic syndrome.	Jacobus Pharmaceutical
101	3,5,3'-triiodothyroacetate	n/a	9/20/2000	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid gland.	Elliot Danforth, Jr., M.D.
102	3,5-diiodothyropropionic acid	n/a	5/14/2013	Treatment of Allan-Herndon-Dudley syndrome	Zarion Pharmaceuticals P/L
103	3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one	n/a	3/23/2000	Treatment of von Hippel-Lindau disease.	Sugen, Inc.
104	3-(3,5-dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one	n/a	9/11/1998	Treatment of Kaposi's sarcoma.	Sugen, Inc.
105	3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxyl-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid	n/a	3/2/2010	Treatment of cystic fibrosis	Vertex Pharmaceuticals Inc.
106	3-bromopyruvate	n/a	3/5/2013	Treatment of liver and intrahepatic bile duct cancer	Primocure Pharma, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
107	3-chloro-4-fluorophenyl-[4-fluoro-4-[[[5-methylpyrimidin-2-ylmethyl)amino)methyl]piperidin-1yl]methanone	n/a	10/25/2013	Treatment of Rett syndrome	Neurolix, Inc.
108	3-fluoro-5-[5-(2-menthyl-thiazol-4-ylethyl)pyridin-2-yl]-benzotrile dihydrochloride	n/a	7/28/2008	Treatment of behavioral abnormalities associated with fragile X syndrome.	Seaside Therapeutics
109	4, 5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/30/2008	Treatment of diffuse large B-cell lymphoma	Kiadis Pharma Canada, Inc.
110	4, 5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/30/2008	Treatment of follicular lymphoma	Kiadis Pharma Canada, Inc.
111	4,5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/23/2007	For immune reconstitution and prevention of graft versus host disease following allogeneic hematopoietic stem cell transplantation.	Kiadis Pharma Canada, Inc.
112	4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein disodium salt	n/a	4/18/2011	Treatment of hepatocellular carcinoma.	Provectus Pharmaceuticals, Inc.
113	4-(2-fluorophenyl)-6-methyl-2-(1-piperziny)	n/a	10/11/2006	Treatment of Chronic Functional Vomiting to include functional vomiting and cyclic vomiting syndrome.	Dynogen Pharmaceuticals, Inc.
114	4-(3-Methanesulfonyl-phenyl)-1-propylpiperidine HCl	n/a	12/12/2005	Treatment of Huntington's disease.	Teva Branded Pharmaceutical Products R&D

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
115	4-(4-([2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl)piperazin-1-yl)-N-({3-nitro-4-[tetrahydro-2H-pyran-4-ylmethyl]amino]phenyl)sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide	n/a	9/20/2012	Treatment of chronic lymphocytic leukemia	AbbVie, Inc.
116	4-(6-(4-(piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline hydrochloride	n/a	4/15/2013	Treatment of fibrodysplasia ossificans progressiva	La Jolla Pharmaceutical Company, Inc.
117	4-Amino-1-[5-O-[(2R, 4S)-2-oxido-4-(4-pyridinyl)-1, 3, 2-dioxaphosphorinan-2-yl]-b-D-arabinofuranosyl]-2(1H)-pyrimidinone	n/a	8/22/2007	Treatment of hepatocellular carcinoma.	Ligand Pharmaceuticals, Inc.
118	4-Aminopyridine	n/a	12/14/2005	Treatment chronic functional motor and sensory deficits from Guillain-Barre syndrome	Acorda Therapeutics, Inc.
119	4-[(5R)-6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile	n/a	9/13/2013	Treatment of Cushing's disease	Novartis Pharmaceuticals corporation
120	4-[131I]iodo-L-phenylalanine	n/a	1/4/2011	Treatment of glioma.	Therapeia GmbH & Co KG

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
121	4-[1]benzofuro[3,2-d]pyrimidin-4-yl-N-(1,3-benzodioxol-5-ylmethyl)piperazine-1-carbothioamide	n/a	7/30/2008	Treatment, in combination with radiotherapy and temozolomide chemotherapy, of patients with glioblastoma multiforme.	SuperGen, Inc.
122	4-[2-(3-Propyl-[1,2,4]Oxadiazol-5-yl)-vinyl]-benzene-1,2-diol	n/a	10/4/2011	Treatment of chronic myeloid leukemia	Piramal Enterprises Limited
123	4-[4-[[[3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl]amino]carbonyl]-amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide, p-toluenesulfonate salt	n/a	9/3/2009	Treatment of Philadelphia chromosome positive chronic myeloid leukemia	Deciphera Pharmaceuticals, LLC
124	4-[[9-(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol	n/a	9/23/2011	Treatment of idiopathic pulmonary fibrosis	Celgene Corporation
125	4-aminosalicylic acid	Pamisyl (P-D), Rezipas (Squibb)	12/13/1989	Treatment of mild to moderate ulcerative colitis in patients intolerant to sulfasalazine.	Beeken, Warren M.D.
126	4-aminosalicylic acid	Paser Granules	4/26/2006	Treatment of acute flares in pediatric patients with ileo-cecal Crohn's disease	Jacobus Pharmaceutical Co., Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
127	4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide monohydrochloride	n/a	7/20/2006	Treatment of acute myeloid leukemia	Johnson & Johnson Pharmaceutical Research & Dev,
128	4-pyridinylmethyl 3(4-chlorophenyl)adamantine carboxamide	n/a	11/2/2010	Treatment of pancreatic cancer.	Apogee Biotechnology Corporation
129	40K PEGylated recombinant factor IX	n/a	3/18/2013	Routine prophylactic administration for prevention of bleeding in patients with hemophilia B (Christmas disease).	Novo Nordisk, Inc.
130	5'-GCCATGGTTTTTCTCAGG-3'	n/a	10/31/2012	Prophylaxis for patients following documented or suspected exposure to ebolavirus	Sarepta Therapeutics, Inc.
131	5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin	n/a	6/15/2007	Treatment of osteosarcoma (bone cancer)	Dr. Reddy's Laboratories, Inc.
132	5,5',5"-[Phosphinothiolydine-tris(imino-2,1-ethanediyl)]tris[5-methylchelidoninium]trihydroide hexahydrochloride	n/a	8/20/2003	Treatment of pancreatic cancer	Now Pharm AG
133	5,6-dihydro-5-azacytidine	n/a	5/11/1992	Treatment of malignant mesothelioma.	ILEX Oncology, Inc.
134	5,7-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one	n/a	6/18/2007	Prevention of acute radiation syndrome	Humanetics Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
135	5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride	n/a	4/18/2011	Treatment of progressive supranuclear palsy.	Mithridion, Inc.
136	5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzop[d]oxazole	n/a	11/22/2011	Treatment of Duchenne Muscular Dystrophy	Summit Corporation plc
137	5-[(E)-2-(4-hydroxyphenyl)-ethenyl] benzene-1,3 diol	Resveratrol	3/13/2008	Treatment of MELAS syndrome	Sirtris Pharmaceuticals, Inc.
138	5-[1-(2,6-Dichlorobenzyl)-piperidin-4-yl]methoxyquinazoline-2,4-diamine	n/a	8/25/2009	Treatment of spinal muscular atrophy	Pfizer Incorporated
139	5-aminolevulinic acid	Gliolan	1/15/2013	Visualization of malignant tissue during surgery for malignant glioma (WHO grade III and IV)	NX Development Corporation
140	5-aza-2'-deoxycytidine	n/a	8/3/1987	Treatment of acute leukemia.	SuperGen, Inc.
141	5-hydroxymethyl-2-furfuraldehyde	n/a	5/26/2006	Treatment of sickle cell disease	AesRx, LLC
142	5-iodo-2-pyrimidinone-2'-deoxyribose	n/a	5/26/2006	Treatment of malignant glioma	Hana Biosciences, Inc.
143	5-methyl-1-phenyl-2-(1H)-pyridone(CAS 53179-13-8)	Pirfenidone	3/5/2004	Treatment of idiopathic pulmonary fibrosis	InterMune, Inc.
144	5'-AATATTAACAIACTGACAAGTC-3' RNA sequence	n/a	10/31/2012	Prophylaxis following documented or suspected exposure to marburg virus	Sarepta Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
145	6,8-bis-benzylsulfanyl-octanoic acid	n/a	2/6/2006	Treatment of pancreatic cancer	Cornerstone Pharmaceuticals, Inc.
146	6,8-bis-benzylsulfanyl-octanoic acid	n/a	8/22/2011	Treatment of acute myeloid leukemia.	Cornerstone Pharmaceuticals, Inc.
147	6,8-bis-benzylsulfanyl-octanoic acid	n/a	9/26/2013	Treatment of myelodysplastic syndrome	Cornerstone Pharmaceuticals, Inc.
148	6-alpha-ethylchenodeoxycholic acid	n/a	4/9/2008	Treatment of primary sclerosing cholangitis	Intercept Pharmaceuticals, Inc.
149	6-amino-5-chloro-N-[1R]-1-[5-[[[5-hloro-4-(trifluoromethyl)-2pyridinyl]amino]carbonyl]-2-thiazoyl]ethyl]-4-pyrimidinecarboxamide	n/a	10/15/2013	Treatment of stage IIb-IV melanoma	Millennium Pharmaceuticals, Inc.
150	6-hydroxymethylacylfulvene	n/a	4/6/1999	Treatment of histologically confirmed advanced or metastatic pancreatic cancer.	Eisai, Inc.
151	6-mercaptopurine oral liquid	n/a	12/7/2009	Treatment of acute lymphoblastic leukemia in the pediatric population	Orbona Pharma Ltd
152	7-B-Hydroxy Cholesteryl-3-B-Oleate-Ester	n/a	6/15/2011	Treatment of gliomas.	Intsel Chimos SA
153	8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naph-thyrin-3(2H)-one mono-hydrochloride	n/a	9/3/2009	Treatment of ovarian cancer.	Merck Sharp & Dohme Corp.
154	8-methoxsalen	Uvadex	6/22/1993	For use in conjunction with the UVAR photopheresis to treat diffuse systemic sclerosis.	Therakos, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
155	8-methoxsalen	Uvadex	5/12/1994	For the prevention of acute rejection of cardiac allografts.	Therakos, Inc.
156	9-nitro-20-(S)-camptothecin	Camvirex	5/15/2001	Treatment of pediatric HIV infection/AIDS	NovoMed Pharmaceuticals, Inc.
157	9-nitro-20-(S)-camptothecin	n/a	9/16/1996	Treatment of pancreatic cancer.	SuperGen, Inc.
158	90Y-hPAMA4	Pan-Cide	1/29/2004	Treatment of pancreatic cancer	Immunomedics, Inc.
159	A10 & AS2-1 Antineoplaston	n/a	9/3/2004	Treatment for patients with brain stem glioma	Burzynski Research Institute, Inc.
160	AAV-G6Pase vector	n/a	3/11/2013	Treatment of glycogen storage disease type Ia	GlyGenix Therapeutics, Inc.
161	ADF-APO-CCN-GUC-K67-MET-MMP-MUC-RGS; HLA class I/II binding tumor associated peptides	n/a	9/28/2012	Treatment of renal cell carcinoma in HLA-A*2 positive patients	Immatics Biotechnologies GmbH
162	ADXS11-001	n/a	8/12/2013	Treatment of HPV-positive associated anal cancer	Advaxis, Inc.
163	AEZS-108 (LHRH-agonist linked to doxorubicin)	n/a	4/30/2010	Treatment of ovarian cancer	Aeterna Zentaris
164	ALX-0081 nanobody, directed towards the human A1 domain of von Willebrand factor	n/a	4/14/2009	Treatment of thrombotic thrombocytopenic purpura	Ablynx NV
165	AQ-13 (4-aminoquinoline analog)	n/a	9/12/2008	Treatment of malaria	Immtech Pharmaceuticals, Inc.
166	Abetimus	n/a	7/28/2000	Treatment of lupus nephritis.	La Jolla Pharmaceutical Co.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
167	Acetylcysteine	Mucomyst/Mucomyst 10 lv	8/13/1987	Intravenous treatment of patients presenting with moderate to severe acetaminophen overdose.	Bristol-Myers Squibb Company
168	ActRIIB-IgG1)	n/a	8/16/2010	Treatment of Duchenne muscular dystrophy	Acceleron Pharma, Inc.
169	Adalimumab	Humira	3/21/2005	Treatment of juvenile rheumatoid arthritis	AbbVie, Inc.
170	Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Receptor	n/a	1/31/2012	Treatment of homozygous familial hypercholesterolemia	ReGenX Biosciences LLC
171	Adeno-associated vector expressing the human lipoprotein lipase protein	n/a	5/21/2007	Treatment of lipoprotein lipase deficiency	uniQure B.V.
172	Adeno-associated viral vector containing the gene for human coagulation factor IX	Coagulin-B	6/13/2001	Intramuscular treatment of patients with moderate to severe hemophilia	Avigen, Inc.
173	Adeno-associated viral vector containing the gene for human coagulation factor IX	Coagulin-B	6/13/2001	Intrahepatic treatment of patients with moderate to severe hemophilia	Avigen, Inc.
174	Adeno-associated viral vector expressing human acid alpha glucosidase gene	n/a	3/20/2007	Treatment of Pompe disease	Applied Genetic Technologies Corporation
175	Adenosine triphosphate type 1 competitive inhibitor of JAK2 V617F tyrosine kinase	n/a	3/3/2011	Treatment of myeloproliferative disorders (polycythemia vera, essential thrombocythemia, and myelofibrosis)	Eli Lilly and Company

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
176	Adenoviral vector expressing Herpes simplex virus thymidine kinase gene	n/a	6/17/2005	Treatment of malignant brain tumors	Advantagene, Inc.
177	Adenovirus-based vector Factor VIII complementary DNA to somatic cells	Miniadviii	12/15/1999	Treatment of hemophilia A.	GenStar Therapeutics Corporation
178	Albendazole	Albenza	1/18/1996	Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis.	SmithKline Beecham Pharmaceuticals
179	Albendazole	Albenza	1/17/1996	Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).	SmithKline Beecham Pharmaceuticals
180	Albuterol	n/a	3/12/2002	Prevention of paralysis due to spinal cord injury	MotoGen, Inc.
181	Aldesleukin	Proleukin	3/22/1989	Treatment of primary immunodeficiency disease associated with T-cell defects.	Prometheus Laboratories, Inc.
182	Aldesleukin	Proleukin	9/14/1988	Treatment of metastatic renal cell carcinoma.	Chiron Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
183	Aldesleukin	Proleukin	9/10/1996	Treatment of metastatic melanoma.	Chiron Corporation
184	Aldesleukin	Proleukin	11/24/1998	For the treatment non-Hodgkin's lymphoma.	Prometheus Laboratories, Inc.
185	Alendronate disodium	Fosamax	2/13/2001	Treatment of the bone manifestations of Gaucher disease	Richard J. Wenstrup, M.D.
186	Alfentanil	n/a	7/8/2005	Management of postherpetic neuralgia	Cinergen, LLC
187	Alfentanil	n/a	8/9/2005	Treatment of painful HIV-associated neuropathy	Cinergen, LLC
188	Alglucerase injection	Ceredase	7/21/1995	Replacement therapy in patients with Type II and III Gaucher's disease.	Genzyme Corporation
189	Alglucerase injection	Ceredase	3/11/1985	For replacement therapy in patients with Gaucher's disease type I.	Genzyme Corporation
190	Alitretinoin	Panretin	3/24/1998	Treatment of AIDS-related Kaposi's sarcoma.	Eisai, Inc
191	Alitretinoin	Panretin	4/10/1992	Treatment of acute promyelocytic leukemia	Ligand Pharmaceuticals, Inc.
192	Allogeneic T-cells cultured with anti-CD3 and IL-2; transduced with retroviral vector (SFCMM-3), expressing herpes simplex 1 virus-thymidine kinase (HSV-TK) and truncated low affinity nerve growth factor receptor; selected with anti-low affinity nerve gro	n/a	1/28/2005	Immunotherapy for acceleration of T-cell reconstitution in patients undergoing allogeneic hematopoietic stem cell transplantation	MolMed S.p.A.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
193	Allogeneic human aortic endothelial cells cultured in a porcine gelatin matrix	Vascugel (R)	4/3/2009	Prevention of arteriovenous fistula or arteriovenous graft failure in patients with end stage renal disease receiving hemodialysis or preparing for hemodialysis	Shire Regenerative Medicine, Inc.
194	Allogeneic motor neuron progenitor cells derived from human embryonic stem cells	Motorgraft (Tm)	1/17/2014	Treatment of Amyotrophic Lateral Sclerosis	California Stem Cell Inc.
195	Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture	Cytoimplant	6/13/1997	Treatment of pancreatic cancer	Applied Immunotherapeutics, LLC
196	Allogeneic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor	n/a	9/1/2004	Treatment of retinitis pigmentosa	Neurotech USA, Inc.
197	Allopurinol sodium	Aloprim For Injection	10/16/1992	Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.	Catalytica Pharmaceuticals, Inc
198	Alpha-galactosidase A	Replagal	6/22/1998	Long-term enzyme replacement therapy for the treatment of Fabry disease	Shire Human Genetic Therapies, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
199	Alpha-galactosidase A	Cc-Galactosidase	6/17/1991	Treatment of alpha-galactosidase A deficiency (Fabry's disease).	David Calhoun, Ph.D.
200	Alpha-galactosidase A	Fabrase	7/20/1990	Treatment of Fabry's disease.	Desnick, Robert J.
201	Alpha-melanocyte stimulating hormone	n/a	8/19/1997	Prevention and treatment of intrinsic acute renal failure due to ischemia.	National Institute of Diabetes, and Digestive and Kidney
202	Alpha-tocopherol quinone	n/a	3/28/2006	Treatment of inherited mitochondrial respiratory chain diseases	Penwest Pharmaceuticals Company
203	Alpha1-Proteinase Inhibitor (Human)	n/a	12/22/2004	Inhalation therapy for the the treatment of congenital deficiency of alpha1-proteinase inhibitor.	Kamada Ltd.
204	Alpha1-Proteinase Inhibitor (Human)	Arc-API	9/1/2004	Treatment of cystic fibrosis	Kamada Ltd.
205	Alpha1-antitrypsin(human)	n/a	4/3/2008	Treatment of bronchiectasis	Kamada, Ltd.
206	Alpha1-proteinase inhibitor (human)	Prolastin	12/7/1984	For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.	Bayer Corporation
207	Altretamine	Hexalen	2/9/1984	Treatment of advanced adenocarcinoma of the ovary.	Medimmune Oncology, Inc.
208	Alvocidib	n/a	4/13/2007	Treatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.	Tolero Pharmaceuticals, Inc.
209	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cyclophosphamide in the treatment of advanced ovarian carcinoma.	Medimmune, LLC

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
210	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cisplatin in the treatment of metastatic melanoma.	Medimmune LLC
211	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cisplatin in the treatment of advanced ovarian carcinoma.	Medimmune Oncology, Inc.
212	Amifostine	Ethyol	10/4/1999	Treatment of myelodysplastic syndromes.	Medimmune Oncology, Inc.
213	Amifostine	Ethyol	11/24/1998	For the reduction of the incidence and severity of toxicities associated with cisplatin administration.	Medimmune LLC
214	Amifostine	Ethyol	5/12/1998	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	Medimmune Oncology, Inc.
215	Amikacin	Arikace	3/9/2006	Treatment of bronchopulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients	Insmmed, Inc.
216	Aminocaproic acid	Caprogel	1/6/1995	For the topical treatment of traumatic hyphema of the eye.	Eastern Virginia Medical School
217	Aminosalicic acid	Paser Granules	2/19/1992	Treatment of tuberculosis infections	Jacobus Pharmaceutical
218	Aminosidine	Paromomycin	9/9/1994	Treatment of visceral leishmaniasis (kala-azar).	Kanyok, Thomas P. Pharm.D.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
219	Aminosidine	Gabbromicina	11/15/1993	Treatment of Mycobacterium avium complex.	Kanyok, Thomas P. Pharm.D.
220	Aminosidine	Gabbromicina	5/14/1993	Treatment of tuberculosis.	Kanyok, Thomas P. Pharm.D.
221	Amiodarone	Amio-Aqueous	8/17/1993	Treatment of incessant ventricular tachycardia.	Academic Pharmaceuticals, Inc.
222	Amiodarone HCl	Cordarone	3/16/1994	For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.	Wyeth-Ayerst Laboratories
223	Ammonium tetrathiomolybdate	Coprexa	1/31/1994	Treatment of Wilson's disease.	Pipex Pharmaceuticals, Inc.
224	Amphotericin B inhalation powder	n/a	12/15/2005	Prevention of pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy including those receiving organ or stem cell transplants, or treated with chemotherapy or radiation for hematologic malignancies	Novartis Pharmaceuticals Corporation
225	Amphotericin B lipid complex	Abelcet	12/5/1991	Treatment of invasive fungal infections.	Liposome Company, Inc.
226	Amyl nitrite, sodium nitrite, sodium thiosulfate	Cyanide Antidote Kit	12/18/2006	Treatment of cyanide poisoning	Akorn, Inc.
227	Anagrelide	Agrylin	1/27/1988	Treatment of essential thrombocythemia.	Roberts Pharmaceutical Corp.
228	Anagrelide	Agrylin	7/14/1986	Treatment of thrombocytosis in chronic myelogenous leukemia.	Roberts Pharmaceutical Corp.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
229	Anagrelide	Agrylin	6/11/1985	Treatment of polycythemia vera.	Roberts Pharmaceutical Corp.
230	Ananain, comosain	Vianain	1/21/1992	For the enzymatic debridement of severe burns.	Genzyme Corporation
231	Anatibant	n/a	4/15/2005	Treatment of patients having experienced a severe traumatic brain injury (Glasgow Coma Scale 3 to 8) in order to decrease early mortality and improve long-term functional and neurological outcome	Xytis, Inc.
232	Ancrod	Viprinex	10/20/1989	To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.	Knoll Pharmaceutical Company
233	Angiotensin (1-7)	n/a	11/26/2013	Treatment of limb-girdle muscular dystrophy	US Biotest, Inc.
234	Angiotensin 1-7	Marstem	8/3/2001	Treatment of myelodysplastic syndrome	Maret Pharmaceutical
235	Angiotensin 1-7	n/a	2/16/2000	Treatment of neutropenia associated with autologous bone marrow transplantation.	Maret Pharmaceuticals
236	Angiotensin-(1-7)	n/a	9/13/2011	Treatment of pulmonary arterial hypertension.	US Biotest, Inc.
237	Anti-T cell receptor murine monoclonal antibody	n/a	4/3/2009	Prophylaxis of acute rejection of solid organ transplantation	Tolera Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
238	Anti-tenascin 81C6 monoclonal antibody labeled w/ I 131	Neuradiab	10/4/2005	Treatment of primary malignant brain tumors	Bradmer Pharmaceuticals, Inc.
239	Anti-thymocyte serum	Nashville Rabbit Anti-Thymocyte Serum	6/2/1993	Treatment of allograft rejection, including solid organ (kidney, liver, heart, lung, and pancreas) and bone marrow transplantation.	Applied Medical Research
240	Anti-von Willebrand Aptamer	n/a	4/9/2008	Treatment of thrombotic thrombocytopenic purpura	Archemix Corporation
241	Antiepilepsirine	n/a	3/23/1989	Treatment of drug resistant generalized tonic-clonic epilepsy in children and adults.	Children's Hospital
242	Antihemophilic factor (human)	Alphanate	1/5/1996	Treatment of von Willebrand's disease	Grifols Biologicals Inc.
243	Antihemophilic factor (recombinant)	Refacto	2/8/1996	For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).	Wyeth Pharmaceuticals, Inc.
244	Antihemophilic factor (recombinant)	Kogenate	9/25/1989	Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.	Bayer Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
245	Antihemophilic factor (recombinant) formulated with sucrose reconstituted with liposome diluent	Kogenate Fs/Liposomal Diluent	4/29/2009	Treatment of hemophilia A	Bayer HealthCare LLC
246	Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized	Humate-P	10/16/1992	Treatment of patients with von Willebrand's disease	CSL Behring
247	Antisense 20-mer oligonucleotide complementary to R2 component of ribonucleotide reductase mRNA	n/a	4/15/2005	Treatment of acute myeloid leukemia	Lorus Therapeutics, Inc.
248	Antisense oligonucleotide directed against connexin43	Nexagon	4/27/2009	Treatment of persistent corneal epithelial defects	CoDa Therapeutics, Inc.
249	Antithrombin III (human)	Atnativ	2/8/1985	For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.	Pharmacia & Upjohn AB
250	Antithrombin III (human)	Thrombate lii	11/26/1984	For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.	Bayer Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
251	Antithrombin III human	Antithrombin Iii Human	1/2/1986	Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone trauma or who are about to undergo surgery or parturition.	American National Red Cross
252	Antivenin crotaline (pit-viper) equine immune F(ab)2)	Antivipmyn	1/29/2004	Treatment of envenomation by Crotaline snakes	Instituto Bioclon, S.A de C.V.
253	Antivenin, crotalidae polyvalent immune Fab (ovine)	Crofab	1/12/1994	Treatment of envenomations inflicted by North American crotalid snakes.	Protherics, Inc.
254	Antivenom (crotalidae) purified (avian)	n/a	2/12/1991	Treatment of envenomation by poisonous snakes belonging to the Crotalidae family.	Ophidian Pharmaceuticals, Inc.
255	Apomorphine	n/a	7/17/1995	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Pentech Pharmaceuticals, Inc.
256	Apomorphine HCl	Apokyn	4/22/1993	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	US WorldMeds, LLC

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
257	Apomorphine hydrochloride	n/a	5/23/2006	For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous)	NeuroHealing Pharmaceuticals, Inc.
258	Aprotinin	Trasylol	11/17/1993	For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary coronary artery bypass graft surgery where the risk of bleeding is especially high (impaired hemostasis) or where transfusion is unavailable or unacceptable.	Bayer Corporation
259	Arenegyr	n/a	8/22/2008	Treatment of malignant pleural mesothelioma	MolMed S.p.A.
260	Arginine butyrate	n/a	4/7/1992	Treatment of beta-hemoglobinopathies and beta-thalassemia.	Perrine, Susan P., M.D.
261	Arsenic trioxide	Trisenox	3/3/1998	Treatment of acute promyelocytic leukemia.	Cephalon
262	Arsenic trioxide	Trisenox	3/4/2005	Treatment of malignant glioma	Teva Branded Pharmaceutical Products R&D, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
263	Arsenic trioxide	Trisenox	4/28/2000	Treatment of multiple myeloma.	TEVA Branded Pharmaceutical Products R & D, Inc.
264	Arsenic trioxide	Trisenox	5/13/2003	Treatment of chronic lymphocytic leukemia	Teva Branded Pharmaceutical Products R&D, Inc.
265	Artesunate	n/a	7/19/1999	Treatment of malaria.	World Health Organization
266	Artesunate	n/a	3/28/2006	Immediate treatment of malaria	US Army Medical Materiel Development Activity
267	Ascorbic acid	Ascor L 500	8/31/2007	Treatment of scurvy	McGuff Pharmaceuticals Inc.
268	Asfotase alfa	n/a	9/12/2008	Treatment of hypophosphatasia	Alexion Pharma International
269	Atovaquone	Mepron	9/10/1990	Treatment of AIDS associated Pneumocystis Carinii Pneumonia.	Glaxo Wellcome Inc.
270	Atovaquone	Mepron	8/14/1991	Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3.	Glaxo Wellcome Research and Development

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
271	Attenuated autologous cancer cells and granulocyte macrophage colony stimulating factor in combination with activated autologous blood derived T-cells	n/a	4/27/2007	Treatment of primary central nervous system malignancies	TVAX Biomedical, LLC
272	Autologous CD34+ cells transfected with lentiviral vector containing the human WAS cDNA (Telethon 003)	n/a	4/30/2010	Treatment of Wiskott Aldrich syndrome	Fondazione Telethon
273	Autologous DNP-conjugated tumor vaccine	M-Vax	2/23/1999	For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).	Avax Technologies, Inc.
274	Autologous Engineered Skin Substitute	Permaderm	6/1/2012	Treatment of hospitalized patients with deep partial and full thickness burns requiring grafting.	Lonza
275	Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	n/a	1/31/2014	For the treatment of Acute Lymphoblastic Leukemia	Novartis Pharmaceuticals Corporation
276	Autologous cultured endothelial cells on a donor human corneal disk	n/a	6/1/2007	Treatment of Fuch's dystrophy, pseudophakic bullous keratopathy, and bullous keratopathy	Cellular Bioengineering, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
277	Autologous dendritic cells pulsed with autologous antigens from primay malignant brain tumor cells	Dcvax-Brain	11/29/2002	Treatment of primary brain malignant cancer	Northwest Biotherapeutics, Inc.
278	Autologous dendritic cells pulsed with recombinant human fusion protein (mucin1-glutathione S transferase) coupled to oxidized polymannose	Cvac(Tm)	9/13/2010	Treatment of ovarian cancer.	Prima Biomed Ltd.
279	Autologous incubated macrophage	n/a	9/3/2004	Therapy to improve the motor and sensory neurological outcome in acute cases of spinal cord injury	Proneuron Biotechnologies, Inc.
280	Autologous lymphoma-derived immunoglobulin idiotype antigen vaccine conjugated to keyhole limpet hemocyanin	Biovaxid	10/18/2011	Treatment of Waldenstrom's macroglobulinemia	Biovest International, Inc.
281	Autologous olfactory neural progenitors	Rhinocytes	2/1/2008	Treatment of spinal cord injury patients with ASIA Impairment grades A, B, or C	RhinoCyte, Inc.
282	Autologous or allogeneic limbal epithelial stem cells expanded ex vivo on human amniotic membrane	n/a	7/14/2005	Treatment of ocular surface diseases that are characterized by total limbal stem cell deficiency	TissueTech, Inc.
283	Autolymphocyte therapy	n/a	7/12/1994	Treatment of renal cell carcinoma.	Cytogen Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
284	Azacitidine	Vidaza	6/18/2008	Treatment of acute myeloid leukemia	Celgene Corporation
285	Azathioprine	Imuran	9/14/1999	Treatment of oral manifestations of graft-versus-host disease.	Oral Solutions, Inc.
286	BF2.649 (Pitolisant)	n/a	5/17/2010	Treatment of narcolepsy	Bioprojet Pharma
287	Bacillus Calmette-Guerin vaccine	n/a	8/9/2006	Treatment of stage IIb through IV metastatic melanoma	OncoVac Corporation
288	Bacitracin	Altracin	3/13/1984	Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.	A. L. Laboratories, Inc.
289	Baclofen	Lioresal Intrathecal	9/26/1994	Treatment of spasticity associated with cerebral palsy.	Medtronic, Inc.
290	Balsalazide disodium	Colazal	8/12/2005	Treatment of pediatric patients with ulcerative colitis	Salix Pharmaceuticals, Inc.
291	Bardoxolone	n/a	8/6/2008	Treatment of pancreatic cancer	Reata Pharmaceuticals, Inc.
292	Basiliximab	Simulect	12/12/1997	Prophylaxis of solid organ rejection.	Novartis Pharmaceuticals
293	Beclomethasone dipropionate	n/a	3/27/1998	For oral administration in the treatment of intestinal graft-versus-host disease.	Soligenix, Inc.
294	Belinostat	Beleodaq	9/3/2009	Treatment of peripheral T-cell lymphoma	Spectrum Pharmaceuticals, Inc.
295	Bendamustine hydrochloride	Treanda	8/17/2007	Treatment of chronic lymphocytic leukemia	Cephalon, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
296	Benzoate and phenylacetate	Ucephan	1/21/1986	For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency.	Immunex/Immunex
297	Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide	Total Block VI Spf 75	8/13/2001	For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy	Fallien Cosmeceuticals Ltd.
298	Benzydamine hydrochloride	Tantum	5/18/1998	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Angelini Pharmaceuticals, Inc.
299	Benzylpenicillin, benzylpenicilloic, benzylpenilloic acid	Pre-Pen/Mdm	9/28/1987	Assessing the risk of administrating penicillin when it is the preferred drug of choice in adult patients who have previously received penicillin and have a history of clinical sensitivity.	AllerQuest LLC
300	Beractant	Survanta Intratracheal Suspension	2/5/1986	Treatment of neonatal respiratory distress syndrome.	Ross Laboratories

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
301	Beractant	Survanta Intratracheal Suspension	2/5/1986	Prevention of neonatal respiratory distress syndrome.	Ross Laboratories
302	Beractant	Survanta Intratracheal Suspension	12/20/1993	Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.	Ross Laboratories
303	Beraprost	n/a	4/29/1999	Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).	LungRx, Inc.
304	Beta alethine	Betathine	3/24/1997	Treatment of multiple myeloma.	Dovetail Technologies, Inc.
305	Beta alethine	Betathine	3/24/1997	Treatment of metastatic melanoma.	Dovetail Technologies, Inc.
306	Betahistine dihydrochloride	n/a	11/8/2007	Treatment of obesity associated with Prader Willi syndrome	Floyd R. Sallee, M.D., Ph.D.
307	Betaine	Cystadane	5/16/1994	Treatment of homocystinuria.	Jazz Pharmaceuticals
308	Betulinic acid	n/a	8/9/2007	Topical treatment of metastatic melanoma	Advanced Life Sciences, Inc. (ALS)
309	Bexarotene	Targretin	6/18/1999	Treatment of cutaneous T-cell lymphoma.	Eisai, Inc.
310	Bindarit	n/a	2/3/1998	Treatment of lupus nephritis.	Angelini Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
311	Bio-engineered oral mucosal tissue	n/a	4/27/2006	For use as a graft for restoring a cornea-like epithelial phenotype to substitute for the normal corneal epithelium that is lost in patients due to total limbal stem cell deficiency	TissueTech, Inc.
312	Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL)	n/a	2/11/2002	Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2	Excorp Medical, Inc.
313	Bis(4-fluorophenyl)phenylacetamide	n/a	3/2/2000	Treatment of sickle cell disease.	ICAgen Inc.
314	Bleomycin	Blenoxane	2/9/1999	Treatment of pancreatic cancer.	Genetronics, Inc.
315	Bleomycin	n/a	12/20/2010	Treatment of pancreatic cancer.	CIRJ Company Ltd.
316	Bleomycin sulfate	Blenoxane	9/17/1993	Treatment of malignant pleural effusion.	Bristol-Myers Squibb Pharmaceutical Research Institute
317	Blinatumomab	n/a	5/16/2008	Treatment of chronic lymphocytic leukemia	Amgen Rockville, Inc.
318	Blinatumomab	n/a	2/6/2006	Treatment of indolent B-cell lymphoma, excluding CLL and NHL with CNS involvement	Amgen Rockville, Inc.
319	Bone marrow-derived mononuclear cells	n/a	5/17/2010	Treatment of thromboangiitis obliterans (Buerger's disease)	t2cure GmbH

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
320	Bosentan	Tracleer	10/6/2000	Treatment of pulmonary arterial hypertension.	Actelion Life Sciences Ltd.
321	Botulinum toxin type A	Dysport	10/20/1999	Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.	Ipsen Limited
322	Botulinum toxin type A	Dysport	8/12/1998	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Biopharm Limited
323	Botulinum toxin type A	Botox	3/22/1984	Treatment of strabismus and blepharospasms	Allergan, Inc.
324	Botulinum toxin type A	Dysport	3/23/1989	Treatment of essential blepharospasm.	Porton International, Inc.
325	Botulinum toxin type A	n/a	9/15/1992	Treatment of synkinetic closure of the eyelid associated with VII cranial nerve aberrant regeneration.	Botulinum Toxin Research Associates, Inc.
326	Botulinum toxin type A	Botox	12/6/1991	Treatment of dynamic muscle contracture in pediatric cerebral palsy patients.	Allergan, Inc.
327	Botulinum toxin type A	Botox	8/20/1986	Treatment of cervical dystonia.	Allergan, Inc.
328	Botulinum toxin type B	Myobloc	1/16/1992	Treatment of cervical dystonia.	Soltice Neurosciences, LLC
329	Botulinum toxin type F	n/a	12/5/1991	Treatment of essential blepharospasm.	Ipsen Limited (name changed from Porton International Inc)
330	Botulinum toxin type F	n/a	10/24/1991	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Limited
331	Botulism immune globulin	Babybig	1/31/1989	Treatment of infant botulism.	California Department of Health

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
332	Bovine colostrum	n/a	11/19/1990	Treatment of AIDS-related diarrhea.	Hastings, Donald DVM
333	Bovine immunoglobulin concentrate, Cryptosporidium parvum	Sporidin-G	3/1/1994	Treatment and symptomatic relief of Cryptosporidium parvum infection of the gastrointestinal tract in immunocompromised patients.	GalaGen, Inc.
334	Bovine whey protein concentrate	Immuno-C	9/30/1993	Treatment of cryptosporidiosis caused by the presence of Cryptosporidium parvum in the gastrointestinal tract of patients who are immunodeficient/immunocompromised or immunocompetent.	Biomune Systems, Inc.
335	Branched chain amino acids	n/a	12/23/1988	Treatment of amyotrophic lateral sclerosis.	Mount Sinai Medical Center
336	Brilliant Blue G	Dorc IIm-Blue	7/31/2012	To selectively stain the thickened internal limiting membrane, which has formed onto the inner side of the retina in vitreo-retinal disorders	Dutch Ophthalmic Research Center
337	Brimonidine	Alphagan	2/7/2000	Treatment of anterior ischemic optic neuropathy.	Allergan, Inc.
338	Brivaracetam	n/a	10/5/2005	Treatment of symptomatic myoclonus	UCB Pharma, Inc.
339	Broxuridine	Broxine/Neomark	9/18/1995	Radiation sensitizer in the treatment of primary brain tumors.	NeoPharm, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
340	Buffered Ursodeoxycholic Acid	Ursocarb	9/3/2004	Treatment of pruritus in patients with Alagille Syndrome	Digestive Care, Inc.
341	Buffered intrathecal electrolyte/dextrose injection	Elliotts B Solution	8/24/1994	For use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment of meningeal leukemia and lymphocytic lymphoma	Lukare Medical, LLC
342	Buprenorphine hydrochloride	Subutex	6/15/1994	Treatment of opiate addiction in opiate users.	Reckitt Benckiser Pharmaceuticals, Inc.
343	Busulfan	Busulfex	7/28/1994	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Otsuka Pharmaceutical Company
344	Busulfan	Spartaject	7/7/1997	Treatment of primary brain malignancies.	SuperGen, Inc.
345	Busulfan	Spartaject	4/21/1994	For use as preparative therapy for malignancies treated with bone marrow transplantation.	Sparta Pharmaceuticals, Inc.
346	Buthionine sulfoxamine	n/a	10/5/2005	Use as a modulator of chemotherapy for the treatment of pediatric patients with primary malignant brain tumors	USC-CHLA Institute for Pediatric Clinical Research
347	Buthionine sulfoxamine	n/a	10/5/2005	For use in children as a modulator of chemotherapy for the treatment of pediatric patients with neuroblastoma	USC-CHLA Institute for Pediatric Clinical Research

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
348	Butyrylcholinesterase	n/a	3/25/1992	For the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.	Shire Laboratories Inc.
349	Butyrylcholinesterase	n/a	9/30/1992	Treatment of post-surgical apnea.	Shire Laboratories Inc.
350	C1 esterase inhibitor (human)	Cinryze(R)	7/16/2004	Treatment of angioedema	ViroPharma Biologics Incorporated
351	C1 esterase inhibitor (human)	n/a	8/21/1996	Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.	Alpha Therapeutic Corporation
352	C1-esterase-inhibitor, human, pasteurized	Berinert (R)	10/16/1992	Prevention and/or treatment of acute attacks of hereditary angioedema.	CSL Behring LLC
353	C20-D3-retinyl acetate	n/a	9/16/2010	Treatment of Stargardt's disease	Alkeus pharmaceuticals, Inc.
354	C66H100N6O27	n/a	3/11/2013	Treatment of of hepatocellular carcinoma	GenSpera, Inc.
355	CD40/CD80/CD86 modified autologous dendritic cell therapy	n/a	12/20/2013	Treatment Type 1 diabetes mellitus patients with residual beta cell function	DiaVacs, Inc.
356	CNDO-109-activated allogeneic natural killer cells	n/a	6/18/2012	Treatment of acute myeloid leukemia	Coronado Biosciences, Inc.
357	Caffeine	Cafcit	9/20/1988	Treatment of apnea of prematurity.	O.P.R. Development, L.P.
358	Calcitonin-human for injection	Cibacalcin	1/20/1987	Treatment of symptomatic Paget's disease (osteitis deformans).	Novartis Pharmaceutical Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
359	Calcium acetate	Phos-Lo	12/22/1988	Treatment of hyperphosphatemia in end stage renal failure.	Fresenius Medical Care North America
360	Calcium acetate	n/a	6/27/1989	Treatment of hyperphosphatemia in end stage renal disease.	Pharmedic Company
361	Calcium carbonate	R & D Calcium Carbonate/600	6/6/1990	Treatment of hyperphosphatemia in patients with end stage renal disease.	R & D Laboratories, Inc.
362	Calcium gluconate	Calgonate	11/20/1997	For use as a wash for hydrofluoric acid spills on human skin.	Calgonate Corp.
363	Calcium gluconate gel	H-F Gel	5/21/1991	For use in the emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Calgonate Corporation
364	Calcium gluconate gel 2.5%	n/a	9/10/1990	Emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Paddock Laboratories, Inc.
365	Calfactant	Infasurf	9/5/2000	Acute respiratory distress syndrome (ARDS)	ONY, Inc.
366	Capsaicin	n/a	8/3/2005	Treatment of postherpetic neuralgia.	TheraQuest Biosciences, LLC
367	Capsaicin	n/a	9/29/2006	Treatment of intermetatarsal neuroma (Morton's Neuroma) that does not respond to conservative treatment and requires either neurectomy or neurolysis	Centrexion Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
368	Carmustine	n/a	7/3/2000	Treatment of intracranial malignancies.	Direct Therapeutics, Inc.
369	Cascara sagrada fluid extract	n/a	3/21/1989	Treatment of oral drug overdosage to speed lower bowel evacuation.	Intramed Corporation
370	Catumaxomab	Removab	6/9/2006	Treatment of ovarian cancer	Neoviibiotech North America, Inc.
371	Ceftriaxone sodium	Rocephin	3/28/2006	Treatment of amyotrophic lateral sclerosis	Mass General Hospital
372	Cells produced using the AastromReplicelle System and SC-I Therapy Kit	n/a	7/10/2002	For use in patients receiving high dose chemotherapy who are unable to generate an acceptable dose of peripheral blood stem cells and who have a sufficient bone marrow aspirate without morphological evidence of tumor	Aastrom Biosciences Incorporated
373	Centruroides immune F(ab)2	Anascorp	6/12/2000	Treatment of scorpion envenomations requiring medical attention.	Rare Disease Therapeutics, Inc.
374	Ceramide trihexosidase/alpha-galactosidase A	Fabrazyme	1/19/1988	Treatment of Fabry's disease.	Genzyme Corporation
375	Chelating agent delivering Holmium-166	n/a	2/10/1999	Treatment of multiple myeloma.	NeoRx Corporation
376	Chenodeoxycholic acid	Chenofalk	1/29/2004	Treatment of cerebrotendinous xanthomatosis	Dr. Falk Pharma GmbH

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
377	Chenodiol	Chenix	9/21/1984	For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age.	Solvay
378	Chimeric (human-murine) G250 IgG monoclonal antibody	n/a	7/24/2000	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH
379	Chimeric monoclonal antibodies	n/a	10/4/2005	For treatment of shiga-toxin producing bacterial infection.	Thallion Pharmaceuticals, Inc.
380	Chimeric monoclonal antibody to mesothelin	n/a	10/31/2006	Treatment of pancreatic cancer	Morphotek, Inc.
381	Chimeric, humanized monoclonal antibody to staphylococcus	n/a	8/3/2000	Prophylaxis of Staphylococcus epidermidis sepsis in low birth weight (1500 grams or less) infants.	Biosynexus, Inc.
382	Chlorhexidine gluconate mouthrinse	Peridex	8/18/1986	For use in the amelioration of oral mucositis associated with cytoreductive therapy used in conditioning patients for bone marrow transplantation therapy.	Procter & Gamble Company
383	Chlorotoxin	n/a	12/18/2007	Treatment of malignant glioma	Morphotek, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
384	Choline chloride	Intrachol	2/10/1994	Treatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition.	Alan L. Buchman, MD, MSPH
385	Choline chloride	Intrachol	7/20/2006	Prevention and/or treatment of choline deficiency in patients on long-term parenteral nutrition	Alan L. Buchman, M.D., M.S.P.H.
386	Chondrocyte-alginate gel suspension	n/a	12/1/1997	For use in correcting vesicoureteral reflux in the pediatric population.	Curis, Inc.
387	Ciliary neurotrophic factor	n/a	1/30/1992	Treatment of amyotrophic lateral sclerosis.	Regeneron Pharmaceuticals Inc
388	Cintredekin Besudotox	n/a	4/30/2010	Treatment of idiopathic pulmonary fibrosis	Insys Therapeutics, Inc.
389	Cisplatin in liposomal formulation	Slit Cisplatin For Inhalation	3/20/2007	Treatment of osteosarcoma	Eleison Pharmaceuticals, LLC
390	Cisplatin/epinephrine	Intradose	9/7/2000	Treatment of metastatic malignant melanoma.	Matrix Pharmaceutical, Inc.
391	Cisplatin/epinephrine	Intradose	4/3/2000	Treatment of squamous cell carcinoma of the head and neck.	Matrix Pharmaceutical, Inc.
392	Citric acid, glucono-delta-lactone and magnesium carbonate	Renacidin Irrigation	8/28/1989	Treatment of renal and bladder calculi of the apatite or struvite variety.	United-Guardian, Inc.
393	Cladribine	Mylinax	4/19/1994	Treatment of the chronic progressive form of multiple sclerosis.	Johnson & Johnson Pharmaceutical R & D, LLC
394	Cladribine	Leustatin Injection	4/19/1993	Treatment of non-Hodgkin's lymphoma.	Janssen Research & Development, LLC

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
395	Cladribine	Leustatin Injection	12/31/1990	Treatment of chronic lymphocytic leukemia.	Janssen Research & Development, LLC
396	Cladribine	Leustatin Injection	11/15/1990	Treatment of hairy cell leukemia.	R. W. Johnson Pharmaceutical Research Institute
397	Cladribine	Leustatin	7/20/1990	Treatment of acute myeloid leukemia.	Janssen Research & Development, LLC
398	Clazosentan	Erajjet	2/16/2006	Treatment of cerebral vasospasm following subarachnoid hemorrhage	Actelion Pharmaceuticals Ltd.
399	Clindamycin	Cleocin	10/28/1988	Prevention of Pneumocystis carinii pneumonia in AIDS patients.	Pfizer Inc.
400	Clindamycin	Cleocin	10/28/1988	Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.	Pharmacia & Upjohn
401	Clindamycin hydrochloride	n/a	8/9/2006	Treatment of sarcoidosis	Autoimmunity Research Foundation
402	Clofazimine	Lamprene	6/11/1984	Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.	Novartis Pharmaceutical Corporation
403	Clonazepam	Klonopin	8/4/1994	Treatment of hyperekplexia (startle disease).	Hoffmann-La Roche, Inc.
404	Clonazepam Intranasal Spray	n/a	12/19/2007	Treatment of recurrent acute repetitive seizures	Jazz Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
405	Clonidine	Duraclon	1/24/1989	For continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates.	Roxane Laboratories, Inc.
406	Clotrimazole	n/a	3/13/2006	Treatment of Huntington's disease	EnVivo Pharmaceuticals, Inc.
407	Clotrimazole	n/a	6/14/2005	Topical treatment of children and adults with pouchitis	AesRx, LLC
408	Clotrimazole	n/a	4/24/1995	Treatment of sickle cell disease.	Brugnara, Carlo M.D.
409	Coagulation Factor IX (human)	Alphanine	7/5/1990	For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis.	Alpha Therapeutic Corporation
410	Coagulation Factor IX (recombinant)	Benefix	10/3/1994	Treatment of hemophilia B.	Genetics Institute, Inc.
411	Coagulation Factor VIIa (Recombinant)	Novoseven	7/16/2004	Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Novo Nordisk, Inc.
412	Coagulation factor IX	Mononine	6/27/1989	Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.	Armour Pharmaceutical Company

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
413	Coagulation factor VIIa (Recombinant)	Novoseven	6/18/2004	Treatment of bleeding episodes in Glanzmann's thrombasthenia	Novo Nordisk, Inc.
414	Coagulation factor VIIa (recombinant)	Novoseven	6/6/1988	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Novo Nordisk, Inc.
415	Coagulation factor VIIa (recombinant)	Novoseven	9/10/2004	Treatment of bleeding episodes in patients with congenital factor VII deficiency	Novo Nordisk, Inc.
416	Coagulation factor VIIa (recombinant)	Novoseven	9/10/2004	Prevention of bleeding episodes in patients with congenital Factor VII deficiency	Novo Nordisk, Inc.
417	Coagulation factor VIIa (recombinant)	Novoseven	7/21/2004	Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Novo Nordisk, Inc.
418	Coagulation factor VIIa (recombinant)	Novoseven	6/18/2004	Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors	Novo Nordisk, Inc.
419	Coagulation factor VIIa (recombinant)	Novoseven	6/18/2004	Prevention of bleeding episodes in Glanzmann's thrombasthenia	Novo Nordisk, Inc.
420	Coenzyme Q10	n/a	3/5/2001	Treatment of Huntington's disease	Integrative Therapeutics, Inc.
421	Colchicine	n/a	9/25/2007	Treatment of Behcet's Syndrome	AR Scientific, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
422	Colfosceril palmitate, cetyl alcohol, tyloxapol	Exosurf Neonatal For Intratracheal Suspension	10/20/1989	Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less.	Glaxo Wellcome Inc.
423	Colfosceril palmitate, cetyl alcohol, tyloxapol	Exosurf Neonatal For Intratracheal Suspension	10/20/1989	Treatment of established hyaline membrane disease at all gestational ages.	Glaxo Wellcome Inc.
424	Combretastatin A4 Phosphate	n/a	7/23/2003	Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer	OXiGENE, Inc
425	Combretastatin A4 phosphate	n/a	5/8/2006	Treatment of ovarian cancer	OXiGENE, Inc.
426	Conjugate of a dengue virus specific small chemical ligand and an amphiphilic PEG based polymer	n/a	8/6/2013	Treatment of dengue fever (includes dengue hemorrhagic fever and dengue shock syndrome)	NanoViricides Incorporated
427	Contulakin-G	n/a	7/7/2005	Intrathecal treatment of neuropathic pain associated with spinal cord injury	Cognetix, Inc.
428	Cordycepin	n/a	7/5/2007	Treatment of TdT-positive acute lymphocytic leukemia	OncoVista, Inc.
429	Corticoirelin ovine triflutate	Acthrel	11/24/1989	For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.	Ferring Laboratories, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
430	Corticotropin-releasing factor, human	Xerecept	4/6/1998	Treatment of peritumoral brain edema.	Neurobiological Technologies, Inc.
431	Coumarin	Onkolox	12/22/1994	Treatment of renal cell carcinoma.	Drossapharm LTD
432	Coxsackievirus A21	Cavatak	12/15/2005	Treatment of stage II (T4), stage III, and stage IV melanoma	Viralytics Limited
433	Creatine	Creapure	10/11/2005	Treatment of Huntington's disease	Avicena Group, Inc.
434	Cromolyn sodium	Gastrocrom	3/8/1984	Treatment of mastocytosis.	Fisons Corporation
435	Cromolyn sodium 4% ophthalmic solution	Opticrom 4% Ophthalmic Solution	7/24/1985	Treatment of vernal keratoconjunctivitis.	Fisons Corporation
436	Cryptosporidium hyperimmune bovine colostrum IgG concentrate	n/a	12/30/1991	Treatment of diarrhea in AIDS patients caused by infection with Cryptosporidium parvum.	ImmuCell Corporation
437	Cyclo {{{(E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl}-L-2-aminobutyl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl}}	n/a	12/20/2006	Treatment and chronic control of non-infectious posterior, intermediate and pan-uveitis	Lux Biosciences, Inc.
438	Cyclosporin A	Mitogard	10/29/2004	Treatment of amyotrophic lateral sclerosis and its variants	Maas Biolab, LLC
439	Cyclosporine	Pluminiq	11/25/2003	Treatment of acute rejection in patients requiring allogenic lung transplants	APT Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
440	Cyclosporine	n/a	11/25/2003	Prophylaxis of organ rejection in patients receiving allogeneic lung transplant	APT Pharmaceuticals, Inc.
441	Cyclosporine 2% ophthalmic ointment	n/a	8/1/1991	For use in corneal melting syndromes of known or presumed immunologic etiopathogenesis, including Mooren's ulcer.	Allergan, Inc.
442	Cyclosporine 2% ophthalmic ointment	n/a	8/1/1991	Treatment of patients at high risk of graft rejection following penetrating keratoplasty.	Allergan, Inc.
443	Cyclosporine A	n/a	5/4/2007	Treatment of vernal keratoconjunctivitis	NOVAGALI Pharma SA
444	Cyclosporine in combination with omega-3 polyunsaturated fatty acids	n/a	12/6/2000	Prevention of solid organ graft rejection.	RTP Pharma Corporation
445	Cyclosporine ophthalmic	Optimmune	11/9/1988	Treatment of severe keratoconjunctivitis sicca associated with Sjogren's syndrome.	University Of Georgia
446	Cys-His-Ala-Val-Cys	n/a	2/14/2008	For use in conjunction with melphalen for the treatment of malignant melanoma, AJCC stages IIB, IIC, III and IV	Adherex Technologies, Inc.
447	Cysteamine	n/a	5/1/1986	Treatment of nephropathic cystinosis.	Thoene, Jess G., M.D.
448	Cysteamine	Cystagon	1/25/1991	Treatment of nephropathic cystinosis.	Mylan Laboratories, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
449	Cysteamine hydrochloride	Cystaran	8/19/1997	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Sigma-Tau Pharmaceuticals, Inc.
450	Cystic fibrosis Tr gene therapy (recombinant adenovirus)	Adgvcftr.10	3/9/1995	Treatment of cystic fibrosis.	GenVec, Inc.
451	Cystic fibrosis transmembrane conductance regulator gene	n/a	1/8/1993	Treatment of cystic fibrosis.	Genetic Therapy, Inc.
452	Cytarabine liposomal	Depocyt	6/2/1993	Treatment of neoplastic meningitis.	Pacira Pharmaceuticals, Inc.
453	Cytarabine:daunorubicin liposome injection	n/a	8/22/2008	Treatment of acute myeloid leukemia	Celator Pharmaceuticals, Inc.
454	Cytomegalovirus DNA Vaccine w/Copolymer/Benzalkonium Chloride	n/a	9/23/2006	For use in prevention of clinically significant CMV viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid organ transplant populations	Vical Inc.
455	Cytomegalovirus DNA vaccine with plasmids expressing pp65 and gB genes	n/a	6/3/2005	Prevention of clinically significant cytomegalovirus (CMV) viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid transplant populations	Astellas Pharma Global Development, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
456	Cytomegalovirus immune globulin (human)	Cytogam	8/3/1987	Prevention or attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants.	CSL Behring LLC
457	Cytomegalovirus immune globulin intravenous (human)	n/a	1/28/1991	For use in conjunction with ganciclovir sodium for the treatment of cytomegalovirus pneumonia in bone marrow transplant patients.	Bayer Corporation
458	D-mannitol and L-proline	Prodarsan	4/20/2009	Treatment of Cockayne syndrome	DNage B.V.
459	D-peptide	Nerofe	2/4/2011	Treatment of acute myelogenous leukemia	Immune System Key, Ltd
460	D-peptide of the sequence AKRHHGYKRKFH - NH2	Pulmadex	10/23/2002	Treatment of cystic fibrosis	Demegen, Inc.
461	DCVAC OvCa	n/a	5/14/2013	Treatment of ovarian cancer	SOTIOS a.s.
462	DEAE-rebeccamycin	n/a	3/1/2004	Treatment of bile duct tumors	Helsinn Healthcare SA
463	DHA-paclitaxel	Taxoprexin	9/25/2001	Treatment of pancreatic cancer	Luitpold Pharmaceuticals, Inc..
464	DHA-paclitaxel	Taxoprexin	5/1/2003	Treatment of adenocarcinoma of the stomach or lower esophagus	Luitpold Pharmaceuticals, Inc.
465	DHA-paclitaxel	Taxoprexin	10/10/2002	Treatment of metastatic malignant melanoma	Luitpold Pharmaceuticals, Inc.
466	DNA plasmid expressing diphtheria toxin triggered by the presence of oncofetal gen H19	n/a	8/20/2009	Treatment of ovarian cancer	BioCancell Therapeutics Ltd.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
467	DNA plasmid vector (pCK-HGFX7) expressing human hepatocyte growth factor	n/a	2/6/2014	Treatment of amyotrophic lateral sclerosis	ViroMed Co., Ltd.
468	DNA plasmid vector expressing eIF5Ak50	n/a	12/13/2010	Treatment of multiple myeloma.	Senesco Technologies, Inc.
469	DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)	n/a	7/24/2012	Treatment of diffuse large B cell lymphoma	Senesco Technologies, Inc.
470	DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)	n/a	7/24/2012	Treatment of mantle cell lymphoma	Senesco Technologies, Inc.
471	DNA plasmid vector expressing human IL-12 gene	n/a	4/4/2005	Treatment of ovarian cancer.	Expression Genetics, Inc.
472	DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2	Leuvectin	4/28/2000	Treatment of renal cell carcinoma.	Vical Incorporated
473	DNP-Modified autologous tumor vaccine	O-Vax	9/21/2000	Adjuvant therapy for the treatment of ovarian cancer	AVAX Technologies, Inc.
474	DOXO-EMCH	n/a	4/18/2011	Treatment of adenocarcinoma of the pancreas.	CytRx Corp.
475	Daclizumab	Zenapax	3/5/1993	Prevention of acute renal allograft rejection.	Hoffmann-La Roche, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
476	Dapsone	n/a	11/7/1994	Prophylaxis of toxoplasmosis in severely immunocompromised patients with CD4 counts below 100.	Jacobus Pharmaceutical Company, Inc.
477	Dapsone USP	Dapsone	1/8/1992	For the combination treatment of Pneumocystis carinii pneumonia in conjunction with trimethoprim.	Jacobus Pharmaceutical Company
478	Dapsone USP	Dapsone	12/24/1991	Prophylaxis for Pneumocystis carinii pneumonia.	Jacobus Pharmaceutical Company
479	Darinaparsin	n/a	9/13/2010	Treatment of peripheral T-cell lymphoma.	Ziopharm Oncology, Inc.
480	Dasatinib	Sprycel	11/28/2005	Treatment of chronic myelogenous leukemia	Bristol-Myers Squibb Company
481	Dasatinib	Sprycel	11/18/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Bristol-Myers Squibb Company
482	Daunorubicin citrate liposome injection	Daunoxome	5/14/1993	Treatment of patients with advanced HIV-associated Kaposi's sarcoma.	NeXstar Pharmaceuticals, Inc.
483	Daunorubicin liposomal	n/a	9/5/2008	Treatment of acute myeloid leukemia	Diatos USA, LLC
484	Decitabine	Dacogen	8/4/2006	Treatment of acute myeloid leukemia	Eisai, Inc.
485	Decitabine	Dacogen	3/8/1999	Treatment of myelodysplastic syndromes.	Eisai, Inc.
486	Decitabine	n/a	3/8/1999	Treatment of chronic myelogenous leukemia.	Eisai, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
487	Deferasirox	Exjade	11/21/2002	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Novartis Pharmaceuticals Corporation
488	Defibrotide	n/a	7/5/1985	Treatment of thrombotic thrombocytopenic purpura.	Crinos International
489	Dehydroepiandrosterone (DHEA)	Fidelin	8/19/2003	Replacement therapy in individuals with adrenal insufficiency	Paladin Labs, Inc.
490	Dehydroepiandrosterone sulfate sodium	n/a	1/28/1997	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Pharmadigm, Inc.
491	Dehydroepiandrosterone sulfate sodium	n/a	1/29/1997	Treatment of serious burns requiring hospitalization.	Pharmadigm, Inc.
492	Dermagraft	n/a	12/13/2010	Treatment of epidermolysis bullosa	Shire Regenerative Medicine, Inc.
493	Deslorelin	Somagard	11/5/1987		Roberts Pharmaceutical Corp.
494	Desmoglein 3 synthetic peptide (PI-0824)	n/a	10/26/2004	Treatment of pemphigus vulgaris	Peptimmune, Inc.
495	Desmopressin acetate	n/a	1/22/1991	Treatment of mild hemophilia A and von Willebrand's disease.	Aventis Behring L.L.C.
496	Dexrazoxane	Zinecard	12/17/1991	For the prevention of cardiomyopathy associated with doxorubicin administration.	Pharmacia & Upjohn

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
497	Dextran 70	Dehydrex	3/5/1990	Treatment of recurrent corneal erosion unresponsive to conventional therapy.	Holles Laboratories, Inc.
498	Dextran and deferoxamine	Bio-Rescue	3/8/1991	Treatment of acute iron poisoning.	Biomedical Frontiers, Inc.
499	Dextran sulfate (inhaled, aerosolized)	Uendex	10/5/1990	For use as an adjunct to the treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s
500	Dextran sulfate sodium	n/a	11/19/1987	Treatment of aquired immunodeficiency syndrome.	Ueno Fine Chemicals Industry, Ltd.
501	Dianeal peritoneal dialysis solution with 1.1% amino acids	Nutrineal (Peritoneal Dialysis Solution With 1.1% Amino Acid	6/11/1992	For use as a nutritional supplement for the treatment of malnourishment in patients undergoing continuous ambulatory peritoneal dialysis.	Baxter Healthcare Corporation
502	Diazepam viscous solution for rectal administration	n/a	2/25/1992	For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity.	Valeant Pharmaceuticals
503	Diethyldithiocarbamate	Imuthiol	4/3/1986	Treatment of AIDS.	Connaught

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
504	Diethylenetriaminepentaacetic acid (DTPA)	n/a	4/28/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination.	Hameln Pharmaceuticals gmbh
505	Digoxin immune FAB (Ovine)	Digibind	11/1/1984	Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.	Glaxo Wellcome Inc.
506	Digoxin immune fab(ovine)	Digidote	3/11/1985	Treatment of life-threatening acute cardiac glycoside intoxication manifested by conduction disorders, ectopic ventricular activity and (in some cases) hyperkalemia.	Boehringer Mannheim Corp.
507	Dihydrotestosterone	Androgel -Dht	2/5/1996	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Besins Internaitonal, US Inc.
508	Dimerizing drug that binds to mutated Fas protein/drug-binding domain fusion protein (FKBP)	n/a	11/24/1999	Treatment of acute graft-versus-host disease in patients undergoing bone marrow transplantation.	Bellicum Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
509	Dimethyl sulfoxide	n/a	11/22/1994	Treatment of increased intracranial pressure in patients with severe, closed-head injury, also known as traumatic brain coma, for whom no other effective treatment is available.	Abela Pharmaceuticals, Inc.
510	Dimethylsulfoxide	n/a	4/15/1997	Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.	Cancer Technologies, Inc.
511	Dimethylsulfoxide	n/a	4/6/1998	Treatment of palmar-plantar erythrodysethesia syndrome.	Cancer Technologies, Inc.
512	Dipalmitoylphosphatidylcholine /phosphatidylglycerol	Alec	7/28/1988	Prevention and treatment of neonatal respiratory distress syndrome.	Forum Products, Inc.
513	Disaccharide tripeptide glycerol dipalmitoyl	Immther	3/1/1990	Treatment of pulmonary and hepatic metastases in patients with colorectal adenocarcinoma.	ImmunoTherapeutics, Inc.
514	Disodium clodronate	n/a	6/16/1993	Treatment of hypercalcemia of malignancy.	Discovery Experimental &
515	Disodium clodronate tetrahydrate	Bonefos	3/5/1990	Treatment of increased bone resorption due to malignancy.	Anthra Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
516	Doripenem	n/a	7/16/2004	Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Pseudomonas aeruginosa or Burkholderia cepacia.	Shionogi, Inc.
517	Dornase alfa	Pulmozyme	1/16/1991	To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.	Genentech, Inc.
518	Double-stranded DNA plasmid carrying the gene for the diphtheria toxin A (DT-A) chain	n/a	8/6/2010	Treatment of pancreatic cancer	BioCancell Therapeutics Israel Ltd.
519	Doxorubicin HCl with pluronic L-61 and pluronic F-127	n/a	10/7/2005	Treatment of esophageal carcinoma	Supratek Pharma Inc.
520	Doxorubicin liposome	Doxil	11/4/1998	Treatment of ovarian cancer.	Alza Corporation
521	Dronabinol	Marinol	1/15/1991	For the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS.	Unimed Pharmaceuticals, Inc.
522	Duramycin	n/a	12/11/1997	Treatment of cystic fibrosis.	Lantibio, Inc.
523	Dynamine	n/a	2/5/1990	Treatment of Lambert Eaton myasthenic syndrome.	Mayo Foundation
524	Dynamine	n/a	10/16/1991	Treatment of hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth disease).	Mayo Foundation
525	Eculizumab	n/a	9/21/2000	Treatment of dermatomyositis	Alexion Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
526	Edotreotide	Onalta(Tm)	7/28/2005	Treatment of somatostatin receptor-positive neuroendocrine gastroenteropancreatic tumors	ITG Isotope Technologies Garchig GmbH
527	Efdispo (tm)	Efdispo (Tm)	1/15/2013	Treatment of Ewings Sarcoma.	TDP Biotherapeutics, Inc.
528	Eflornithine	n/a	9/29/2006	Treatment of anaplastic glioma	Orbus Therapeutics, Inc.
529	Eflornithine HCl	Ornidyl	4/23/1986	Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).	Hoechst Marion Roussel
530	Elcatonin	n/a	9/25/1995	Intrathecal treatment of intractable pain.	Innapharma, Inc.
531	Elesclomol	n/a	12/18/2007	Treatment of metastatic melanoma in combination with paclitaxel	Synta Pharmaceuticals Corporation
532	Enadoline hydrochloride	n/a	1/28/1997	Treatment of severe head injury.	Warner-Lambert Company
533	Encapsulated porcine islet preparation	Betarx	7/5/1995	Treatment of type I diabetic patients who are already on immunosuppression.	VivoRx
534	Engineered variant of recombinant human fibroblast growth factor 19	n/a	2/6/2014	Treatment of primary biliary cirrhosis	NGM Biopharmaceuticals, Inc.
535	Enzastaurin	n/a	9/19/2005	Treatment of glioblastoma multiforme	Eli Lilly and Company
536	Epidermal growth factor (human)	n/a	10/5/1987	For acceleration of corneal epithelial regeneration and the healing of stromal tissue in the condition of non-healing corneal defects.	Chiron Vision

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
537	Epirubicin	Ellence	9/14/1999	Treatment of breast cancer.	Pharmacia & Upjohn Company
538	Epitalon	n/a	9/2/2010	Treatment of retinitis pigmentosa	BioDiem Ltd
539	Epoetin alfa	n/a	12/20/1993	Treatment of myelodysplastic syndrome.	Johnson & Johnson Pharmaceutical Research & Dev.,
540	Epoetin alfa	Epogen	4/10/1986	Treatment of anemia associated with end stage renal disease.	Amgen, Inc.
541	Epoetin alfa	Epogen	7/1/1991	Treatment of anemia associated with HIV infection or HIV treatment.	Amgen, Inc.
542	Epoetin alpha	Procrit	8/27/1987	Treatment of anemia associated with end stage renal disease.	R. W. Johnson Pharmaceutical Research Institute
543	Epoetin alpha	Procrit	3/7/1989	Treatment of HIV associated anemia related to HIV infection or HIV treatment.	R. W. Johnson Pharmaceutical Research Institute
544	Epoetin beta	Marogen	10/22/1987	Treatment of anemia associated with end stage renal disease.	Chugai-USA, Inc.
545	Epoprostenol	Flolan	9/25/1985	Treatment of primary pulmonary hypertension.	Glaxo Wellcome Inc.
546	Eprodinate	Kiacta(Tm)	4/6/1999	Treatment of secondary amyloidosis	C. T. Development America, Inc.
547	Epstein Barr Virus specific cytotoxic T lymphocytes	n/a	12/27/2006	Prevention and treatment of EBV-post transplant lymphoproliferative disease after hematopoietic stem cell transplant or solid organ transplant.	Center for Cell and Gene Therapy

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
548	Erlotinib Hydrochloride	Tarceva	7/18/2003	Treatment of malignant gliomas	Genentech, Inc
549	Erwinia L-asparaginase	Erwinase	7/30/1986	Treatment of acute lymphocytic leukemia.	Jazz Pharmaceuticals, Inc.
550	Erythropoietin (recombinant human)	n/a	8/19/1987	Treatment of anemia associated with end stage renal disease.	McDonnell Douglas Corp
551	Estradiol Gel	Estrogel (R)	10/31/2006	Estrogen replacement therapy in females with Turner syndrome	Ascend Therapeutics, Inc.
552	Ethanol gel	n/a	3/29/2006	Treatment of congenital venous malformations	Orfagen
553	Ethanol gel	n/a	3/13/2006	Treatment of congenital lymphatic malformations	Orfagen
554	Ethanolamine oleate	Ethamolin	3/22/1984	Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding.	QOL Medical
555	Ethyl eicosapentaenoate	n/a	4/6/2000	Treatment of Huntington's disease.	Laxdale Ltd.
556	Etidronate disodium	Didronel	3/21/1986	Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.	MGI Pharma, Inc.
557	Etiocholanedione	n/a	5/7/1996	Treatment of Prader-Willi syndrome.	SuperGen, Inc.
558	Etiocholanedione	n/a	11/3/1995	Treatment of aplastic anemia.	SuperGen, Inc.
559	Ex vivo cultured adult human mesenchymal stem cells	Prochymal(R)	12/14/2005	Treatment of acute graft versus host disease	Mesoblast, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
560	Exemestane	Aromasin	9/19/1991	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	Pharmacia & Upjohn
561	Exisulind	n/a	2/14/1994	For the suppression and control of colonic adenomatous polyps in the inherited disease adenomatous polyposis coli.	OSI Pharmaceuticals, Inc.
562	Exon 44 specific phosphorothioate oligonucleotide	n/a	11/5/2009	Treatment of Duchenne Muscular Dystrophy in patients who have a mutation correctable by skipping of exon 44 of the dystrophin gene.	Prosensa Therapeutics B.V.
563	Exon 45 specific phosphorothioate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 45	Prosensa Therapeutics B V
564	Exon 46 specific phosphorothioate oligonucleotide	n/a	11/18/2005	Treatment of Duchenne muscular dystrophy	GlaxoSmithKline
565	Exon 51 specific phosphorothioate oligonucleotide	n/a	8/25/2009	Treatment of Duchenne Muscular Dystrophy.	GlaxoSmithKline

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
566	Exon 52 specific phosphorothiate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 52	Prosensa Therapeutics B V
567	Exon 55 specific phosphorothioate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 55	Prosensa Therapeutics B.V.
568	Extract of sea cucumber, sea sponge, shark fin, sea urchin, and sargassum grass	n/a	5/14/2012	Treatment of multiple myeloma	Unicorn Pacific Corporation
569	FTV1+GDP-fucose	n/a	3/18/2011	To improve homing to bone (treatment of myeloablation) in patients receiving hematopoietic stem cell transplantation.	America Stem Cell, Inc.
570	Facilitated DNA Plasmid Vaccine	n/a	3/8/1995	Treatment of cutaneous T cell lymphoma.	Wyeth-Lederle Vaccines and
571	Factor XIII [A2] homodimer, recombinant DNA origin	n/a	5/21/2003	Treatment of congenital FXIII deficiency	Novo Nordisk Pharmaceuticals, INC.
572	Fampridine	Neurelan	6/2/1997	Treatment of chronic, incomplete spinal cord injury.	Acorda Therapeutics, Inc.
573	Fast skeletal muscle troponin activator	n/a	3/2/2010	Treatment of amyotrophic lateral sclerosis (ALS)	Cytokinetics Inc.
574	Felbamate	Felbatol	1/24/1989	Treatment of Lennox-Gastaut syndrome.	Wallace Laboratories

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
575	Fenobam hydrochloride	n/a	11/20/2006	Treatment of fragile X syndrome	Neuropharm, Ltd.
576	Fenretinide	n/a	4/7/2010	Treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients	McGill University
577	Fenretinide	n/a	10/5/2005	Treatment of neuroblastoma	USC-CHLA Institute for Pediatric Clinical Research
578	Fibrin-based agent containing a N-terminally modified parathyroid hormone fragment TGplPTH1-34	n/a	2/1/2007	Treatment of solitary (unicameral) bone cysts	Kuros Biosurgery AG
579	Fibrinogen (human)	n/a	8/23/1995	For the control of bleeding and prophylactic treatment of patients deficient in fibrinogen.	Alpha Therapeutic Corporation
580	Fibronectin (human plasma derived)	n/a	9/5/1988	Treatment of non-healing corneal ulcers or epithelial defects which have been unresponsive to conventional therapy and the underlying cause has been eliminated.	Melville Biologics, Inc.
581	Fibronectin Peptide	n/a	6/29/2011	Prevention of burn injury progression of acute, deep dermal burns in hospitalized patients.	NeoMatrix Formulations, Inc.
582	Filgrastim	Neupogen	11/7/1990	Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm <sup>3</sup> ).	Amgen, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
583	Filgrastim	Neupogen	11/20/2013	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Amgen, Inc.
584	Filgrastim	Neupogen	11/7/1996	Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.	Amgen, Inc.
585	Filgrastim	Neupogen	7/17/1995	For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.	Amgen, Inc.
586	Filgrastim	Neupogen	10/1/1990	Treatment of neutropenia associated with bone marrow transplants.	Amgen, Inc.
587	FliC Flagellin Deletion Variant TLR5 Agonist	n/a	11/23/2010	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	Cleveland BioLabs, Inc.
588	Floxuridine, FUDR	n/a	12/22/2004	Intraperitoneal treatment of gastric cancer.	Franco Muggia, M.D.
589	Fludarabine phosphate	Fludara	4/18/1989	Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL.	Berlex Laboratories, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
590	Fludarabine phosphate	Fludara	4/18/1989	Treatment and management of patients with non-Hodgkins lymphoma.	Berlex Laboratories, Inc.
591	Fludarabine phosphate oral tablets	n/a	12/18/2007	Treatment of B-cell chronic lymphocytic leukemia	Sanofi-Aventis U.S., Inc.
592	Flunarizine	Sibelium	1/6/1986	Treatment of alternating hemiplegia.	Janssen Research Foundation
593	Fluocinolone	Retisert	7/31/2000	Treatment uveitis involving the posterior segment of the eye.	Bausch & Lomb Pharmaceuticals, Inc.
594	Fluorouracil	n/a	4/18/1990	For use in combination with interferon alpha-2a, recombinant, for the treatment of advanced colorectal carcinoma.	Hoffmann-La Roche, Inc.
595	Fluorouracil	n/a	6/29/2000	Treatment of glioblastoma multiforme.	Ethypharm SA
596	Fluorouracil	n/a	10/27/1989	For use in combination with interferon alpha-2a, recombinant, for the treatment of esophageal carcinoma.	Hoffmann-La Roche, Inc.
597	Fluoxetine	Prozac	4/30/1999	Treatment of autism.	Neuropharm, Ltd.
598	Fluoxetine	Prozac	4/14/2004	Treatment of body dysmorphic disorder in children and adolescents	Hollander, Eric MD

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
599	Follitropin alfa, recombinant	Gonal-F	12/21/1998	For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism. AMENDED indication 6/27/00: For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.	EMD Serono, Inc.
600	Fomepizole	Antizole	12/22/1988	Treatment of methanol or ethylene glycol poisoning.	Jazz Pharmaceuticals
601	Fosphenytoin	Cerebyx	6/4/1991	For the acute treatment of patients with status epilepticus of the grand mal type.	Warner-Lambert Company
602	Full Phosphorothioate Antisense Oligonucleotide against EWS-Fli-1 nanoparticles	n/a	9/22/2008	Treatment of Ewing's sarcoma	The Cure Our Children Foundation
603	Fully human anti-interferon gamma monoclonal antibody	Ni-0501	3/26/2010	Treatment of hemophagocytic lymphohistiocytosis	NovImmune S.A.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
604	Fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1	n/a	1/11/2006	Treatment of X-linked hypohidrotic ectodermal dysplasia	Edimer Pharmaceuticals, Inc.
605	G17DT Immunogen	Gastrimmune(Tm)	7/10/2002	Treatment of adenocarcinoma of the pancreas	Cancer Advances, Inc.
606	G17DT Immunogen	Gastrimmune(Tm)	7/18/2002	Treatment of gastric cancer.	Cancer Advances, Inc.
607	GNE Lipoplex	n/a	11/13/2008	Treatment of hereditary inclusion body myopathy-2	Gradalis, Inc.
608	GNE plasmid(H001)	n/a	3/26/2010	Treatment of hereditary inclusion body myopathy type 2	HIBM Research Group
609	GVAX melanoma	n/a	12/23/2010	Treatment of stage IIb to IV melanoma	Aduro BioTech, Inc.
610	Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteiny-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteiny-L-threonine-cyclic(2-7)disulfide	n/a	12/31/2013	Diagnostic for the Management of Gastro-Entero-Pancreatic Neuroendocrine Tumors	Advanced Accelerator Applications
611	Gallium-68 (DOTA0-Phel-Tyr3)octreotide	n/a	10/23/2013	The management of neuroendocrine tumors	Society of Nuclear Medicine & Molecular Imaging

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
612	Gamma hydroxybutyrate	n/a	12/3/1987	Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations and automatic behavior.	Biocraft Laboratories, Inc.
613	Gammalinolenic acid	n/a	7/27/1994	Treatment of juvenile rheumatoid arthritis.	Zurier, Robert B. M.D.
614	Ganaxolone	n/a	5/25/1994	Treatment of infantile spasms.	Marinus Pharmaceuticals, Inc.
615	Ganciclovir intravitreal implant	Vitrasert Implant	6/7/1995	Treatment of cytomegalovirus retinitis.	Bausch & Lomb Surgical, Chiron Vision
616	Gastrin 17C Diphtheria Toxoid Immunogen	n/a	7/7/2009	Treatment of pancreatic cancer	Astrimmune Ltd.
617	Gemtuzumab zogamicin	Mylotarg	11/24/1999	Treatment of CD33-positive acute myeloid leukemia.	Wyeth-Ayerst Laboratories
618	Genetically engineered human recombinant IgG4 monoclonal antibody directed against human TNF alpha	n/a	12/11/1997	Treatment of Crohn's disease.	Celltech Chiroscience Limited
619	Geneticin	n/a	6/6/2005	Treatment of amoebiasis.	ProcesScience, Inc
620	Gentamicin impregnated PMMA beads on surgical wire	Septopal	1/31/1991	Treatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin.	Lipha Pharmaceuticals, Inc.
621	Gentamicin liposome injection	Maitec	7/10/1990	Treatment of disseminated Mycobacterium avium-intracellulare infection.	Liposome Company, Inc.
622	Glatiramer acetate	Copaxone	11/9/1987	Treatment of multiple sclerosis.	Teva Pharmaceuticals USA

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
623	Glatiramer acetate for injection	Copaxone	6/5/2001	Treatment of primary-progressive multiple sclerosis	TEVA Pharmaceuticals, USA
624	Glutamine	Nutrestore	3/6/1995	For use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).	Emmaus Medical, Inc.
625	Glutathione pegylated liposomal doxorubicin hydrochloride	n/a	8/16/2010	Treatment of glioma	to-BBB technologies BV
626	Glyceryl tri (4-phenylbutyrate)	n/a	5/24/2005	Treatment of spinal muscular atrophy	Ucyclyd Pharma, Inc
627	Glyceryl trioleate and glyceryl trierucate	n/a	2/14/1995	Treatment of adrenoleukodystrophy.	Moser, Hugo W. M.D.
628	Glyeraldehyde-3-phosphate dehydrogenase	Proenzy	4/30/2010	Treatment of pediatric multiple sclerosis	BPT Pharmaceuticals, Inc.
629	Gonadorelin acetate	Lutrepulse	4/22/1987	For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.	Ferring Laboratories, Inc.
630	Gossypol	n/a	10/22/1990	Treatment of cancer of the adrenal cortex.	Reidenberg, Marcus M. M.D.
631	Gp100 adenoviral gene therapy	n/a	3/25/1997	Treatment of metastatic melanoma.	Genzyme Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
632	Growth hormone releasing factor	n/a	8/7/1989	For the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Valeant Pharmaceuticals North America
633	H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)arginyl-(D)glutaminy-(D)arginyl-(D)arginine acetate salt	n/a	12/22/2011	For use in combination with cisplatin and pemetrexed for the treatment of patients with mesothelioma	CanBas Company, Ltd.
634	H-Leu-Pro-Pro-Ser-Arg-OH	n/a	9/20/2012	Treatment of Kaposi sarcoma	Immuno Tech, Inc.
635	H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Arg-Arg-Ser-Ser-Ile-Glu-Ser-Asp-Val-OH	n/a	5/14/2013	Treatment of subarachnoid hemorrhage	NoNO, Inc.
636	HIRMAb-IDS	n/a	5/15/2013	Treatment of mucopolysaccharidosis Type II (Hunter Syndrome)	ArmaGen Technologies, Inc.
637	HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex	Allovectin-7	9/30/1999	Treatment of invasive and metastatic melanoma (Stages II, III, and IV).	Vical Incorporated
638	HPV-16 cancer therapeutic trojan peptide vaccine	n/a	1/12/2009	Treatment of HPV-16 expressing head and neck squamous cell carcinoma.	Gliknik, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
639	HPV16 E6/E7 synthetic long peptides vaccine	n/a	9/1/2011	Treatment of epithelial neoplasias of the vulva positive for human papilloma virus type 16.	ISA Therapeutics BV
640	Halofantrine	Halfan	11/4/1991	Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.	SmithKline Beecham Pharmaceuticals
641	Halofuginone	Stenorol	2/7/2000	Treatment of systemic sclerosis.	Collgard Biopharmaceuticals
642	Hanferon	Hanferon	3/9/2012	Treatment of Behcet's disease	HanAll BioPharma Co., Ltd.
643	Hantaan virus and Puumala virus DNA vaccines	n/a	11/13/2012	Prevention of hemorrhagic fever with renal syndrome caused by Hantaan virus and Puumala virus.	Surgeon General of the U. S. Army
644	Heat Shock Protein (hsp60) antigen	Diapep277	5/21/2012	For use in type 1 diabetic mellitus patients with residual beta-cell function	Andromeda Biotech, LTD
645	Heat Shock Protein 70	n/a	3/18/2011	Treatment of amyotrophic lateral sclerosis	ALS Biopharma, LLC
646	Heme arginate	Normosang	3/10/1988	Treatment of symptomatic stage of acute porphyria.	Orphan Europe SARL
647	Heme arginate	Normosang	3/1/1994	Treatment of myelodysplastic syndromes.	Orphan Europe

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
648	Hemin	Panhematin	3/16/1984	Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.	Abbott Laboratories
649	Hemin and zinc mesoporphyrin	Hemex	12/20/1993	Treatment of acute porphyric syndromes.	Bonkovsky, Herbert L. M.D.
650	Hemoximer (pyridoxalated hemoglobin polyoxyethylene)	n/a	12/18/2007	Treatment of cardiogenic shock	Apex Bioscience, Inc.
651	Heparin sodium	n/a	6/29/2006	Treatment of cystic fibrosis	Ockham Biotech
652	Heparin-binding epidermal growth factor-like growth factor	n/a	9/18/2006	Prevention and treatment of necrotizing enterocolitis (NEC) in preterm infants with birth weight less than 1,500 grams	Trillium Therapeutics, Inc.
653	Hepatitis B immune globulin intravenous (human)	Nabi-Hb	3/8/1995	Prophylaxis against hepatitis B virus reinfection in liver transplant patients.	Biotest Pharmaceuticals Corporation
654	Hepatitis C virus immune globulin (human)	Civacir(Tm)	11/14/2002	Prophylaxis of hepatitis C infection in liver transplant recipients.	Biotest Pharmaceuticals Corporation
655	Heptadecasodium salt of an 18-base residue phosphorothioate oligonucleotide	n/a	4/18/2011	Treatment of spinal muscular atrophy	Isis Pharmaceuticals, Inc.
656	Herpes simplex virus gene	n/a	10/16/1992	Treatment of primary and metastatic brain tumors.	Genetic Therapy, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
657	His-His-Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr	n/a	3/11/2013	Treatment of retinal detachment	ONL Therapeutics, LLC
658	Histamine	Maxamine	2/1/2000	For use as an adjunct to cytokine therapy in the treatment of malignant melanoma.	EpiCept Corporation
659	Histamine	Ceplene	12/15/1999	Adjunct to cytokine therapy in the treatment of acute myeloid leukemia.	EpiCept Corporation
660	Histrelin	n/a	5/3/1991	Treatment of acute intermittent porphyria, hereditary coproporphryia, and variegate porphyria.	Anderson, Karl E., M.D.
661	Histrelin	Supprelin La	11/18/2005	Treatment of central precocious puberty	Endo Pharmaceuticals Solutions, Inc.
662	Histrelin acetate	Supprelin Injection	8/10/1988	Treatment of central precocious puberty.	Roberts Pharmaceutical Corp.
663	Hu1D10, humanized monoclonal antibody	Remitogen	11/28/2001	For use in the treatment of 1D10+ B cell non-Hodgkin's lymphoma	PDL BioPharma, Inc.
664	Human Hemin	n/a	8/6/2013	Prevention of ischemia reperfusion injury in patients undergoing solid organ transplantation	Borders Technology Management Ltd
665	Human T-lymphotropic virus type III Gp160 antigens	Vaxsyn Hiv-1	11/20/1989	Treatment of AIDS.	MicroGeneSys, Inc.
666	Human alpha 2,6 sialyltransferase adenoviral gene therapy	n/a	4/4/2005	Treatment of patients with invasive (malignant) brain and central nervous system tumors lacking alpha 2,6 sialyltransferase.	Falk Center for Molecular Therapeutics

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
667	Human anti-CD30 monoclonal antibody	n/a	9/27/2004	Treatment of Hodgkin's disease	Bristol-Myers Squibb, Inc.
668	Human anti-integrin receptor av monoclonal antibody	n/a	5/5/2005	Treatment of patients with angiosarcoma	Janssen Research & Development, LLC
669	Human autologous bone-forming cell derived from bone marrow stem cells	n/a	3/24/2008	Treatment of osteonecrosis	Bone Therapeutics S.A.
670	Human cytomegalovirus immunoglobulin	n/a	12/20/2006	Prevention of congenital cytomegalovirus (CMV) infection following primary CMV infection in pregnant women	Biotest Pharmaceuticals Corporation
671	Human factor X	n/a	11/8/2007	Treatment of hereditary factor X deficiency	Bio Products Laboratory
672	Human immune globulin	Xepol(Tm)	3/29/2006	Treatment of post-polio syndrome	Instituto Grifols, S.A.
673	Human immunoglobulin anti-CD30 monoclonal antibody	n/a	1/10/2006	Treatment of CD30+ T-cell lymphoma	Bristol-Myers Squibb
674	Human monoclonal antibody against platelet-derived growth factor D	n/a	11/2/2004	To slow the progression of IgA nephropathy and delay kidney failure in patients affected by the disease.	CuraGen Corporation
675	Human monoclonal antibody directed against serotype 011 Pseudomonas aeruginosa	Aerumab 11	9/18/2006	Treatment of hospital acquired pneumonia caused by serotype 011 positive Pseudomonas aeruginosa	Kenta Biotech Limited
676	Human monoclonal antibody inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2)	n/a	12/16/2013	Prevention (inhibition) of complement-mediated thrombotic microangiopathy	Omeros Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
677	Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)	n/a	4/30/2010	Treatment of ovarian cancer	Ortho Biotech
678	Human plasma coagulation Factor VIII and human plasma von Willebrand Factor	Wilate	4/18/2007	Treatment of von Willebrand disease except for surgical and/or invasive procedures in patients with von Willebrand disease in whom desmopressin is either ineffective or contraindicated	Octapharma USA, Inc.
679	Human prothrombin complex concentrate	Octaplex	2/1/2008	Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures	Octapharma USA, Inc.
680	Human telomerase reverse transcriptase peptide vaccine	n/a	7/20/2006	Treatment of pancreatic cancer	GemVax A/S
681	Human umbilical tissue-derived cells	n/a	3/13/2006	Treatment of retinitis pigmentosa	Janssen Research and Development, LLC
682	Humanized 3F8-IgG1 monoclonal antibody	n/a	6/24/2013	Treatment of neuroblastoma	Memorial Sloan-Kettering Cancer
683	Humanized anti-CD3 monoclonal antibody	n/a	9/29/2006	Treatment of recent-onset Type I diabetes	MacroGenics, Inc.
684	Humanized anti-tac	Zenapax	3/5/1993	Prevention of acute graft-vs-host disease following bone marrow transplantation.	Hoffmann-La Roche, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
685	Humanized monoclonal antibody to TumorEndothelial Marker-1	n/a	4/29/2011	Treatment of soft tissue sarcoma	Morphotek
686	Hydralazine	n/a	4/9/2004	Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure greater than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy	Bioniche Pharma USA LLC
687	Hydroxocobalamin	n/a	9/22/2000	Treatment of acute cyanide poisoning	Jazz Pharmaceuticals
688	Hydroxocobalamin	Cyanokit	11/25/2003	Treatment of acute cyanide poisoning	Merck Sante, s.a.a.
689	Hydroxy-Propyl-Beta-Cyclodextrin	Trappsol	5/17/2010	Treatment of Niemann Pick Disease, Type C	Childrens Hospital & Research Center
690	Hydroxyurea	Droxia	10/1/1990	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Bristol-Myers Squibb Pharmaceutical Research Institute
691	Hypericin	n/a	8/3/2000	Treatment of glioblastoma multiforme.	HyBiopharma, Inc.
692	Hypericin	n/a	2/7/2000	Treatment of cutaneous T-cell lymphoma.	HyBiopharma, Inc.
693	Hypothiocyanite and lactoferrin	Meveol	11/5/2009	Treatment of cystic fibrosis	Alaxia Biotechnologies Sante
694	I(131)-TM-601 (chlorotoxin)	n/a	2/14/2002	Treatment of malignant glioma	Morphotek, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
695	IDUA-HIRMAb fusion protein	Agt-181	1/10/2008	Treatment of mucopolysaccharidosis Type 1 (MPS)	ArmaGen Technologies, Inc.
696	IL-12 secreting dendritic cells loaded with autologous tumor lysate	n/a	6/24/2013	Treatment of malignant glioma	Activartis Biotech GmbH
697	IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL)	n/a	4/6/2000	Treatment of astrocytic glioma.	Medicenna Therapeutics, Inc.
698	IL13-PE38QQR	n/a	11/2/2001	Treatment of malignant glioma	Insys Therapeutics, Inc.
699	Ibuprofen i.v. solution	Salprofen	10/29/1996	Prevention of patent ductus arteriosus.	Farmacon-IL, LLC
700	Ibuprofen lysine	Neoprofen	10/29/1996	Treatment of patent ductus arteriosus	Lundbeck, Inc.
701	Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution	Extraneal (With 7.5% Icodextrin) Peritoneal Dialysis Solutio	7/18/1997	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Baxter Healthcare Corporation
702	Idarubicin HCl for injection	Idamycin	7/25/1988	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Adria Laboratories, Inc.
703	Idoxuridine	n/a	4/8/1996	Treatment of nonparenchymatous sarcomas.	NeoPharm, Inc.
704	Ifosfamide	Ifex	8/7/1985	Treatment of bone sarcomas	Bristol-Myers Squibb Company
705	Ifosfamide	Ifex	1/20/1987	Treatment of testicular cancer.	Bristol-Myers Squibb Pharmaceutical Research Institute

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
706	Ifosfamide	Ifex	8/7/1985	Treatment of soft tissue sarcomas.	Bristol-Myers Squibb Pharmaceutical Research Institute
707	IgG1 chimeric monoclonal antibody	n/a	6/22/2011	Treatment of multiple myeloma.	Immune System Therapeutics Ltd
708	Iloprost inhalation solution	Ventavis	8/17/2004	Treatment of pulmonary arterial hypertension	CoTherix, Inc.
709	Imatinib	Gleevec	1/31/2001	Treatment of chronic myelogenous leukemia	Novartis Pharmaceuticals
710	Imatinib mesylate	Gleevec	9/9/2005	Treatment of systemic mastocytosis without the D816V c-kit mutation	Novartis Pharmaceuticals Corporation
711	Imatinib mesylate	Gleevec	8/25/2005	Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia	Novartis Pharmaceuticals Corporation
712	Imatinib mesylate	Gleevec	10/5/2005	Treatment of myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements	Novartis Pharmaceuticals Corporation
713	Imciromab pentetate	Myoscint	1/25/1989	Detecting early necrosis as an indication of rejection of orthotopic cardiac transplants.	Centocor, Inc.
714	Imexon	n/a	11/8/1996	Treatment of multiple myeloma.	AmpliMed Corporation
715	Imiglucerase	Cerezyme	11/5/1991	Replacement therapy in patients with types I, II, and III Gaucher's disease.	Genzyme Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
716	Immortalized human liver cells found in the extracorporeal liver assist device	Elad	7/16/2004	Treatment of fulminant hepatic failure (acute liver failure)	Vital Therapies, Inc.
717	Immune Globulin (Human)	Gamunex(R)-C	7/27/2004	Treatment of chronic inflammatory demyelinating polyneuropathy	Grifols Therapeutics, Inc.
718	Immune Globulin (Human) containing high titers of West Nile virus antibodies	Omr-Igg-Am (Tm) 5% (Wnv)	3/17/2004	Treatment of the West Nile virus infection	OMRIX Biopharmaceuticals, Ltd.
719	Immune Globulin Intravenous (human)	Carimune Nf	5/4/2004	Treatment for Guillain Barre Syndrome	ZLB Bioplasma AG
720	Immune globulin intravenous, human	Gamimune N	2/18/1993	Infection prophylaxis in pediatric patients affected with the human immunodeficiency virus.	Bayer Corporation
721	Immunotherapeutic vaccine consisting of (PAM)2-Lys-Ser-Ser-Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Ala-Ala-Ala-Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val	n/a	3/16/1994	Treatment of chronic active hepatitis B infection in HLA-A2 positive patients.	Cytel Corporation
722	Imported fire ant venom, allergenic extract	n/a	5/12/1992	For skin testing of victims of fire ant stings to confirm fire ant sensitivity and if positive, for use as immunotherapy for the prevention of IgE-mediated anaphylactic reactions.	ALK Laboratories, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
723	Inalimarev and falimarev	n/a	1/10/2006	Treatment of adenocarcinoma of the pancreas	Therion Biologics Corporation
724	Indium-111 pentetretotide	Neuroendomedix	6/16/2006	Treatment of neuroendocrine tumors	Radiolotope Therapy of America (RITA) Foundation
725	Infliximab	Remicade	11/12/2003	Treatment of pediatric (0 to 16 years of age) Crohn's Disease	Centocor, Inc.
726	Infliximab	Remicade	5/21/2003	Treatment of chronic sarcoidosis	Centocor, Inc.
727	Inhibitor of Tissue Factor Pathway Inhibitor (TFPI)	n/a	1/29/2010	Treatment of hemophilia A and hemophilia B.	Baxter Healthcare Corporation, Baxter BioScience
728	Inosine pranobex	Isoprinosine	9/20/1988	Treatment of subacute sclerosing panencephalitis.	Newport Pharmaceuticals
729	Interferon alfa-2a	Roferon A	6/6/1989	Treatment of chronic myelogenous leukemia.	Hoffmann-La Roche, Inc.
730	Interferon alfa-2a (recombinant)	Roferon-A	12/14/1987	Treatment of AIDS related Kaposi's sarcoma.	Hoffmann-La Roche, Inc.
731	Interferon alfa-2a (recombinant)	Roferon-A	5/14/1990	For the concomitant administration with fluorouracil for the treatment of advanced colorectal cancer.	Hoffmann-La Roche, Inc.
732	Interferon alfa-2a (recombinant)	Roferon-A	5/11/1990	For the treatment of metastatic malignant melanoma in combination with Teceleukin.	Hoffmann-La Roche, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
733	Interferon alfa-2a (recombinant)	Roferon-A	5/2/1990	For the concomitant administration with Teceleukin for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
734	Interferon alfa-2a (recombinant)	Roferon-A	10/27/1989	For use in combination with fluorouracil for the treatment of esophageal carcinoma.	Hoffmann-La Roche, Inc.
735	Interferon alfa-2a (recombinant)	Roferon-A	4/18/1988	Treatment of renal cell carcinoma.	Hoffmann-La Roche, Inc.
736	Interferon alfa-2b (recombinant)	Intron A	6/24/1987	Treatment of AIDS-related Kaposi's sarcoma.	Schering Corporation
737	Interferon beta-1a	Rebif	3/11/1996	Treatment of patients with secondary progressive multiple sclerosis.	EMD Serono, Inc.
738	Interferon beta-1a	Avonex	12/16/1991	Treatment of multiple sclerosis.	Biogen, Inc.
739	Interferon beta-1a (recombinant human)	n/a	7/24/1992	Treatment of acute non-A, non-B hepatitis.	Biogen, Inc.
740	Interferon beta-1a (recombinant)	Rebif	12/2/1992	Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells per mm <sup>3</sup> .	EMD Serono, Inc.
741	Interferon beta-1b	Betaseron	11/17/1988	Treatment of multiple sclerosis.	Chiron Corp. & Berlex Laboratories
742	Interferon gamma	n/a	10/11/2007	Treatment of idiopathic pulmonary fibrosis	mondoBIOTECH Laboratories AG
743	Interferon gamma 1-b	Actimmune	9/30/1988	Treatment of chronic granulomatous disease.	Vidara Therapeutics Research Limited

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
744	Interferon gamma-1b	Actimmune	12/4/1995	Treatment of renal cell carcinoma.	Vidara Therapeutics Research Limited
745	Interferon gamma-1b	Actimmune	9/30/1996	Delaying time to disease progression in patients with severe, malignant osteopetrosis.	Vidara Therapeutics Research Limited
746	Interferon-alfa-1b	n/a	4/17/2001	Treatment of multiple myeloma	Ernest C.Borden
747	Interleukin-1 Trap	n/a	4/4/2005	Treatment of Still's disease including juvenile rheumatoid arthritis and adult-onset Still's disease	Regeneron Pharmaceuticals, Inc.
748	Interleukin-1 receptor antagonist, human recombinant	Antril	10/16/1992	Prevention and treatment of graft versus host disease in transplant recipients.	Amgen, Inc.
749	Interleukin-1 receptor antagonist, human recombinant	Antril	9/23/1991	Treatment of juvenile rheumatoid arthritis.	Amgen, Inc.
750	Interleukin-2	Teleleukin	2/6/1990	Treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc.
751	Interleukin-2	Teceleukin	2/5/1990	Treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
752	Interleukin-2	Teceleukin	5/3/1990	In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
753	Interleukin-2	Teceleukin	5/11/1990	In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
754	Intraoral fluoride releasing system	lfrs	7/31/2001	Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer	Digestive Care, Inc.
755	Intravenous immune globulin	Vitigam	7/26/2007	Treatment of Stage IIB to IV malignant melanoma	GammaCan Ltd.
756	Intravenous immune globulin (human) 10%	Octagam(R)	7/31/2008	Treatment of stiff-person syndrome	Octapharma USA, Inc.
757	Iobenguane I 123	Adreview	12/1/2006	For the diagnosis of pheochromocytomas	GE Healthcare, Inc.
758	Iobenguane I 123	Adreview	12/1/2006	For the diagnosis of neuroblastomas	GE Healthcare, Inc.
759	Iobenguane I 131	Azedra Ultratrace	1/18/2006	Treatment of neuroendocrine tumors	Molecular Insight Pharmaceuticals
760	Iobenguane Sulfate I-123	Omaclear	10/17/2005	For scintigraphic detection, localization and staging of neuroblastoma.	Brogan Pharmaceuticals, LLC
761	Iodine 131 6B-iodomethyl-19-norcholesterol	n/a	8/1/1984	For use in adrenal cortical imaging.	David E. Kuhl, M.D.
762	Iodine I 123 murine monoclonal antibody to hCG	n/a	11/7/1988	Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Immunomedics, Inc.
763	Iodine I 131 bis(indium-diethylenetriaminepentaacetic acid)tyrosyllysine/hMN-14 x m734 F(ab')2 bispecific monoclonal antibody	Pentacea	2/22/2000	Treatment of small-cell lung cancer.	IBC Pharmaceuticals, L.L.C.
764	Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B)	131ichtnt-1	2/12/1999	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	Peregrine Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
765	Isobutyramide	n/a	5/25/1994	Treatment of sickle cell disease and beta thalassemia.	Alpha Therapeutic Corporation
766	Isobutyramide	Isobutyramide Oral Solution	12/18/1992	Treatment of beta-hemoglobinopathies and beta-thalassemia syndromes.	Perrine, Susan P., M.D.
767	Itraconazole suspension	n/a	10/30/2008	Topical treatment of fungal otitis externa (otomycosis)	Fairfield Clinical Trials, LLC
768	Japanese encephalitis vaccine (live, attenuated)	n/a	5/19/1999	Prevention of Japanese encephalitis.	Glovax Co., Ltd.
769	Japanese encephalitis vaccine, inactivated, adsorbed	Ixiaro	9/25/2012	Prevention of Japanese encephalitis virus in pediatric patients.	Intercell AG
770	Kre-Celazine	n/a	4/1/2013	Treatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population	All American Pharmaceutical & Natural Foods Corpor
771	L-2-oxothiazolidine-4-carboxylic acid	Procysteine	6/14/1994	Treatment of adult respiratory distress syndrome.	Transcend Therapeutics, Inc.
772	L-2-oxothiazolidine-4-carboxylic acid	Procysteine	7/30/1996	Treatment of amyotrophic lateral sclerosis.	Transcend Therapeutics, Inc.
773	L-5 Hydroxytryptophan	n/a	11/1/1984	Treatment of postanoxic intention myoclonus.	Watson Laboratories, Inc.
774	L-5-hydroxytryptophan	n/a	1/20/1999	Treatment of tetrahydrobiopterin deficiency.	Watson Laboratories, Inc.
775	L-amino acids, vitamins and minerals combined with omega-3 fatty acids	n/a	1/12/2011	Treatment of patients with pediatric Crohn's disease	Immunopath Profile, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
776	L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal	n/a	1/18/2006	Treatment of Duchenne and Becker muscular dystrophy	CepTor Corporation
777	L-arginyl-L-isoleucyl-L-valyl-L-prolyl-L-alanine-amide	n/a	9/11/2013	Treatment of acute radiation syndrome	Soligenix, Inc.
778	L-asparaginase encapsulated in red blood cells	Graspa	1/6/2010	Treatment of acute lymphoblastic leukemia	Erytech Pharma
779	L-asparaginase encapsulated in red blood cells	Graspa	7/6/2012	Treatment of pancreatic cancer.	ERYTECH Pharma
780	L-baclofen	n/a	1/6/1998	Treatment of trigeminal neuralgia	Osmotica Pharmaceutical Corp.
781	L-baclofen	Neuralgon	1/30/1992	Treatment of intractable spasticity in children with cerebral palsy.	Osmotica Pharmaceutical Corp.
782	L-baclofen	Neuralgon	12/17/1991	Treatment of spasticity associated with spinal cord injury or multiple sclerosis.	Osmotica Pharmaceutical Corp.
783	L-baclofen	n/a	7/13/1990	Treatment of trigeminal neuralgia.	Fromm, Gerhard M.D.
784	L-cycloserine	n/a	8/1/1989	Treatment of Gaucher's disease.	Lev, Meir M.D.
785	L-cysteine	n/a	5/16/1994	For the prevention and lessening of photosensitivity in erythropoietic protoporphyria.	Brigham and Women's Hospital
786	L-glutamine	n/a	8/1/2001	Treatment of sickle cell disease	Emmaus Medical, Inc.
787	L-glutamyl-L-tryptophan	n/a	10/20/1999	Treatment of AIDS-related Kaposi's sarcoma.	Implicit Bioscience Pty Ltd

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
788	L-ornithine phenylacetate	n/a	4/7/2010	Treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure or acute on chronic liver disease	Ocera Therapeutics, Inc.
789	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	9/13/2011	Treatment of neuropathic pain in patients with sarcoidosis.	Araim Pharmaceuticals, Inc.
790	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	9/18/2009	Prevention of delayed graft function following renal transplant	Araim Pharmaceuticals, Inc.
791	L-threonyl-L-prolyl-L-prolyl-L-threonine	n/a	4/26/2005	Treatment of neuropathic pain associated with spinal cord injury	Nyxis Neurotherapies, Inc.
792	L-tyrosine-L-serine-L-leucine	Cms-024	9/10/2004	Treatment of hepatocellular carcinoma.	CMS Peptides Patent Holding Company
793	L. reuteri	n/a	8/1/2013	Prevention of necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 grams	Infant Bacterial Therapeutics
794	Lactic acid	Aphthaid	6/29/1999	Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.	Frontier Pharmaceutical, Inc.
795	Lamotrigine	Lamictal	8/23/1995	Treatment of Lennox-Gastaut syndrome.	Glaxo Wellcome Research and Development
796	Lanreotide	Somatuline Depot	9/11/2000	Treatment for acromegly	IPSEN, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
797	Latrodectus immune F(ab)2	Analatro	6/18/2001	Treatment of black widow spider envenomations	Instituto Bioclon, S.A. de C.V.
798	Leflunomide	n/a	10/18/1996	Prevention of acute and chronic rejection in patients who have received solid organ transplants.	Williams, MD, James W.
799	Lentiviral vector containing the human ABCA4 gene	Stargen (Tm)	4/30/2010	Treatment of Stargardt disease	Oxford Biomedica (UK) Ltd.
800	Lentiviral vector containing the human MYO7A gene (UshStat)	n/a	5/17/2010	Treatment of retinitis pigmentosa associated with Usher syndrome 1B gene defect.	Oxford BioMedica (UK) Ltd.
801	Lentiviral vector encoded with a human beta-globin gene plasmid	Thalagen	1/11/2006	Treatment of beta-thalassemia major and beta-thalassemia intermedia	Memorial Sloan-Kettering Cancer Center
802	Lepirudin	Refluden	2/13/1997	Treatment of heparin-associated thrombocytopenia type II.	Hoechst Marion Roussel
803	Lestaurtinib	n/a	3/24/2006	Treatment of acute myeloid leukemia	Teva Branded Pharmaceutical Products R&D, Inc.
804	Leucovorin	Leucovorin Calcium	8/17/1988	For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma.	Immunex Corporation
805	Leucovorin	Leucovorin Calcium	12/8/1986	For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.	Immunex Corporation
806	Leupeptin	n/a	9/18/1990	For use as an adjunct to microsurgical peripheral nerve repair.	Neuromuscular Adjuncts, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
807	Leuprolide acetate	Lupron Injection	7/25/1988	Treatment of central precocious puberty	Tap Pharmaceuticals, Inc.
808	Levocarnitine	Carnitor	11/15/1989	For the prevention of secondary carnitine deficiency in valproic acid toxicity.	Sigma-Tau Pharmaceuticals, Inc.
809	Levocarnitine	Carnitor	4/7/1997	Treatment of zidovudine-induced mitochondrial myopathy.	Sigma-Tau Pharmaceuticals, Inc.
810	Levocarnitine	Carnitor	2/28/1984	Treatment of genetic carnitine deficiency.	Sigma-Tau Pharmaceuticals, Inc.
811	Levocarnitine	Carnitor	11/22/1993	Treatment of pediatric cardiomyopathy.	Sigma-Tau Pharmaceuticals, Inc.
812	Levocarnitine	Carnitor	7/26/1984	Treatment of primary and secondary carnitine deficiency of genetic origin.	Sigma-Tau Pharmaceuticals, Inc.
813	Levocarnitine	Carnitor	9/6/1988	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Sigma-Tau Pharmaceuticals, Inc.
814	Levocarnitine	Carnitor	11/15/1989	For the treatment of secondary carnitine deficiency in valproic acid toxicity.	Sigma-Tau Pharmaceuticals, Inc.
815	Levodopa and carbidopa	Duodopa	1/18/2000	Treatment of late stage Parkinson's disease	AbbVie, Inc.
816	Levofloxacin	n/a	2/27/2008	Treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis patients	Mpex Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
817	Levoleucovorin	Fusilev	8/1/1991	For use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.	Spectrum Pharmaceuticals, Inc.
818	Levomethadyl acetate hydrochloride	Orlaam	1/24/1985	Treatment of heroin addicts suitable for maintenance on opiate agonists.	Biodevelopment Corporation
819	Lidocaine patch 5%	Lidoderm Patch	10/24/1995	For relief of allodynia (painful hypersensitivity), and chronic pain in postherpetic neuralgia.	Teikoku Pharma USA, Inc.
820	Liothyronine sodium injection	Triostat	7/30/1990	Treatment of myxedema coma/precoma.	SmithKline Beecham Pharmaceuticals
821	Lipid/DNA human cystic fibrosis gene	n/a	4/8/1996	Treatment of cystic fibrosis.	Genzyme Corporation
822	Liposomal Glutathione	n/a	4/30/2010	Support of glutathione deficiency in individuals with inborn errors of metabolism of glutathione (IEMG)	Your Energy Systems, LLC
823	Liposomal N-Acetylglucosminyl-N-Acetylmuramyl-L-Ala-D-isoGln-L-Ala - glycerolidpalmitoyl	Immther	6/10/1998	Treatment of Ewing's sarcoma.	Endorex Corp.
824	Liposomal N-Acetylglucosminyl-N-Acetylmuramyl-L-Ala-D-isoGln-L-Ala - glycerolidpalmitoyl	Immther	6/10/1998	Treatment of osteosarcoma.	Endorex Corp.
825	Liposomal amphotericin B	Ambisome	12/10/1996	Treatment of cryptococcal meningitis.	Fujisawa USA, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
826	Liposomal amphotericin B	Ambisome	12/6/1996	Treatment of visceral leishmaniasis.	Fujisawa USA, Inc.
827	Liposomal amphotericin B	Ambisome	12/10/1996	Treatment of histoplasmosis.	Fujisawa USA, Inc.
828	Liposomal annamycin	n/a	6/17/2005	Treatment of acute myeloid leukemia	Callisto Pharmaceuticals, Inc.
829	Liposomal annamycin	n/a	6/17/2005	Treatment of acute lymphoblastic leukemia	Callisto Pharmaceuticals, Inc.
830	Liposomal ciprofloxacin for inhalation	n/a	4/19/2006	Management of cystic fibrosis	Aradigm Corporation
831	Liposomal ciprofloxacin for inhalation	n/a	12/27/2006	Management of bronchiectasis	Aradigm Corporation
832	Liposomal cisplatin	Lipova-Pt	5/23/2006	Treatment of ovarian cancer	Eleison Pharmaceuticals, LLC
833	Liposomal cyclosporin A	Cyclospire	4/30/1998	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation.	Vernon Knight, M.D.
834	Liposomal doxorubicin hydrochloride	Sarcodoxome	12/27/2006	Treatment of soft tissue sarcomas	GP-Pharm SA
835	Liposomal nystatin	Nyotran	6/13/2000	Treatment of invasive fungal infections.	The University of Texas
836	Liposome encapsulated recombinant interleukin-2	n/a	6/20/1994	Treatment of cancers of the kidney and renal pelvis	Oncothyreon Canada, Inc.
837	Liposome encapsulated recombinant interleukin-2	n/a	11/25/1991	Treatment of brain and CNS tumors.	Oncothyreon Canada, Inc.
838	Lisofylline	n/a	6/10/1999	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Cell Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
839	Lodoxamide tromethamine	Alomide Ophthalmic Solution	10/16/1991	Treatment of vernal keratoconjunctivitis.	Alcon Laboratories, Inc.
840	Lonafarnib	n/a	11/19/2013	Treatment of Hepatitis Delta Virus (HDV)infection	Eiger Biopharmaceuticals,
841	Lucinactant	Surfaxin	5/23/2006	Prevention of bronchopulmonary dysplasia in premature infants	Discovery Laboratories, Inc
842	Lucinactant	Surfaxin	10/21/2005	Treatment of bronchopulmonary dysplasia in premature infants.	Discovery Laboratories, Inc.
843	Lucinactant	Surfaxin	7/17/1995	Treatment of acute respiratory distress syndrome in adults.	Discovery Laboratories, Inc.
844	Lucinactant	Surfaxin	10/18/1995	Treatment of respiratory distress syndrome in premature infants.	Discovery Laboratories, Inc.
845	Lucinactant	Surfaxin(R), Aerosurf(R)	10/21/2010	Treatment of cystic fibrosis.	Discovery Laboratories, Inc.
846	MA09-hRPE cells	n/a	2/2/2010	Treatment of Stargardt's macular dystrophy.	Advanced Cell Technology, Inc.
847	MAGE-A3 cancer therapeutic Trojan peptide vaccine	n/a	11/24/2008	Treatment of MAGE-A3 expressing head and neck squamous cell carcinoma	Gliknik, Inc.
848	MCMV5322A/MCMV3068A	n/a	11/22/2011	Prevention of maternal-fetal transmission of congenital CMV in pregnant women who acquire CMV infection during pregnancy	Genentech
849	MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)	n/a	2/4/2011	Treatment of Myelodysplastic syndrome	Millennium Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
850	MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)	n/a	2/4/2011	Treatment of acute myelogenous leukemia.	Millennium Pharmaceuticals
851	MN14 monoclonal antibody to carcinoembryonic antigen	Cea-Cide	11/24/1998	Treatment of pancreatic cancer.	Immunomedics, Inc.
852	MN14 monoclonal antibody to carcinoembryonic antigen	Cea-Cide	9/18/1998	Treatment of small cell lung cancer	Immunomedics, Inc.
853	MOD-423 hGH analogue	n/a	9/29/2010	Treatment of growth hormone deficiency.	PROLOR-Biotech, Ltd.
854	MTC-DOX for Injection	n/a	1/3/2001	Treatment of hepatocellular carcinoma	FeRx Incorporated
855	Mafenide acetate solution	Sulfamylon Solution	7/18/1990	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	Mylan Laboratories, Inc.
856	Mafosfamide	n/a	1/21/2003	Treatment of neoplastic meningitis	Baxter Healthcare Corporation
857	Manganese superoxide dismutase mimetic	n/a	2/27/2008	Prevention of radiation- or chemotherapy-induced oral mucositis in cancer patients	Galera Therapeutics, LLC
858	Mannitol	Bronchitol	2/11/2005	For use to facilitate clearance of mucus in patients with bronchiectasis and in patients with cystic fibrosis at risk for bronchiectasis	Pharmaxis Ltd.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
859	Marijuana	n/a	5/25/1999	Treatment of HIV-associated wasting syndrome.	Multidisciplinary Association for Psychedelic Studies,
860	Marizomib	n/a	12/13/2013	Treatment of multiple myeloma	Triphase Research and Development I
861	Matrix metalloproteinase inhibitor	Galardin	12/5/1991	Treatment of corneal ulcers.	Glycomed, Inc
862	MaxAdFVIII	n/a	3/3/2003	Treatment of Hemophilia A	GenStar Therapeutics Corporation
863	Maytansinoid DM-1 Conjugated Humanized Monoclonal Antibody N901	n/a	8/17/2010	Treatment of small cell lung cancer.	ImmunoGen, Inc.
864	Mazindol	Sanorex	12/8/1986	Treatment of Duchenne muscular dystrophy.	Collipp, Platon J. M.D.
865	Mecamylamine	Inversine	10/14/1998	Treatment of Tourette's syndrome.	Targacept, Inc.
866	Mecasermin	Increlex	12/12/1995	Treatment of growth hormone insensitivity syndrome.	Ipsen Biopharmaceuticals, Inc.
867	Medroxyprogesterone acetate	Hematrol	2/22/2001	Treatment of immune thrombocytopenic purpura.	ZaBeCor Pharmaceutical
868	Mefloquine HCl	Mephaquin	7/22/1987	Treatment of chloroquine-resistant Falciparummalaria.	Mepha AG
869	Mefloquine HCl	Mephaquin	7/22/1987	Prevention of chloroquine-resistant Falciparum malaria.	Mepha AG
870	Megestrol acetate	Megace	4/13/1988	Treatment of patients with anorexia, cachexia, or significant weight loss (= $\geq$ 10% of baseline body weight) and confirmed diagnosis of AIDS.	Bristol-Myers Squibb Pharmaceutical Research Institute

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
871	Melanoma autologous dendritic cell vaccine	n/a	9/6/2006	Treatment of stage IIIb through IV metastatic melanoma	California Stem Cell, Inc.
872	Melanoma cell vaccine	Canvaxin	10/13/1994	Treatment of invasive melanoma.	CancerVax Corporation
873	Melanoma peptide vaccine	n/a	3/29/2005	Treatment of HLA-A2+ patients with stage IIB, IIC, III, and IV malignant melanoma	Bristol-Myers Squibb Research Inst
874	Melanoma vaccine	Melacine	12/20/1989	Treatment of stage III - IV melanoma.	Ribi ImmunoChem Research, Inc.
875	Melatonin	n/a	11/15/1993	Treatment of circadian rhythm sleep disorders in blind people with no light perception.	Sack, Robert, M.D.
876	Melatonin	Circadin	7/9/2004	Treatment of non-24-hour sleep-wake disorder in blind individuals without light perception	Neurim Pharmaceuticals, Ltd.
877	Melphalan	Alkeran For Injection	2/24/1992	Treatment of patients with multiple myeloma for whom oral therapy is inappropriate.	Glaxo Wellcome Inc.
878	Mepivacaine	n/a	10/18/2006	Treatment of painful HIV-associated neuropathy	Cinergen
879	Mesna	Mesnex	11/14/1985	For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.	Degussa Corporation
880	Methionine/L-methionine	n/a	8/21/1996	Treatment of AIDS myelopathy.	Genopia USA, Inc.
881	Methotrexate sodium	Methotrexate	10/21/1985	Treatment of osteogenic sarcoma.	Lederle Laboratories

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
882	Methotrexate with laurocapram	Methotrexate/Azone	10/15/1990	Topical treatment of mycosis fungoides.	Echo Therapeutics, Ltd.
883	Methoxsalen	Uvadex(R)	10/14/1998	For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.	Therakos, Inc.
884	Methyl O-4-O-[2-[2-[2-[2-[[N-[(1R)-1-[4-(aminoiminomethyl)phenyl]methyl]-2-oxo-2-(1-piperidinyl)ethyl]-N2-[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]-L-Asparaginyl-4-aminobutanoyl]-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[	n/a	4/18/2011	Prevention of ischemia reperfusion injury associated with solid organ transplantation	Endotis Pharma
885	Metronidazole	Metrogel	10/24/1991	Treatment of perioral dermatitis.	Galderma Laboratories, Inc.
886	Metronidazole (topical)	Metrogel	10/22/1987	Treatment of acne rosacea.	Galderma Laboratories, Inc.
887	Metronidazole 10% ointment	n/a	11/8/2007	Topical treatment of active perianal Crohn's disease	SLA Pharma (UK) Ltd
888	Microbubble contrast agent	Filmix Neurosonographic Contrast Agent	11/16/1990	Intraoperative aid in the identification and localization of intracranial tumors.	Cav-Con, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
889	Microvesiculated modified glycosylated tissue factor	n/a	1/25/2007	Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in hemophiliac patients	Thrombotargets Corp.
890	Microvesiculated modified glycosylated tissue factor	n/a	10/11/2007	Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in patients with von Willebrand disease.	Thrombotargets Corp.
891	Midodrine HCl	Amatine	6/21/1985	Treatment of patients with symptomatic orthostatic hypotension.	Schier Ridgewood F.K.A. (Roberts Pharmaceutical Corp.)
892	Midostaurin	n/a	7/7/2009	Treatment of acute myeloid leukemia	Novartis Pharmaceuticals
893	Midostaurin	Rydapt	4/30/2010	Treatment of mastocytosis	Novartis Oncology
894	Mifepristone	n/a	2/7/2005	Treatment of Cushing's syndrome secondary to ectopic ACTH secretion	HRA Pharma
895	Minnelide	Minnelide (Tm)	2/18/2013	Treatment of pancreatic cancer	Minneamrita Therapeutics, LLC
896	Minocycline hydrochloride	n/a	3/28/2006	Treatment of sarcoidosis	Autoimmunity Research Foundation
897	Mitoguazone	Apep	3/18/1994	Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.	ILEX Oncology, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
898	Mitolactol	n/a	7/12/1995	As adjuvant therapy in the treatment of primary brain tumors.	Targent, INC.
899	Mitolactol	n/a	1/23/1989	Treatment of invasive carcinoma of the uterine cervix	Targent, Inc..
900	Mitomycin-C	n/a	8/20/1993	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	IOP Inc.
901	Mitoxantrone	Novantrone	8/13/1999	Treatment of secondary-progressive multiple sclerosis.	Serono, Inc.
902	Mitoxantrone	Novantrone	8/21/1996	Treatment of hormone refractory prostate cancer.	Serono
903	Mitoxantrone	Novantrone	8/13/1999	Treatment of progressive-relapsing multiple sclerosis.	Serono, Inc.
904	Mitoxantrone HCl	Novantrone	7/13/1987	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Lederle Laboratories
905	Modafinil	Provigil	3/15/1993	Treatment of excessive daytime sleepiness in narcolepsy.	Cephalon, Inc.
906	Monoclonal antibody for immunization against lupus nephritis	n/a	1/7/1993	Treatment of lupus nephritis.	VivoRx Autoimmune, Inc.
907	Monoclonal antibody-B43.13	Ovarex Mab-B43.13	11/25/1996	Treatment of epithelial ovarian cancer.	Quest PharmaTech, Inc.
908	Monolaurin	Glylorin	4/29/1993	Treatment of congenital primary ichthyosis.	Glaxo Wellcome Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
909	Monooctanoin	Moctanin	5/30/1984	For dissolution of cholesterol gallstones retained in the common bile duct.	Ethitek Pharmaceuticals, Inc.
910	Morphine sulfate concentrate (preservative free)	Infumorph	7/12/1990	For use in microinfusion devices for intraspinal administration in the treatment of intractable chronic pain.	Elkins-Sinn, Inc.
911	Multi-ligand somatostatin analog	n/a	7/27/2004	Treatment of patients with functional gastroenteropancreatic (GEP) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma.	Novartis Pharmaceuticals Corporation
912	Multi-peptide cancer vaccine	n/a	6/23/2013	Treatment of multiple myeloma	OncoPep, Inc.
913	Multi-vitamin infusion (neonatal formula)	n/a	12/12/1989	For establishment and maintenance of total parenteral nutrition in very low birth weight infants.	Astra Pharmaceuticals, L.P.
914	Multistem(r)	n/a	9/15/2010	Prophylaxis of graft vs host disease	Athersys, Inc.
915	Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma	Oncolym	11/27/1998	Treatment of B-cell non-Hodgkin's lymphoma.	Peregrine Pharmaceuticals, Inc.
916	Murine MAb to polymorphic epithelial mucin, human milk fat globule 1	Theragyn	3/22/1999	Adjuvant treatment of ovarian cancer.	Antisoma plc

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
917	Mx-dnG1	Rexin-G(R)	6/24/2008	Treatment of soft tissue sarcoma	Epeius Biotechnologies
918	Mx-dnG1	Rexin-G	6/24/2008	Treatment of osteosarcoma.	Epeius Biotechnologies
919	Mx-dnG1 or Rexin-G retroviral vector	Rexin-G	8/15/2003	Treatment of pancreatic cancer	Epeius Biotechnologies
920	Mycobacterium avium sensitin RS-10	n/a	10/11/1995	For use in the diagnosis of invasive Mycobacterium avium disease in immunocompetent individuals.	Statens Seruminstitut
921	N,N'-bis(2-mercaptoethyl)isophthalamide (NBMI)	n/a	4/6/2012	Treatment of mercury toxicity	CTI Science, Inc.
922	N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide	n/a	2/1/2008	Treatment of acute myeloid leukemia	MethylGene
923	N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide	n/a	8/8/2007	Treatment of Hodgkin's lymphoma	MethylGene, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
924	N-(4-Fluoro-benzoyl)-L-arginyl-L-arginyl-[L-3-(naphthyl-alanyl)-L-cysteinyl-L-tyrosyl-L-citrullinyl-L-lysyl-D-lysyl-L-prolyl-L-trosyl-L-arginyl-L-citrullinyl-L-cysteinyl-L-arginine amide, cyclic (4-13)-disulfide	n/a	7/6/2012	For use in combination with G-CSF to mobilize HSCs from the marrow to peripheral blood for collection for autologous or allogeneic transplantation	BioLineRx, Ltd.
925	N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride salt	n/a	3/18/2009	Treatment of acute myeloid leukemia	Ambit Biosciences Corporation
926	N-(cyanomethyl)-4-(2-{{4-(morpholin-4-yl(phenyl)amino}pyrimidin-4-yl)benzamide	n/a	8/5/2010	Treatment of myelofibrosis	Gilead Sciences, Inc.
927	N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole) mesylate	n/a	10/17/2005	Treatment of multiple myeloma.	AB Science
928	N-Acetylmannosamine (ManNAc)	n/a	4/5/2010	Treatment of hereditary inclusion body myopathy type 2	New Zealand Pharmaceuticals Ltd
929	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butrylamino)benzamide	n/a	1/13/2012	Treatment of meningioma	Arno Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
930	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butylamino)benzamide	n/a	1/13/2012	Treatment of Schwannoma of the central nervous system	Arno Therapeutics, Inc.
931	N-[(2S)-2,3-dihydroxypropyl]-3-[[2-fluoro-4-iodophenyl]amino]isonicotinamide hydrochloride	n/a	1/29/2010	Treatment of pancreatic cancer	EMD Serono, Inc.
932	N-[(2S)-2,3-dihydroxypropyl]-3-[[2-fluoro-4-iodophenyl]amino]isonicotinamide hydrochloride	n/a	1/12/2011	Treatment of acute myeloid leukemia (AML).	EMD Serono, Inc.
933	N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide	n/a	9/30/2004	Treatment of neuroblastoma	AbbVie, Inc.
934	N-[3-(4',5'-bipyrimidin-2-ylamino)-4-methylphenyl]-4-[[{(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)benzamide	n/a	12/27/2006	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia.	CytRx Corporation
935	N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea	n/a	10/23/2007	Treatment of acute myelogenous leukemia	AbbVie, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
936	N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl)urea	n/a	5/23/2007	Treatment of hepatocellular carcinoma	AbbVie, Inc.
937	N-[4-(trifluoromethyl)phenyl] 5 methylisoxazole-4-carboxamide	n/a	5/25/1995	Treatment of malignant glioma.	Sugen, Inc.
938	N-[4-(trifluoromethyl)phenyl]-5-methylisoxazole-4-carboxamide	n/a	3/12/1996	Treatment of ovarian cancer.	Sugen, Inc.
939	N-acetyl cysteine amide	n/a	12/31/2013	Treatment of retinitis pigmentosa	Brighton Biotech, Inc.
940	N-acetyl-glucosamine thiazoline	n/a	2/6/2006	Treatment of adult Tay-Sachs disease	ExSAR Corporation
941	N-acetyl-procainamide	n/a	12/10/1996	Prevention of life-threatening ventricular arrhythmias in patients with documented procainamide-induced lupus.	NAPA of the Bahamas
942	N-acetylcysteinate Lysine	Nacystelyn Dry Powder Inhaler	12/27/2000	For the management of cystic fibrosis	Galephar Pharmaceutical
943	N-acetylcysteine	n/a	7/19/2012	Prevention of ototoxicity caused by platinum-based chemotherapeutic agents used to treat pediatric cancers	Edward A. Neuwelt, MD
944	N-acetylcysteine	n/a	9/9/2002	Treatment of acute liver failure	Cumberland Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
945	N-acetylgalactosamine-4-sulfatase, recombinant human	Naglazyme	2/17/1999	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	BioMarin Pharmaceutical, Inc.
946	N-adamantanyl-N'-Geranyl-ethylenediamine	n/a	10/16/2007	Treatment of tuberculosis.	Sequella, Inc.
947	N-methyl-4-({4-[(3-methyl(methylsulfonyl)amino)pyrazin-2-yl)methyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide hydrochloride	n/a	7/18/2013	Treatment of mesothelioma	Verastem, Inc.
948	N-tert-butyl-3-[(5-methyl-2-[[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino]pyrimidin-4-yl)amino]benzenesulfonamide dihydrochloride monohydrate	n/a	3/21/2013	Treatment of polycythemia vera	sanofi-aventis U.S. LLC
949	N-tert-butyl-3-[5-methyl-2-[[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino]pyrimidin-4-yl-amino]benzenesulfonamide dihydrochloride monohydrate	n/a	5/18/2009	Treatment of secondary and primary myelofibrosis	Sanofi-Aventis US, LLC a Sanofi company

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
950	N-{3-[(2-[[4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl]amino]-5-(trifluoromethyl)pyrimidin-4-yl)amino]phenyl}prop-2-enamide	n/a	5/14/2013	Treatment of non-small cell lung cancer and mutations in the epidermal growth factor receptor	Clovis Oncology, Inc.
951	N-[[[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide	n/a	2/4/2011	Treatment of tuberculosis.	Sequella, Inc.
952	N2'-Deacetyl-N2'-[4-methyl-4-(oxobuthyldithio)-1-oxopentyl]-maytansine-chimerized anti-CD138 IgG4 Monoclonal Antibody	n/a	2/27/2008	Treatment of multiple myeloma	Biotest Pharmaceuticals Corporation
953	N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-Maystansine-Conjugated Humanized C242 Monoclonal Antibody	n/a	12/7/2000	For pancreatic cancer	SmithKline Beecham Pharmaceuticals
954	NDX-peptides	n/a	12/14/2010	Treatment of amyotrophic lateral sclerosis	NeoDiagnostic Research Ltd
955	Nafarelin acetate	Synarel Nasal Solution	7/20/1988	Treatment of central precocious puberty.	Syntex (USA), Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
956	Naltrexone HCl	Trexan	3/11/1985	For blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent individuals.	DuPont Pharmaceuticals
957	NanoDTPA(tm)	n/a	6/17/2011	Treatment of known or suspected cases of internal contamination with plutonium, americium, or curium	Nanotherapeutics, Inc.
958	Natural human lymphoblastoid interferon-alpha	n/a	1/18/2000	Treatment of Behcet's disease	Amarillo Biosciences, Inc.
959	Natural human lymphoblastoid interferon-alpha	n/a	8/10/2000	Treatment of papillomavirus warts in the oral cavity of HIV positive patients.	Amarillo Biosciences, Inc.
960	Nebacumab	Centoxin	10/1/1986	Treatment of patients with gram-negative bacteremia which has progressed to endotoxin shock.	Centocor, Inc.
961	Neurotrophin-1	n/a	9/13/1994	Treatment of motor neuron disease/amyotrophic lateral sclerosis.	Ericsson, Arthur Dale, M.D.
962	Neutrophil-endothelial interaction inhibitor	Cylexin	12/22/1993	Treatment of post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension.	Cytel Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
963	Nifedipine	n/a	6/13/1991	Treatment of interstitial cystitis.	Fleischmann, Jonathan M.D.
964	Nikkomyacin Z	n/a	2/14/2006	Treatment of coccidioidomycosis	Valley Fever Center for Excellence (1-111
965	Nimotuzumab	n/a	11/17/2004	Treatment of glioma	InnoKeys PTE Ltd.
966	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of myelodysplastic syndromes requiring therapy	The Vaccine Company
967	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of acute myelogenous leukemia	The Vaccine Company
968	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of chronic myelogenous leukemia.	The Vaccine Company
969	Nitazoxanide	Alinia	12/12/1996	Treatment of cryptosporidiosis.	Romark Laboratories, L.C.
970	Nitisinone	Orfadin	10/19/2001	Treatment of alkaptonuria	Swedish Orphan AB
971	Nitisinone	Orfadin	5/16/1995	Treatment of tyrosinemia type 1.	Swedish Orphan Biovitrum AB (PUBL)
972	Nitric oxide	Inomax	9/27/2004	To reduce the risk of chronic lung disease in premature neonates	INO Therapeutics
973	Nitric oxide	n/a	2/16/2005	Diagnosis of sarcoidosis	SensorMedics Corporation
974	Nitric oxide	n/a	9/11/2013	Treatment of cystic fibrosis	Novoteris, LLC
975	Nitric oxide	n/a	7/10/1995	Treatment of acute respiratory distress syndrome in adults.	INO Therapeutics, Inc.
976	Nitric oxide	Inomax	6/22/1993	Treatment of persistent pulmonary hypertension in the newborn.	INO Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
977	Nitroprusside	n/a	2/21/2001	Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.	Thomas, MD, Jeffrey Evan
978	NorLeu3-Angiotensin(1-7) [NorLeu3-A(1-7)]	n/a	12/31/2013	Treatment of leakage from the surgical site following penetrating keratoplasty	US Biotest, Inc.
979	NorLeu3-Angiotensin(1-7) [NorLeu3-A(1-7)]	n/a	1/31/2014	Treatment of dermal injury due to nuclear/radiation incident	US Biotest, Inc.
980	Nucleic acid aptamer binding to tumor cell nucleolin	n/a	9/10/2009	Treatment of acute myeloid leukemia	Antisoma, Inc.
981	Nucleic acid aptamer binding to tumor cell nucleolin	n/a	8/17/2004	Treatment of pancreatic cancer	Antisoma Research Ltd.
982	Nucleic acid aptamer binding to tumor cell nucleon	n/a	7/28/2005	Treatment of renal cell carcinoma	Antisoma Inc.
983	O-(3-piperidino-2-hydroxyl-1-propyl)-nicotinic acid amidoxime hydrochloride	n/a	1/15/2013	Treatment of Duchenne Muscular Dystrophy	N-Gen Research Laboratories, Inc.
984	O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazene-1,2-diolate	n/a	3/16/2012	Treatment of acute myeloid leukemia	JSK Therapeutics, Inc.
985	O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazene-1,2-diolate	n/a	12/13/2013	Treatment of multiple myeloma	JSK Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
986	Octreotide	Sandostatin Lar	8/24/1998	Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).	Novartis Pharmaceuticals Corporation
987	Octreotide	Sandostatin Lar	8/24/1998	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Novartis Pharmaceuticals Corporation
988	Octreotide	Sandostatin Lar	8/24/1998	Treatment of acromegaly.	Novartis Pharmaceuticals
989	Ofloxacin	Ocuflox Ophthalmic Solution	4/18/1991	Treatment of bacterial corneal ulcers.	Allergan, Inc.
990	Omega-3 (n-3) polyunsaturated fatty acid with all double bonds in the cis configuration	n/a	11/22/1995	Prevention of organ graft rejection.	Research Triangle Pharmaceuticals
991	Omega-3 (n-3) polyunsaturated fatty acids	Omacor	5/4/2000	Treatment of IgA nephropathy.	Pronova Biocare, AS
992	Omegaven emulsion	Omegaven	2/27/2008	Treatment of parenteral nutrition associated liver disease	Fresenius Kabi Deutschland GmbH
993	Oprelvekin	Neumega	12/17/1996	Prevention of severe chemotherapy-induced thrombocytopenia.	Genetics Institute, Inc.
994	Oxaliplatin	n/a	10/6/1992	Treatment of ovarian cancer.	Debio Pharm S.A.
995	Oxalobacter formigenes	n/a	3/29/2006	Treatment of primary hyperoxaluria	OxThera, Inc.
996	Oxandrolone	Oxandrin	9/6/1991	Adjunctive therapy for AIDS patients suffering from HIV-wasting syndrome.	Bio-Technology General Corp.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
997	Oxandrolone	Oxandrin	4/22/1997	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Savient Pharmaceuticals, Inc.
998	Oxymorphone	Numorphan H.P.	3/19/1985	For relief of severe intractable pain in narcotic-tolerant patients.	DuPont Merck Pharmaceutical Company
999	Oxypurinol	n/a	11/9/1998	Treatment of hyperuricemia in patients intolerant to allopurinol.	Cardiome Pharma Corp.
1000	P140K MGMT transduced human CD34 cells	n/a	1/9/2013	For bone marrow protection in the treatment of glioblastoma multiforme	Lentigen Corporation
1001	PEG-glucocerebrosidase	Lysodase	12/9/1992	For use as chronic enzyme replacement therapy in patients with Gaucher's disease who are deficient in glucocerebrosidase.	National Institute of Mental Health, NIH
1002	PEG-interleukin-2	n/a	2/1/1990	Treatment of primary immunodeficiencies associated with T-cell defects.	Chiron Corporation
1003	PEGylated recombinant anti-Pseudomonas aeruginosa PcrV Fab' antibody	n/a	10/25/2013	Treatment of cystic fibrosis patients with Pseudomonas aeruginosa lung infections	KaloBios Pharmaceuticals, Inc.
1004	PG2 (Astragalus polysaccharides extracted and purified from the dry root of Astragalus membranaceus)	n/a	7/5/2012	Treatment of idiopathic thrombocytopenic purpura	EcoPharm Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1005	PGC-C12E-terlipressin	n/a	12/27/2012	Treatment of refractory ascites due to all etiologies except for cancer	PharmaIN Corporation
1006	Paclitaxel	Taxol	3/25/1997	Treatment of AIDS-related Kaposi's sarcoma.	Bristol-Myers Squibb Pharmaceutical Research Institute
1007	Paclitaxel	Paxene	4/15/1997	Treatment of AIDS-related Kaposi's sarcoma.	Baker Norton Pharmaceuticals, Inc.
1008	Paclitaxel protein-bound particles for injection suspension	Abraxane	10/1/2009	Treatment of stage IIb to IV melanoma	Abraxis BioScience, LLC
1009	Pafuramidine maleate	n/a	5/14/2007	Treatment of malaria	Immtech Pharmaceuticals, Inc.
1010	Pafuramidine maleate	n/a	8/31/2007	Treatment of human African trypanosomiasis (sleeping sickness)	Immtech Pharmaceuticals, Inc.
1011	Palifosfamide	n/a	5/5/2008	Treatment of soft tissue sarcomas	ZIOPHARM Oncology, Inc.
1012	Papain, trypsin, and chymotrypsin	Wobe-Mugos	12/21/1998	Treatment of multiple myeloma.	Marlyn Nutraceuticals, Inc.
1013	Parvovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine	Medi-491	5/7/1999	Prevention of transient aplastic crisis in patients with sickle cell anemia.	MedImmune, Inc.
1014	Patul-end	n/a	2/18/1997	Treatment of patulous eustachian tube.	Ear Foundation
1015	Pegademase bovine	Adagen	5/29/1984	For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.	Sigma-tau Pharmaceuticals, Inc.
1016	Pegaspargase	Oncaspar	10/20/1989	Treatment of acute lymphocytic leukemia.	Sigma-tau Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1017	Pegfilgrastim	Neulasta	11/20/2013	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Amgen, Inc.
1018	Peginterferon alfa-2a	Pegasys	9/30/1999	Treatment of chronic myelogenous leukemia.	Hoffman-La Roche Inc.
1019	Peginterferon alfa-2a	Pegasys	7/13/1998	Treatment of renal cell carcinoma.	Hoffman-La Roche Inc.
1020	Pegvisomant	Somavert	6/24/1997	Treatment of acromegaly.	Sensus Corporation
1021	Pegylated arginine deiminase	Melanocid	4/12/1999	Treatment of invasive malignant melanoma.	Polaris Pharmaceuticals, Inc.
1022	Pegylated recombinant human megakaryocyte growth and development factor	Megagen	10/20/1997	For reducing the period of thrombocytopenia in patients undergoing hematopoietic stem cell transplantation.	Amgen, Inc.
1023	Peldesine	n/a	10/5/1993	Treatment of cutaneous T-cell lymphoma.	BioCryst Pharmaceuticals, Inc.
1024	Pentamidine isethionate	Nebupent	1/12/1988	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Fujisawa USA, Inc.
1025	Pentamidine isethionate	n/a	10/29/1984	Treatment of Pneumocystis carinii pneumonia.	Aventis Behring L.L.C.
1026	Pentamidine isethionate	Pentam 300	2/28/1984	Treatment of Pneumocystis carinii pneumonia.	Fujisawa USA, Inc.
1027	Pentamidine isethionate (inhalation)	Pneumopent	10/5/1987	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Fisons Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1028	Pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-D-glucopyranosyl unit, and one alpha-L-fucopyranosyl unit	Cylexin	7/18/1997	Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.	Cytel Corporation
1029	Pentastarch	Pentaspán	8/28/1985	As an adjunct in leukapheresis to improve the harvesting and increase the yield of leukocytes by centrifugal means.	Du Pont Pharmaceuticals
1030	Pentosán polysulfate sodium	Elmiron	8/7/1985	Treatment of interstitial cystitis.	Alza Corporation
1031	Pentostatin	Nipent	1/29/1991	Treatment of patients with chronic lymphocytic leukemia.	SuperGen, Inc.
1032	Pentostatin	Nipent	11/24/1999	Treatment of peripheral T-cell lymphomas.	SuperGen, Inc.
1033	Pentostatin	Nipent	3/27/1998	Treatment of cutaneous T-cell lymphoma.	SuperGen, Inc.
1034	Pentostatin for injection	Nipent	9/10/1987	Treatment of hairy cell leukemia.	SuperGen, Inc.
1035	Peptide 144 TGF beta-1 inhibitor	n/a	4/27/2006	Treatment of systemic sclerosis	Digna Biotech, S.L.
1036	Peptide 144 TGF beta-1-inhibitor	n/a	4/26/2006	Treatment of localized scleroderma	Digna Biotech, S.L.
1037	Peptide that inhibits mechanosensitive ion channel (MSC) activity	n/a	9/15/2010	Treatment of Duchenne Muscular Dystrophy (DMD.)	Rose Pharmaceuticals

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1038	Peptidomimetic analog of hexarelin	n/a	5/14/2007	Diagnosis of growth hormone deficiency	Aeterna Zentaris GmbH
1039	Perflubron	Liquivent	4/26/2001	Treatment of acute respiratory distress disease (ARDS) in adults	Alliance Pharmaceutical Corp.
1040	Phenylacetate	n/a	3/6/1998	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Elan Drug Delivery, Inc.
1041	Phenylalanine ammonia-lyase	Phenylase. Ravpal-Peg	3/8/1995	Treatment of hyperphenylalaninemia	BioMarin Pharmaceutical
1042	Phenylbutyrate	n/a	1/19/2000	Treatment of acute promyelocytic leukemia.	Elan Drug Delivery, Inc.
1043	Phosphatidylinositol 3-Kinase "PI3K" Inhibitor	n/a	11/2/2010	Treatment of chronic lymphocytic leukemia (CLL)	Semafore Pharmaceuticals
1044	Picoplatin	n/a	11/2/2005	Treatment of small cell lung cancer	Poniard Pharmaceuticals
1045	Pilocarpine	Salagen	9/24/1990	Treatment of xerostomia induced by radiation therapy for head and neck cancer.	MGI Pharma, Inc.
1046	Pilocarpine HCl	Salagen	2/28/1992	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	MGI Pharma, Inc.
1047	Plasmid DNA vector expressing cystic fibrosis transmembrane gene	n/a	3/29/2005	Treatment of cystic fibrosis	Copernicus Therapeutics, Inc.
1048	Plitidepsin	Aplidin	9/30/2004	Treatment of multiple myeloma	PharmaMar USA, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1049	Poloxamer 188	n/a	8/5/1997	Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.	CytRx Corporation
1050	Poloxamer 188	n/a	11/8/2013	Treatment of Acute Limb Ischemia	Mast Therapeutics, Inc
1051	Poloxamer 188	Florcor	2/22/1990	Treatment of severe burns requiring hospitalization.	CytRx Corporation
1052	Poloxamer 331	Protox	3/21/1991	Initial therapy of toxoplasmosis in patients with AIDS.	CytRx Corporation
1053	Poly I: poly C12U	Ampligen	12/9/1993	Treatment of invasive metastatic melanoma (stage IIb, III, IV).	Hemispherx Biopharma, Inc.
1054	Poly I: poly C12U	Ampligen	5/20/1991	Treatment of renal cell carcinoma.	Hemispherx Biopharma, Inc.
1055	Poly I: poly C12U	Ampligen	12/9/1993	Treatment of chronic fatigue syndrome.	Hemispherx Biopharma, Inc.
1056	Poly-ICLC	Hiltonol	3/17/1997	Treatment of primary brain tumors.	Oncovir
1057	Polyethylene glycol-modified uricase	n/a	6/6/2005	Treatment of hyperuricemia in patients with gout refractory to conventional therapy or in whom conventional therapy is contraindicated	EnzymeRx, LLC
1058	Polyethylene glycol-modified uricase	Zurase	12/21/1998	Treatment of tumor lysis syndrome in cancer patients undergoing chemotherapy.	EnzymeRx, LLC

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1059	Polyethylene glycol-modified uricase	Zurase	9/14/1999	Prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.	EnzymeRx, LLC
1060	Polymeric oxygen	n/a	3/25/1992	Treatment of sickle cell anemia.	Capmed USA
1061	Polyribonucleotide; Polyribo- inosinic/-cyclidylic/-uridylic acid	Ampligen	7/19/1988	Treatment of AIDS.	Hemispherx Biopharma, Inc.
1062	Polyvalent, shed-antigen melanoma vaccine	n/a	6/9/2006	Treatment of stage IIb to stage IV melanoma	Polynoma LLC
1063	Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue	N-Graft	6/24/1997	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Titan Pharmaceuticals, Inc.
1064	Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation	Neurocell-Pd	12/17/1996	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin/Genzyme LLC
1065	Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared for intracerebral implantation.	Neurocell-Pd	12/17/1996	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin/Genzyme LLC

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1066	Porcine fetal neural gabaergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation	Neurocell-Hd	12/10/1996	Treatment of Huntington's disease.	Diacrin/Genzyme LLC
1067	Porcine fetal neural gabaergic cells and/or precursors aseptically prepared for intracerebral implantation for Huntington's disease.	Neurocell-Hd	12/10/1996	Treatment of Huntington's disease.	Diacrin/Genzyme LLC
1068	Porfimer sodium	Photofrin	11/18/2004	Treatment of cholangiocarcinoma	Pinnacle Biologics, Inc.
1069	Porfimer sodium	Photofrin	11/15/1989	For the photodynamic therapy of patients with transitional cell carcinoma in situ of the urinary bladder.	QLT Phototherapeutics, Inc.
1070	Porfimer sodium	Photofrin	6/6/1989	For the photodynamic therapy of patients with primary or recurrent obstructing (either partially or completely) esophageal carcinoma.	QLT Phototherapeutics, Inc.
1071	Porfiromycin	Promycin	9/19/1995	Treatment of head and neck cancer.	Boehringer Ingelheim Pharmaceuticals, Inc.
1072	Porfiromycin	Promycin	3/13/1997	Treatment of cervical cancer.	Boehringer Ingelheim Pharmaceuticals, Inc.
1073	Posaconazole	Posoril	7/16/2004	Treatment of zygomycosis	Schering-Plough Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1074	Potassium Iodide Oral Solution	Thyroshield	11/17/2004	For use as a thyroid blocking agent in pediatric patients exposed to radioactive iodine	Fleming & Company, Pharmaceuticals
1075	Potassium citrate	Urocit-K	11/1/1984	For avoidance of the complication of calcium stone formation in patients with uric lithiasis.	University of Texas Health Science Center at Dallas
1076	Potassium citrate	Urocit-K	11/1/1984	Prevention of uric acid nephrolithiasis.	University of Texas Health Science Center at Dallas
1077	Potassium citrate	Urocit-K	11/1/1984	Prevention of calcium renal stones in patients with hypocitraturia.	University of Texas Health Science Center at Dallas
1078	Primaquine phosphate	n/a	7/23/1993	For use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS.	Sanofi Winthrop, Inc.
1079	Procarbazine HCl	Matulane	8/8/2006	Treatment of malignant glioma	Sigma-Tau Pharmaceuticals, Inc.
1080	Prostaglandin E1 enol ester (AS-013)	Circulase	6/12/1998	Treatment of Fontaine Stage IV chronic critical limb ischemia.	LTT Baio-Pharma Co., Ltd
1081	Protaxel	n/a	5/21/2003	Treatment of ovarian cancer	Biophysica, Inc.
1082	Protein C concentrate	Ceprotrin	6/23/1992	For replacement therapy in congenital protein C deficiency for the prevention and treatment of thrombosis, pulmonary emboli, and purpura fulminans.	Baxter Healthcare Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1083	Protein C concentrate	Protein C Concentrate (Human) Vapor Heated, Immuno	6/19/1992	For replacement therapy in patients with congenital or acquired protein C deficiency for the prevention and treatment of warfarin-induced skin necrosis during oral anticoagulation.	Immuno Clinical Research Corp.
1084	Pulmonary surfactant replacement, porcine	Curosurf	8/2/1993	For the treatment and prevention of respiratory distress syndrome in premature infants.	Dey Laboratories
1085	Purified extract of Pseudomonas aeruginosa	Immudyn	9/22/1997	Treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.	Able Laboratories, Inc.
1086	Purified type II collagen	Colloral	2/9/1995	Treatment of juvenile rheumatoid arthritis.	AutoImmune, Inc.
1087	Pyruvate	n/a	2/21/2001	Treatment of interstitial lung disease.	Cellular Sciences, Inc
1088	R-(-)-gossypol	n/a	10/24/2006	Treatment of chronic lymphocytic leukemia.	Ascenta Therapeutics, Inc.
1089	R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1H-1,4-benzodiazepine-3-yl]-3-(3-methylaminophenyl)urea	n/a	9/10/2009	Treatment of gastric carcinoids	Trio Medicines Ltd.
1090	R-4-amino-3-(4-chlorophenyl)butanoic acid	n/a	11/28/2008	Treatment of the behavioral abnormalities associated with fragile X syndrome	Seaside Therapeutics, Inc.
1091	REMUNE HIV 1	n/a	2/14/2014	Treatment of pediatric HIV/AIDS (age through 16 years)	Immune Response BioPharma, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1092	RII retinamide	n/a	5/6/1993	Treatment of myelodysplastic syndromes.	Sparta Pharmaceuticals, Inc.
1093	Rabbit anti-human thymocyte globulin (rATG)	Thymoglobulin	9/26/2006	Induction treatment to prevent rejection and to minimize maintenance immunosuppression in pediatric liver transplant recipients	Children's Hospital of Pittsburgh
1094	Raloxifene	Evista	7/14/2005	Reduction of the risk of breast cancer in postmenopausal women	Eli Lilly and Company
1095	Ramucirumab; rHuman MAb to VEGFR-2	n/a	11/4/2011	Treatment of hepatocellular carcinoma.	ImClone Systems LLC
1096	Rapamycin	n/a	3/20/2007	Treatment of tuberous sclerosis complex	Oncolmmune, Inc.
1097	Re188 P2045 somatostatin analog	n/a	2/6/2014	Treatment of small cell lung cancer	Andarix Pharmaceuticals
1098	Recombinant Epstein-Barr virus gp350 glycoprotein vaccine	n/a	8/18/2005	Prevention of post-transplantation lymphoproliferative disorders in pediatric recipients of solid-organ transplantation	Henogen S.A.
1099	Recombinant Fusion Protein	n/a	7/24/2012	Treatment of Myelodysplastic Syndrome	Apogenix GmbH
1100	Recombinant Human Alpha-Fetoprotein (rhAFP)	n/a	2/22/2001	Treatment of myasthenia gravis	Merrimack Pharmaceuticals, Inc.
1101	Recombinant Human Factor VIIa Variant	n/a	11/30/2012	Routine prophylaxis to prevent bleeding episodes in patients with hemophilia A and B patients with inhibitors	Pfizer, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1102	Recombinant Human Interleukin-21 (rIL-21)	n/a	10/4/2005	Treatment of stage II (T4), III or IV malignant melanoma.	Zymo Genetics, Inc
1103	Recombinant Human soluble Fc-gamma Receptor IIb	n/a	3/22/2010	Treatment of idiopathic thrombocytopenic purpura	SuppreMol GmbH
1104	Recombinant P-Selectin glycoprotein ligand	n/a	3/29/2006	Prevention of delayed graft function in renal transplant patients	Y's Therapeutics, Inc.
1105	Recombinant P-selectin glycoprotein ligand-immunoglobulin Ig	n/a	7/26/2007	Prevention of ischemia reperfusion injury in all solid organ transplants	Y's Therapeutics, Inc.
1106	Recombinant Porcine Factor VIII, B-domain Deleted	n/a	3/16/2004	Treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor VIII	Baxter Healthcare Corporation, Baxter BioScience
1107	Recombinant T-cell receptor ligand	n/a	5/2/2003	Treatment of multiple sclerosis patients who are both HLA-DR2 positive and autoreactive to myelin oligodendrocyte glycoprotein residues 35-55	Artielle ImmunoTherapeutics, Inc.
1108	Recombinant adeno-associated virus (serotype 2) (rAAV2) gene transfer agent expressing RPE65	n/a	5/11/2009	Treatment of Leber's congenital amaurosis	AmpliPhi Biosciences Corporation
1109	Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2	n/a	6/24/2008	Treatment of Leber congenital amaurosis due to RPE65 mutations.	Center for Cellular & Molecular Therapeutics
1110	Recombinant antibody construct against human CD30 and CD16A	n/a	8/20/2009	Treatment of Hodgkin lymphoma	Affimed Therapeutics AG

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1111	Recombinant coagulation factor VIIa	Novoseven	4/26/2006	Treatment of diffuse alveolar hemorrhage	PharmaOrigin ApS
1112	Recombinant derivative of C3 transferase	Cethrin(TM)	11/18/2005	Treatment of acute spinal cord injury.	BioAxone BioSciences, Inc.
1113	Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	n/a	7/29/2008	Prevention of thrombotic thrombocytopenic purpura including its congenital, acquired idiopathic and secondary forms.	Baxter Healthcare Corporation
1114	Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	n/a	7/29/2008	Treatment of thrombotic thrombocytopenic purpura including its congenital, acquired idiopathic, and secondary forms.	Baxter Healthcare Corporation
1115	Recombinant fully human monoclonal antibody to anthrax protective antigen	Valortim	2/16/2006	Treatment of anthrax infection	PharmAthene, Inc.
1116	Recombinant fusion protein of Mycobacterium bovis BCG Hsp65 and HPV16 E7	n/a	3/19/2001	Treatment of recurrent respiratory papillomatosis (RRP)	StressGen Biotechnologies, Inc. is now Nventa
1117	Recombinant fusion protein-extracellular portion of CD95 fused to the Fc part of human IgG1	n/a	10/13/2009	Treatment of glioblastoma multiforme	Apogenix GmbH
1118	Recombinant human C1 inhibitor	n/a	6/9/2006	Prevention and/or treatment of delayed graft function after solid organ transplantation	Pharming Group N.V.
1119	Recombinant human C1 inhibitor	n/a	6/9/2006	Treatment of capillary leakage syndrome	Pharming Technologies B.V.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1120	Recombinant human C1-esterase inhibitor	n/a	2/23/1999	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V.
1121	Recombinant human C1-esterase inhibitor	n/a	2/23/1999	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V.
1122	Recombinant human CD4 immunoglobulin G	n/a	8/30/1990	Treatment of AIDS resulting from infection with HIV-1.	Genentech, Inc.
1123	Recombinant human Clara Cell 10kDa protein	n/a	7/13/1998	Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.	Clarassance, Inc.
1124	Recombinant human acid alpha-glucosidase	1. Myozyme 2.Lumizyme	8/19/1997	Treatment of glycogen storage disease type II.	Genzyme Corporation
1125	Recombinant human alpha 1-antitrypsin	n/a	4/28/2005	Prevention of bronchopulmonary dysplasia	Arriva Pharmaceuticals, Inc.
1126	Recombinant human alpha-mannosidase	n/a	2/2/2006	Treatment of alpha-mannosidosis	Zymenex A/S
1127	Recombinant human antithrombin III	n/a	4/6/2000	Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.	AT III LLC
1128	Recombinant human endostatin protein	n/a	8/13/2001	Treatment of neuroendocrine tumors	EntreMed, Inc.
1129	Recombinant human fibrinogen	n/a	10/4/2007	Treatment of bleeding in patients deficient in fibrinogen	Pharming Technologies B.V.
1130	Recombinant human gelsolin	n/a	1/12/1994	Treatment of the respiratory symptoms of cystic fibrosis.	BioAegis Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1131	Recombinant human gelsolin	n/a	3/6/1995	Treatment of acute and chronic respiratory symptoms of bronchiectasis.	BioAgeis, Therapeutics, Inc.
1132	Recombinant human glutamic acid decarboxylase 65KDa isoform	n/a	3/22/2010	Treatment of Type I diabetes with residual beta cell function	Diamyd Therapeutics AB
1133	Recombinant human granulocyte colony stimulating factor	n/a	7/24/2006	Prevention of implantation failure	Nora Therapeutics, Inc.
1134	Recombinant human highly phosphorylated acid alpha-glucosidase	Tbd	9/20/2000	For enzyme replacement therapy in patients with all subtypes of glycogen storage disease type II (GSDII, Pompe Disease)	Novazyme Pharmaceuticals, Inc.
1135	Recombinant human highly phosphorylated alpha-L-iduronidase (rhHP-IDUA)	n/a	4/11/2001	Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.	Novazyme Pharmaceuticals, Inc.
1136	Recombinant human insulin-like growth factor-I	Pv802	2/16/2000	Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.	GroPep Pty Ltd.
1137	Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3	n/a	6/15/1999	Treatment of major burns that require hospitalization.	Insmed, Inc.
1138	Recombinant human interleukin-12	n/a	10/20/1997	Treatment of renal cell carcinoma.	Genetics Institute, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1139	Recombinant human keratinocyte growth factor	n/a	12/20/1999	Reducing the incidence and severity of radiation-induced xerostomia.	Amgen Inc.
1140	Recombinant human luteinizing hormone	Luveris	10/7/1994	For use in association with recombinant human follicle stimulating hormone for the treatment of women with chronic anovulation due to hypogonadotropic hypogonadism.	EMD Serono, Inc.
1141	Recombinant human lysosomal acid lipase or cholesteryl ester hydrolase	Cholestrase	7/14/2005	Treatment of lipase deficiencies, including Wolman Disease and cholesteryl ester storage disease	Lysosomal Acid Lipase, LLC
1142	Recombinant human microplasmin	n/a	1/23/2006	Treatment of peripheral arterial occlusion	ThromboGenics Ltd
1143	Recombinant human nerve growth factor	n/a	4/16/1999	Treatment of HIV-associated sensory neuropathy.	Genentech, Inc.
1144	Recombinant human platelet derived growth factor BB	n/a	2/1/2007	Treatment of osteonecrosis of the jaws	Luitpold Pharmaceuticals, Inc.
1145	Recombinant human thrombopoietin	n/a	9/29/1997	For use in accelerating platelet recovery in patients undergoing hematopoietic stem cell transplantation.	Genentech, Inc.
1146	Recombinant humanized MAb 5c8	n/a	3/22/1999	Prevention of rejection of pancreatic islet cell transplants.	Biogen, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1147	Recombinant humanized MAb 5c8	n/a	10/14/1998	Prevention and treatment of Factor VIII/Factor IX inhibitors in patients with hemophilia A or B.	Biogen, Inc.
1148	Recombinant humanized MAb 5c8	n/a	3/22/1999	Prevention of rejection of solid organ transplants.	Biogen, Inc.
1149	Recombinant humanized anti-LOXL2 monoclonal antibody	n/a	4/18/2011	Treatment of idiopathic pulmonary fibrosis	Gilead Sciences, Inc.
1150	Recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)	n/a	6/1/2011	Treatment of myelofibrosis.	Gilead Sciences, Inc.
1151	Recombinant humanized monoclonal antibody 5c8	n/a	2/3/1998	Treatment of immune thrombocytopenic purpura.	Biogen, Inc.
1152	Recombinant humanized monoclonal antibody 5c8	n/a	2/18/1998	Treatment of systemic lupus erythematosus.	Biogen, Inc.
1153	Recombinant humanized monoclonal antibody directed against an epidermal growth factor receptor	n/a	2/17/2012	Treatment of glioblastoma multiforme (GBM).	AbbVie, Inc.
1154	Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin	n/a	2/11/2002	Treatment of malignant mesothelioma	National Institutes of Health

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1155	Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin	n/a	2/11/2002	Treatment of epithelial ovarian cancer	National Institutes of Health
1156	Recombinant methionyl brain-derived neurotrophic factor	n/a	11/28/1994	Treatment of amyotrophic lateral sclerosis.	Amgen, Inc.
1157	Recombinant replication deficient adenovirus vector carrying human p53 gene	n/a	4/12/1999	Treatment of primary ovarian cancer.	Schering Corporation
1158	Recombinant retroviral vector - glucocerebrosidase	n/a	11/15/1993	For use as enzyme replacement therapy for patients with types I, II, or III Gaucher disease.	Genetic Therapy, Inc.
1159	Recombinant secretory leucocyte protease inhibitor	n/a	3/29/1991	Treatment of cystic fibrosis.	Amgen, Inc.
1160	Recombinant soluble human CD4 (rCD4)	n/a	3/23/1989	Treatment of AIDS in patients infected with HIV virus.	Genentech, Inc.
1161	Recombinant truncated SPINT2 protease inhibitor	n/a	6/24/2005	Treatment of cystic fibrosis	Aerovance, Inc.
1162	Recombinant urate oxidase	n/a	10/11/2000	Prophylaxis of chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research
1163	Reduced L-glutathione	Cachexon	2/14/1994	Treatment of AIDS-associated cachexia.	Telluride Pharmaceutical

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1164	Replication defective recombinant adenovirus serotype 5 vector carrying the p53 gene in its E1 deleted region	Advexin	1/27/2003	Treatment of head and neck cancer	Introgen Therapeutics, Inc.
1165	Replication-incompetent GM-CSF-expressing gene-modified allogeneic acute myeloid leukemia cancer cell lines	Gvax Acute Myeloid Leukemia	3/2/2010	Treatment of acute myeloid leukemia	Aduro BioTech, Inc.
1166	Replication-incompetent GM-CSF-expressing gene-modified allogeneic chronic myeloid leukemia cancer cell lines	Gvax Chronic Myeloid Leukemia	4/30/2010	Treatment of chronic myeloid leukemia	Aduro BioTech, Inc.
1167	Replication-incompetent GM-CSF-expressing gene-modified allogeneic pancreatic cancer cell lines	Gvax Pancreas	3/1/2010	Treatment of pancreatic cancer.	Aduro BioTech, Inc.
1168	Respiratory Syncytial Virus Immune Globulin (human)	Hyperimmune Rsv	9/27/1990	Treatment of respiratory syncytial virus lower respiratory tract infections in hospitalized infants and young children.	MedImmune, Inc.
1169	Respiratory syncytial virus immune globulin (Human)	Respigam	9/27/1990	Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.	MedImmune & Massachusetts Public Health Biologics Labs.
1170	Reversal agent linked to chloroquine-like moiety	n/a	3/26/2010	Treatment of malaria	DesignMedix

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1171	Revimmune	n/a	2/18/2011	Treatment of autoimmune hemolytic anemia.	Accentia Biopharmaceuticals
1172	Reviparin sodium	Clivarine	6/18/2001	Long-term treatment of acute deep vein thrombosis with or without pulmonary embolism in pregnant patients	Abbott
1173	Reviparin sodium	Clivarine	6/18/2001	Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients	Abbott
1174	Rho (D) immune globulin intravenous (human)	Winrho Sd	11/9/1993	Treatment of immune thrombocytopenic purpura.	Rh Pharmaceuticals, Inc.
1175	Ricin (blocked) conjugated murine MCA (anti-B4)	n/a	11/17/1988	Treatment of B-cell leukemia and B-cell lymphoma.	ImmunoGen, Inc.
1176	Ricin (blocked) conjugated murine MCA (anti-my9)	n/a	8/3/1989	Treatment of myeloid leukemia, including AML, and blast crisis of CML.	ImmunoGen, Inc.
1177	Ricin (blocked) conjugated murine MCA (anti-my9)	n/a	2/1/1990	For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia.	ImmunoGen, Inc.
1178	Ricin (blocked) conjugated murine MCA (n901)	n/a	1/25/1991	Treatment of small cell lung cancer	ImmunoGen, Inc.
1179	Ricin (blocked) conjugated murine mca (anti-b4)	n/a	1/24/1991	For the ex-vivo purging of leukemic cells from the bone marrow of non-T cell acute lymphocytic leukemia patients who are in complete remission.	ImmunoGen, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1180	Ricin (blocked) conjugated murine monoclonal antibody (CD6)	n/a	9/6/1994	Treatment of cutaneous T-cell lymphomas, acute T-cell leukemia-lymphoma, and related mature T-cell malignancies.	ImmunoGen, Inc.
1181	Rifabutin	n/a	12/18/1989	Treatment of disseminated Mycobacterium avium complex disease.	Pfizer, Inc.
1182	Rifabutin	Mycobutin	12/18/1989	Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.	Adria Laboratories, Inc.
1183	Rifalazil	n/a	4/13/1999	Treatment of pulmonary tuberculosis.	PathoGenesis Corporation
1184	Rifampin	Rifadin I.V.	12/9/1985	For antituberculosis treatment where use of the oral form of the drug is not feasible.	Hoechst Marion Roussel
1185	Rifampin, isoniazid, pyrazinamide	Rifater	9/12/1985	For the short-course treatment of tuberculosis.	Hoechst Marion Roussel
1186	Rifapentine	Priftin	6/9/1995	Treatment of pulmonary tuberculosis.	Hoechst Marion Roussel
1187	Rifapentine	Priftin	6/9/1995	Treatment of Mycobacterium avium complex in patients with AIDS.	Hoechst Marion Roussel , Inc.
1188	Rifapentine	Priftin	3/12/1996	Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.	Hoechst Marion Roussel, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1189	Rilonacept	Arcalyst	12/20/2004	Treatment of CIAS1-Associated Periodic Syndromes	Regeneron Pharmaceuticals, Inc.
1190	Riluzole	Rilutek	10/15/1996	Treatment of Huntington's disease.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.
1191	Riluzole	Rilutek	3/16/1993	Treatment of amyotrophic lateral sclerosis.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.
1192	Rose Bengal Disodium	n/a	12/20/2006	Treatment of metastatic melanoma	Provectus Pharmaceuticals, Inc.
1193	S(-)-3-[3-amino-phthalimido]-glutaramide	n/a	3/14/2002	Treatment of multiple myeloma	EntreMed Incorporated
1194	S-59 treated FFP (plasma treated with amotosalen hydrochloride & ultraviolet A light	Intercept Blood System For	2/14/2011	Treatment of thrombotic thrombocytopenic purpura	Cerus Corporation
1195	S-[2,3-bispalmitoyloxy-(2R)-propyl]-cysteinyl-GNNDSESNISFKEK	n/a	10/20/2009	Treatment of pancreatic cancer	MBiotec GmbH
1196	S-adenosylmethionine	n/a	4/30/1998	Treatment of AIDS-myelopathy.	Genopia USA, Inc.
1197	S-nitroglutathione	n/a	5/12/2009	Management of cystic fibrosis patients to improve airway clearance and to improve or stabilize pulmonary function	N30 PHARMAceuticals, LLC
1198	S-nitrosoglutathione	n/a	12/28/2012	Treatment of severe pre-eclampsia	Salupont Consulting Ltd
1199	SC-1 monoclonal antibody	n/a	11/12/2003	Treatment of patients with CD55 (sc-1) positive gastric tumors	Patrys Limited
1200	SDF-1 (108) Lysine Dimer	n/a	7/7/2005	Treatment of osteogenic sarcoma	Chemokine Therapeutics

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1201	Sacrosidase	Sucraid	12/10/1993	Treatment of congenital sucrase-isomaltase deficiency	QOL Medical, LLC
1202	Sar9, Met(O2)11-Substance P	Homspera	3/16/2011	Treatment of idiopathic pulmonary fibrosis	ImmuneRegen BioSciences, Inc.
1203	Sargramostim	Leukine	3/6/1995	To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.	Immunex Corporation
1204	Sargramostim	Leukine	5/3/1990	Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.	Immunex Corporation
1205	Satumomab pendetide	Oncoscint Cr/Ov	9/25/1989	Detection of ovarian carcinoma.	Cytogen Corporation
1206	Secalciferol	Osteo-D	7/26/1993	Treatment of familial hypophosphatemic rickets.	Teva Pharmaceuticals USA
1207	Secretory leukocyte protease inhibitor	n/a	6/30/1992	Treatment of bronchopulmonary dysplasia.	Synergen, Inc.
1208	Selective inhibitor of polymorphonuclear leukocyte (PMN) elastase	n/a	6/4/1996	Therapeutic management of patients with lung disease attributable to cystic fibrosis.	DuPont Pharmaceuticals Company

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1209	Selegiline HCl	Eldepryl	11/7/1984	As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism.	Somerset Pharmaceuticals, Inc.
1210	Seneca Valley virus	n/a	8/22/2008	Treatment of neuroendocrine tumors	Neotropix, Inc.
1211	Sermorelin acetate	Geref	9/14/1988	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	EMD Serono, Inc.
1212	Serratia marcescens extract (polyribosomes)	Imuvert	9/7/1988	Treatment of primary brain malignancies.	Cell Technology, Inc.
1213	Short chain fatty acid enema	Colomed	8/19/1997	Treatment of chronic radiation proctitis.	Richard I. Breuer, M.D.
1214	Short chain fatty acid solution	Colomed	5/29/1990	Treatment of the active phase of ulcerative colitis with involvement restricted to the left side of the colon.	Richard I. Breuer
1215	Silibinin-C-2',3-dihydrogensuccinate, disodium salt	Legalon Sil	2/17/2012	Prevention of recurrent hepatitis C in liver transplant patients	Rottapharm S.p.A.
1216	Silver sulfadiazine and cerium nitrate	Flammacerium	11/17/1999	Treatment of patients with severe dermal burns	Sinclair Pharmaceuticals Ltd
1217	Siponimod	n/a	11/26/2013	Treatment of polymyositis	Novartis Pharmaceuticals

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1218	Sitaxsentan Sodium	n/a	11/2/2004	For the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure.	Pfizer Global Research and Development
1219	Sodium Monomercaptoundecahydro-closo-dodecaborate	Borocell	4/15/1992	For use in boron neutron capture therapy (BNCT) in the treatment of glioblastoma multiforme.	Neutron Technology Corp.& Neutron R&D Partner
1220	Sodium Thiosulfate	n/a	2/16/2012	Treatment of uremic and non-uremic calciphylaxis	Luitpold Pharmaceuticals, Inc.
1221	Sodium aluminosilicate	n/a	3/4/2005	Treatment of chronic hepatic encephalopathy	Framework Therapeutics, LLC
1222	Sodium ascorbate and menadione sodium bisulfite	Apatone	7/31/2007	Treatment of metastatic or locally advanced inoperable transitional cell carcinoma of the urothelium (stage III and IV bladder cancer)	IC-MedTech Corporation
1223	Sodium dichloroacetate	n/a	6/11/1990	Treatment of homozygous familial hypercholesterolemia.	Stacpoole, Peter W. M.D., Ph.D.
1224	Sodium dichloroacetate	n/a	6/11/1990	Treatment of congenital lactic acidosis	Stacpoole, Peter W. M.D., Ph.D.
1225	Sodium dichloroacetate	n/a	11/10/1994	Treatment of lactic acidosis in patients with severe malaria.	Stacpoole, Peter W. M.D., Ph.D.
1226	Sodium nitrite	n/a	4/18/2007	Treatment of cyanide poisoning	Hope Pharmaceuticals
1227	Sodium nitrite	n/a	1/17/2007	Prevention of vasospasm associated with subarachnoid hemorrhage	Hope Pharmaceuticals

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1228	Sodium nitrite	n/a	4/2/2007	Treatment of vaso-occlusive crisis associated with sickle cell disease	Hope Pharmaceuticals
1229	Sodium nitrite/sodium thiosulfate	Cyanide Antidote Package	3/23/2007	Treatment of cyanide poisoning	Keystone Pharmaceuticals, Inc.
1230	Sodium phenylacetate/sodium benzoate 10%/10% Injection	Ammonul(R)	6/3/2005	Treatment of grade III and IV hepatic encephalopathy	Ucyclyd Pharma, Inc.
1231	Sodium phenylbutyrate	n/a	4/24/1998	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Elan Drug Delivery, Inc.
1232	Sodium phenylbutyrate	n/a	3/20/2007	Treatment of spinal muscular atrophy	Tikvah Therapeutics, Inc.
1233	Sodium phenylbutyrate	Buphenyl	1/25/2007	Treatment of spinal muscular atrophy	OrphaMed, Inc.
1234	Sodium pyruvate	n/a	3/31/2003	Treatment of cystic fibrosis	Cellular Sciences, Inc.
1235	Sodium stibogluconate	n/a	6/16/2006	Treatment of cutaneous leishmaniasis	VioQuest Pharmaceuticals, Inc.
1236	Sodium tetradecyl sulfate	Sotradecol	6/10/1986	Treatment of bleeding esophageal varices.	Elkins-Sinn, Inc.
1237	Sodium thiosulfate	n/a	3/17/2004	Prevention of platinum-induced ototoxicity in pediatric patients	Adherex Technologies, Inc.
1238	Sodium thiosulfate and sodium nitrite	n/a	12/18/2006	Treatment of cyanide poisoning	Akorn, Inc.
1239	Sodium thiosulfate, sodium nitrite, amyl nitrite	Cyanide Antidote Package	6/16/2006	Treatment of cyanide poisoning	Keystone Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1240	Solasonine and solamargine	Coramsine	2/6/2006	Treatment of high risk stage II, stage III and stage IV melanoma	Solbec Pharmaceuticals Limited
1241	Solasonine and solamargine	Coramsine	11/2/2005	Treatment of renal cell carcinoma	Solbec Pharmaceuticals
1242	Soluble complement receptor type 1	n/a	3/6/2000	Prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass.	Avant Immunotherapeutics, Inc.
1243	Soluble recombinant human complement receptor type 1	n/a	11/21/1994	Prevention or reduction of adult respiratory distress syndrome.	T Cell Sciences, Inc.
1244	Somatostatin	n/a	12/22/1994	Treatment of bleeding esophageal varices.	Eumedita Pharmaceuticals A.G. (Schweiz)
1245	Somatostatin	Zecnil	6/20/1988	Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.	Ferring Laboratories, Inc.
1246	Somatrem for injection	Protropin	12/9/1985	For long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc.
1247	Somatrem for injection	Protropin	12/9/1985	Treatment of short stature associated with Turner's syndrome.	Genentech, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1248	Somatropin	Nutropin	3/6/1987	For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc.
1249	Somatropin	Serostim	3/16/2004	Treatment of patients with HIV-associated adipose redistribution syndrome	EMD Serono, Inc.
1250	Somatropin	Norditropin	8/9/2006	Treatment of short stature in patients with Noonan syndrome	Novo Nordisk Inc.
1251	Somatropin	Genotropin	9/6/1994	Treatment of adults with growth hormone deficiency.	Pharmacia & Upjohn
1252	Somatropin	Humatrope	5/8/1990	Treatment of short stature associated with Turner syndrome.	Eli Lilly and Company
1253	Somatropin	Humatrope	12/15/2005	Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency	Eli Lilly and Company
1254	Somatropin (rDNA)	Saizen	5/3/1989	For the enhancement of nitrogen retention in hospitalized patients suffering from severe burns.	EMD Serono, Inc.
1255	Somatropin (r-DNA)	Zorbtive	3/6/1995	For use alone or in combination with glutamine in the treatment of short bowel syndrome.	EMD Serono, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1256	Somatropin (r-DNA) for injection	Serostim	3/26/1996	Treatment of children with AIDS-associated failure-to-thrive including AIDS-associated wasting.	EMD Serono, Inc.
1257	Somatropin (rDNA origin)	Saizen	3/6/1987	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	EMD Serono, Inc.
1258	Somatropin (rDNA origin)	Nutropin Depot	10/28/1999	Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc.
1259	Somatropin (rDNA origin) injection	Norditropin	7/10/1987	Treatment of growth failure in children due to inadequate growth hormone secretion.	Novo Nordisk Pharmaceuticals
1260	Somatropin [rDNA]	Genotropin	7/6/1999	Treatment of short stature in patients with Prader-Willi syndrome.	Pharmacia & Upjohn
1261	Somatropin for injection	Serostim	11/15/1991	Treatment of AIDS-associated catabolism/weight loss.	EMD Serono, Inc.
1262	Somatropin for injection	Nutropin	8/4/1989	Treatment of growth retardation associated with chronic renal failure.	Genentech, Inc.
1263	Somatropin for injection	Nutropin	3/23/1989	Treatment of short stature associated with Turner's syndrome.	Genentech, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1264	Somatropin for injection	Humatrope	6/12/1986	For the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.	Eli Lilly and Company
1265	Somatropin for injection	Nutropin	11/18/1996	As replacement therapy for growth hormone deficiency in adults after epiphyseal closure.	Genentech, Inc.
1266	Sorafenib	Nexavar	10/8/2004	Treatment of renal cell carcinoma.	Bayer Pharmaceutical Corporation
1267	Sorafenib	Nexavar	4/20/2006	Treatment of hepatocellular carcinoma	Bayer Pharmaceuticals
1268	Sorafenib	Nexavar	9/29/2006	Treatment of stage IIB through stage IV melanoma	Bayer Pharmaceuticals
1269	Sotalol HCl	Betapace	9/23/1988	Treatment of life-threatening ventricular tachyarrhythmias.	Berlex Laboratories, Inc.
1270	Staphylococcus aureus Immune Globulin (Human)	Altastaph	1/29/2004	Prophylaxis against Staphylococcus aureus infections in low birth weight neonates	Biotest Pharmaceuticals Corporation
1271	Stem and progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood	Stemex	3/4/2005	For use as hematopoietic support in patients with relapsed or refractory hematologic malignancies who are receiving high-dose therapy	Gamida Cell Ltd - Teva Joint Venture

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1272	Sterile Bicarbonate Infusate, Hemofiltration, Hemodiafiltration, and Hemodialysis Solution	Accusol	5/29/2009	For use as a replacement solution in adults and children during Continuous Renal Replacement Therapy	Baxter Healthcare Corporation
1273	Sterile talc	Steritalc	12/8/1997	Treatment of malignant pleural effusion.	Novatech SA
1274	Sterile talc	Steritalc	12/8/1997	Treatment of pneumothorax.	Novatech SA
1275	Sterile talc powder	Sclerosol Intrapleural Aerosol	9/18/1995	Treatment of malignant pleural effusion.	Bryan Corporation
1276	Succimer	Chemet	11/5/1990	Prevention of cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development.	Sanofi Winthrop, Inc.
1277	Succimer	Chemet Capsules	5/9/1984	Treatment of lead poisoning in children.	Bock Pharmacal Company
1278	Succimer	Chemet	3/22/1991	Treatment of mercury intoxication.	Sanofi Winthrop, Inc.
1279	Sucralfate suspension	n/a	3/4/1991	Treatment of oral ulcerations and dysphagia in patients with epidermolysis bullosa.	Darby Pharmaceuticals, Inc.
1280	Sucralfate suspension	n/a	3/12/1990	Treatment of oral complications of chemotherapy in bone marrow transplant patients.	Darby Pharmaceuticals, Inc.
1281	Sulfadiazine	n/a	3/14/1994	For use in combination with pyrimethamine for the treatment of Toxoplasma gondii encephalitis in patients with and without AIDS.	Eon Labs Manufacturing, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1282	Sulfapyridine	n/a	9/10/1990	Treatment of dermatitis herpetiformis.	Jacobus Pharmaceutical
1283	Superoxide dismutase (human)	n/a	3/6/1985	For protection of donor organ tissue from damage or injury mediated by oxygen-derived free radicals that are generated during the necessary periods of ischemia (hypoxia, anoxia), and especially reperfusion, associated with the operative procedure.	Pharmacia-Chiron Partnership
1284	Suramin	Metaret	5/6/1997	Treatment of hormone-refractory prostate cancer.	Warner-Lambert Company
1285	Surface active extract of saline lavage of bovine lungs	Infasurf	6/7/1985	Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.	ONY, Inc.
1286	Synsorb Pk	n/a	7/17/1995	Treatment of verocytotoxogenic E. coli infections.	Synsorb Biotech Inc.
1287	Synthetic derivative of 16-hydroxy-9Z, 12Z, 14E-octadecatrienoic acid	Drepanol	10/24/1991	Prophylactic treatment of sickle cell disease.	Omex International, Inc.
1288	Synthetic double-stranded siRNA oligonucleotide against caspase 2 mRNA	n/a	9/25/2012	Treatment of ischemic optic neuropathy	Quark Pharmaceuticals, Inc.
1289	Synthetic human secretin	Chirostim	6/16/1999	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1290	Synthetic human secretin	n/a	9/18/2006	For use in conjunction with diagnostic procedures (excluding ERCP) for pancreatic disorders to increase pancreatic fluid secretion	Repligen Corporation
1291	Synthetic human secretin	n/a	6/16/1999	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc.
1292	Synthetic human secretin	n/a	6/16/1999	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc.
1293	Synthetic human secretin	n/a	3/7/2000	For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc.
1294	Synthetic porcine secretin	n/a	6/18/1999	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc.
1295	Synthetic porcine secretin	Secreflo	6/18/1999	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1296	Synthetic porcine secretin	Secreflo	3/7/2000	For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc.
1297	Synthetic porcine secretin	Secreflo	6/18/1999	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc.
1298	T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccine	Neurovax	2/6/2014	Treatment of Pediatric Multiple Sclerosis	Immune Response BioPharma, Inc.
1299	T-cell depleted stem cell enriched cellular product from peripheal b lood stem cells	n/a	11/1/2001	Treatment of chronic granulomatous disease	Nexell Therapeutics Inc.
1300	T4 endonuclease V, liposome encapsulated	n/a	6/27/1989	To prevent cutaneous neoplasms and other skin abnormalities in xeroderma pigmentosum.	AGI Dermatics
1301	TD-K6a.513a.12	Reveker	6/15/2006	Treatment of pachyonychia congenita	TransDerm, Inc.
1302	TXA127	n/a	10/25/2013	Treatment of acute radiation syndrome	US Biotest, Inc.
1303	Tacrolimus	Prograf	6/6/2005	Prophylaxis of organ rejection in patients receiving heart transplants.	Astellas Pharma US, Inc.
1304	Tacrolimus	Prograf	4/6/1998	Prophylaxis of graft-versus-host-disease.	Fujisawa USA, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1305	Tacrolimus	n/a	12/20/2013	Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant	Veloxis Pharmaceuticals, Inc.
1306	Taliglucerase alfa	Elelyso For Injection	9/3/2009	Treatment of Gaucher's disease	Pfizer, Inc.
1307	Tamibarotene	n/a	10/11/2007	Treatment of acute promyelocytic leukemia (APL).	CytRx Corporation
1308	Tanespimycin	n/a	9/9/2004	Treatment of multiple myeloma	Bristol-Myers Squibb
1309	Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell	Lymphoscan	4/7/1992	Diagnostic imaging in the evaluation of the extent of disease in patients with histologically confirmed diagnosis of non-Hodgkin's B-cell lymphoma, acute B-cell lymphoblastic leukemia (in children and adults), and chronic B-cell lymphocytic leukemia.	Immunomedics, Inc.
1310	Technetium Tc99m rh-Annexin V	Apomate	11/3/2000	Diagnosis or assessment of rejection status in heart, heart-lung, single lung, or bilateral lung transplants.	Theseus Imaging Corporation
1311	Technetium Tc99m sulfur colloid injection, lyophilized	Technetium Tc99m Sulfur Colloidi	3/17/2009	For localization of sentinel lymph nodes in patients with melanoma.	Pharmalucence, Inc.
1312	Tegafur/gimeracil/oteracil	n/a	7/20/2006	Treatment of gastric cancer	Taiho Pharma USA,

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1313	Temoporfin	Foscan	10/28/1999	Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy.	Biolitec Pharma Ireland Ltd.
1314	Temozolomide	Temodal	10/18/2004	Treatment of newly diagnosed high grade glioma	Schering-Plough Research Institute
1315	Temozolomide	Temodal	10/14/1998	Treatment of advanced metastatic melanoma.	Schering-Plough Research Institute
1316	Temsirolimus	Torisel	12/16/2004	Treatment of renal cell carcinoma	Wyeth Pharmaceuticals, Inc.
1317	Teniposide	Vumon For Injection	11/1/1984	Treatment of refractory childhood acute lymphocytic leukemia.	Bristol-Myers Squibb Pharmaceutical Research Institute
1318	Teriparatide	Parathar	10/28/1999	Treatment of idiopathic osteoporosis.	Biomeasure, Inc.
1319	Teriparatide	Parathar	1/9/1987	Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.
1320	Terlipressin	Glypressin	3/6/1986	Treatment of bleeding esophageal varices.	Ferring Laboratories, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1321	Testosterone	Theraderm Testosterone Transdermal System	9/22/1997	For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.	Watson Laboratories
1322	Testosterone propionate ointment 2%	n/a	7/31/1991	Treatment of vulvar dystrophies.	Star Pharmaceuticals, Inc.
1323	Tetrabenazine	n/a	5/12/1998	Treatment of moderate/severe tardive dyskinesia.	Prestwick Pharmaceuticals, Inc.
1324	Tetrabenazine	Xenazine	12/11/1997	Treatment of Huntington's disease	Prestwick Pharmaceuticals, Inc
1325	Tetraiodothyroacetic acid	n/a	5/1/2000	Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.	Danforth, Jr., MD, Elliot
1326	Tezacitabine	n/a	1/27/2003	Treatment of adenocarcinoma of the esophagus and stomach	Sanofi-Aventis US, Inc.
1327	Thalidomide	n/a	3/5/1990	Treatment of graft versus host disease.	Andrulis Research Corporation
1328	Thalidomide	Thalomid	10/14/1998	Treatment of multiple myeloma	Celgene Corporation
1329	Thalidomide	n/a	7/29/1998	Treatment of Kaposi's sarcoma.	Celgene Corporation
1330	Thalidomide	n/a	2/27/1998	Treatment of primary brain malignancies.	Celgene Corporation
1331	Thalidomide	Synovir	3/11/1996	Treatment of HIV-associated wasting syndrome.	Celgene Corporation
1332	Thalidomide	Thalomid	7/26/1995	Treatment of erythema nodosum leprosum.	Celgene Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1333	Thalidomide	n/a	5/15/1995	Treatment and prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients.	Andrulis Research Corporation
1334	Thalidomide	n/a	5/1/1995	Treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients.	Celgene Corporation
1335	Thalidomide	n/a	1/12/1993	Treatment of the clinical manifestations of mycobacterial infection caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.	Celgene Corporation
1336	Thalidomide	Thalomid	4/6/1999	Treatment of Crohn's disease.	Celgene Corporation
1337	Thalidomide	n/a	3/5/1990	Prevention of graft versus host disease.	Andrulis Research Corporation
1338	Thalidomide	n/a	9/19/1988	Prevention of graft versus host disease in patients receiving bone marrow transplantation.	Pediatric Pharmaceuticals, Inc.
1339	Thalidomide	n/a	9/19/1988	Treatment of graft versus host disease in patients receiving bone marrow transplantation.	Pediatric Pharmaceuticals, Inc.
1340	Thalidomide	n/a	11/15/1988	Treatment and maintenance of reactional lepromatous leprosy.	Pediatric Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1341	Thalidomide	Thalomid	9/27/2004	Treatment of myelodysplastic syndrome	Celgene Corporation
1342	Thawed donor matched banked umbilical cord blood enriched by cell sorting to produce a subpopulation expressing high levels of intracellular aldehyde dehydrogenase	n/a	10/23/2008	To improve patient outcomes by decreasing time to platlet and neutrophil engraftment in patients with inherited metabolic diseases (IMD) undergoing umbilical cord blood transplantation.	Aldagen, Inc.
1343	Thiotepa	Tepadina	4/2/2007	Conditioning treatment prior to hematopoietic stem cell transplantation	Adienne S.r.l.
1344	Thymalfasin	Zadaxin	1/8/1998	Treatment of DiGeorge anomaly with immune defects.	SciClone Pharmaceuticals, Inc.
1345	Thymalfasin	Zadaxin	3/6/2000	Treatment of hepatocellular carcinoma.	SciClone Pharmaceuticals, Inc.
1346	Thymalfasin	Zadaxin	3/13/2006	Treatment of stage IIb through Stage IV malignant melanoma	SciClone Pharmaceuticals, Inc.
1347	Thymalfasin	Zadaxin	5/3/1991	Treatment of chronic active hepatitis B.	SciClone Pharmaceuticals, Inc.
1348	Thymosin beta 4	n/a	5/28/2004	Treatment of epidermolysis bullosa.	RegeneRx Biopharmaceuticals,
1349	Thyrotropin alfa	Thyrogen	8/3/2001	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid	Genzyme Corporation
1350	Thyrotropin alpha	Thyrogen	2/24/1992	As an adjunct in the diagnosis of thyroid cancer.	Genzyme Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1351	Tiazofurin (2-Beta-D-ribofuranosyl-4-thiazolecarboxamide)	n/a	12/27/2000	Chronic myelogenous leukemia (CML)	Valeant Pharmaceuticals North America
1352	Tilarginine acetate	n/a	4/11/2005	Treatment of cardiogenic shock	Arginox Pharmaceuticals, Inc.
1353	Tinidazole	Tindamax	8/20/2003	Treatment of amebiasis	Presutti Laboratories,
1354	Tiopronin	Thiola	1/17/1986	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Pak, Charles Y.C. M.D.
1355	Tiotropium bromide	Spiriva	1/8/2008	To improve pulmonary function in conjunction with standard therapy in the management of patients with cystic fibrosis	Boehringer Ingelheim Pharmaceuticals, Inc.
1356	Tipifarnib	Zarnestra	7/6/2004	Treatment of acute myeloid leukemia	Johnson & Johnson Pharmaceutical Research & Dev.
1357	Tiratricol	Triacana	8/13/1991	For use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine alone.	Laphal Laboratoires
1358	Tissue Plasminogen activator	n/a	4/18/2011	Treatment of acute ischemic stroke (AIS) in children age 16 years and younger.	Catherine Amliel-Lefond, MD

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1359	Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system	n/a	3/13/2006	Treatment of osteonecrosis.	Aastrom Biosciences, Inc.
1360	Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system	n/a	1/25/2007	Treatment of dilated cardiomyopathy	Aastrom Biosciences, Inc.
1361	Tizanidine HCl	Zanaflex	1/31/1994	Treatment of spasticity associated with multiple sclerosis and spinal cord injury.	Athena Neurosciences, Inc.
1362	Tobramycin	Tobi	6/18/1999	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	Novartis Pharmaceuticals Corp.
1363	Tobramycin for inhalation	Tobi	10/13/1994	Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.	Novartis Pharmaceuticals Corp
1364	Tolcapone	n/a	12/24/2013	Treatment of transthyretin amyloidosis	SOM Innovation Biotech SL (SOM
1365	Topiramate	Topamax	11/25/1992	Treatment of Lennox-Gastaut syndrome.	Johnson & Johnson Pharmaceutical R &
1366	Toremifene	n/a	8/17/1993	Treatment of desmoid tumors.	Orion Corporation
1367	Toremifene	Fareston	9/19/1991	Hormonal therapy of metastatic carcinoma of the breast.	Orion Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1368	Tosedostat	n/a	12/10/2008	Treatment of acute myeloid leukemia	Cell Therapeutics Inc.
1369	Tositumomab and iodine I 131 tositumomab	Bexxar	5/16/1994	Treatment of non-Hodgkin's B-cell lymphoma.	GlaxoSmithKline LLC
1370	Tramadol hydrochloride	n/a	4/26/2005	Management of postherpetic neuralgia	TheraQuest Biosciences, LLC
1371	Tramadol hydrochloride	n/a	1/28/2005	Treatment of painful HIV-associated neuropathy	TheraQuest Biosciences, LLC
1372	Tranilast	Rizaben	12/2/2003	For the treatment of malignant glioma	Angiogen Pharmaceuticals, Pty.
1373	Transforming growth factor-beta 2	n/a	12/18/1992	Treatment of full thickness macular holes.	Celtrix Pharmaceuticals, Inc.
1374	Transgenic human alpha 1 antitrypsin	n/a	5/19/1999	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	PPL Therapeutics (Scotland) Limited
1375	Treosulfan	Ovostat	5/16/1994	Treatment of ovarian cancer.	Medac GmbH
1376	Tretinoin	n/a	4/15/1985	Treatment of squamous metaplasia of the ocular surface epithelia (conjunctiva and/or cornea) with mucous deficiency and keratinization.	Hannan Ophthalmic Marketing Services, Inc
1377	Tretinoin	Atra-lv	4/11/2003	Treatment of T-cell non-Hodgkin's lymphoma	Antigenics, Inc.
1378	Tretinoin	Atra-lv	1/14/1993	Treatment of acute and chronic leukemia.	Antigenics, Inc.
1379	Tretinoin	Vesanoid	10/24/1990	Treatment of acute promyelocytic leukemia.	Hoffmann-La Roche, Inc.
1380	Trientine HCl	Syprine	12/24/1984	Treatment of patients with Wilson's disease who are intolerant, or inadequately responsive to penicillamine.	Merck Sharp & Dohme Research

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1381	Triheptanoin	Triheptanoim-Sasol Special Oil	5/26/2006	Treatment of fatty acid disorders	Baylor Research Institute
1382	Triheptanoin	Triheptanoin-Sasol Special Oil	2/1/2008	Treatment of glycogen storage disorder II (Pompe disease)	Baylor Research Institute
1383	Trimetrexate glucuronate	Neutrexin	5/15/1986	Treatment of Pneumocystis carinii pneumonia in AIDS patients.	Medimmune Oncology, Inc.
1384	Trisaccharides A and B	Biosynject	4/12/1987	Treatment of moderate to severe clinical forms of hemolytic disease of the newborn arising from placental transfer of antibodies against blood group substances A and B.	Chembiomed, Ltd.
1385	Trisaccharides A and B	Biosynject	4/20/1987	For use in ABO-incompatible solid organ transplantation, including kidney, heart, liver and pancreas.	Chembiomed, Ltd.
1386	Trisaccharides A and B	Biosynject	4/15/1988	Prevention of ABO medical hemolytic reactions arising from ABO-incompatible bone marrow transplantation.	Chembiomed, Ltd.
1387	Trisodium citrate concentration	Hemocitrate	6/15/1995	For use in leukapheresis procedures.	Hemotec Medical Products, Inc.
1388	Trisodium zinc Diethylenetriaminepentaacetate	n/a	2/27/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination.	CustomCare Pharmacy

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1389	Trypan blue	Membraneblue	8/2/2006	Selectively staining epiretinal membranes during ophthalmic surgical vitrectomy procedures	Dutch Ophthalmic Research Center Int'l BV
1390	Tumor necrosis factor-binding protein 1	n/a	1/6/1993	Treatment of symptomatic patients with AIDS including all patients with CD4 counts less than 200 cells per mm <sup>3</sup> .	EMD Serono, Inc.
1391	Tumor necrosis factor-binding protein II	n/a	1/6/1993	Treatment of symptomatic patients with the AIDS including all patients with CD4 T-cell counts less than 200 cells per mm <sup>3</sup> .	EMD Serono, Inc.
1392	Tyloxapol	Supervent	3/8/1995	Treatment of cystic fibrosis.	Kennedy & Hoidal,
1393	Type 1 native bovine skin collagen	n/a	2/1/2008	Treatment of diffuse systemic sclerosis	arGentis Pharmaceuticals, LLC
1394	Ubiquinol	Ubi-Q-Nol, Li-Q-Nol	4/12/2004	Treatment of Huntington's Disease	Gel-Tec, Division of Tishcon Corp
1395	Ubiquinol, coenzyme Q10, ubiquinone	Ubi-Q-Nol	4/12/2004	Treatment of pediatric congestive heart failure	Gel-Tec, Division of TISHCON Corporation
1396	Ubiquinone	Ubi-Q-Gel	12/14/1999	Treatment of mitochondrial cytopathies.	Gel-Tec, Division of Tishcon Corp.
1397	Unconjugated Chimeric (human-murine) G250 IgG monoclonal antibody	n/a	3/22/2001	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH
1398	Urea for intravitreal injection	Neurosolve	12/14/2005	Treatment of retinitis pigmentosa	Vitreo Retinal Technologies, Inc

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1399	Urofollitropin	Metrodin	11/25/1987	For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.	EMD Serono, Inc.
1400	Urogastrone	n/a	11/1/1984	For acceleration of corneal epithelial regeneration and healing of stromal incisions from corneal transplant surgery.	Chiron Vision
1401	Ursodiol	Urso 250	6/20/1991	Treatment of patients with primary biliary cirrhosis	Aptalis Pharma US, Inc.
1402	Vaccinia Immune Globulin (Human) Intravenous	n/a	6/18/2004	Treatment of severe complications from the smallpox vaccine	DynPort Vaccine Company LLC
1403	Vaccinia Immune Globulin (Human) Intravenous	Cnj-016	6/18/2004	Treatment of complications of vaccinia vaccination	Cangene Corporation
1404	Valine, isoleucine and leucine	Vil	1/5/1996	Treatment of hyperphenylalaninemia	Leas Research Products
1405	Valproate	n/a	5/5/2008	Treatment of fragile X syndrome	Neuropharm Ltd,
1406	Valrubicin	Valstar	5/23/1994	Treatment of carcinoma in situ of the urinary bladder.	Anthra Pharmaceuticals, Inc.
1407	Vapreotide	Sanvar	4/6/2004	Treatment of symptomatic carcinoid tumors	H3 Pharma, Inc.
1408	Varbulin	Azixa	11/5/2009	Treatment of glioblastoma multiforme.	Myrexix, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1409	Varicella Zoster Immune Globulin (Human)	Varizig	11/7/2006	Passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella	Cangene bioPharma, Inc.
1410	Vasoactive intestinal peptide	n/a	3/9/2001	Treatment of Acute Respiratory Distress Syndrome.	mondoBIOTECH
1411	Vasoactive intestinal polypeptide	n/a	6/23/1993	Treatment of acute esophageal food impaction.	Research Triangle Pharmaceuticals
1412	Virulizin	Virulizin	2/1/2001	Treatment of pancreatic cancer.	ZOR Pharmaceuticals, LLC
1413	Water-miscible vitamin A palmitate	Aquasol A Parenteral	3/26/2010	Prevention of bronchopulmonary dysplasia.	Fox Pharma, Inc.
1414	Xenogeneic hepatocytes	Hepatassist Liver Assist System	11/27/1998	Treatment of severe liver failure.	Circe Biomedical, Inc.
1415	Yttrium (90Y) antiferritin polyclonal antibodies	Ferritarg P	9/18/2006	Treatment of Hodgkin's disease.	MAT Biopharma
1416	Yttrium(90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10	n/a	12/3/2012	Treatment of soft tissue sarcoma	OncoTherapy Science, Inc.
1417	Yttrium-90 radiolabeled humanized monoclonal anti-carcinoembryonic antigen IgG antibody	Cea-Cide	8/3/1999	Treatment of ovarian carcinoma.	Immunomedics, Inc.
1418	Zalcitabine	n/a	12/9/1986	Treatment of AIDS.	National Cancer Institute, DCT
1419	Zalcitabine	Hivid	6/28/1988	Treatment of AIDS.	Hoffmann-La Roche,

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1420	Zidovudine	Retrovir	7/17/1985	Treatment of AIDS related complex.	Glaxo Wellcome Inc.
1421	Zinc acetate	Galzin	11/6/1985	Treatment of Wilson's disease.	Lemmon Company
1422	Zoledronate	Zometa, Zabel	8/18/2000	Treatment of tumor induced hypercalcemia.	Novartis Pharmaceuticals
1423	Zosuquidar trihydrochloride	n/a	12/15/2005	Treatment of acute myeloid leukemia	Kanisa Pharmaceuticals, Inc.
1424	[131I]-N-(2-(diethylamino) ethyl-4-(4 flurobenzamido)-5-(iodo)-2-methoxybenzamide	n/a	9/17/2008	Treatment of metastatic melanoma, stages IIB, IIC, III and IV	Molecular Insight Pharmaceuticals, Inc.
1425	[5,10,15,20-tetrakis(1,3-diethylimidazolium-2-yl)porphyrinato] manganese(III)pentachloride	n/a	11/4/2003	Treatment of Amyotrophic Lateral Sclerosis	Aeolus Pharmaceuticals, Inc.
1426	[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride salt	n/a	2/14/2014	Treatment of pigmented villonodular synovitis/giant cell tumor of the tendon sheath	Plexxikon, Inc.
1427	[5-Chloro-N2-[2-isopropoxy-5-methyl-4-(4-piperidiny) phenyl]-N4-[2(isopropyl sulfonyl) phenyl]-2,4-pyrimidinediamine]]	n/a	9/27/2013	Treatment of non-small cell lung cancer that is anaplastic lymphoma kinase(ALK)-postive	Novartis Pharmaceuticals Corp.
1428	[AC3-γCD2(V)] and Flucytosine (5-FC XR)	n/a	1/12/2011	Treatment of glioblastoma multiforme	Tocagen, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1429	[Lu-177]-DOTA-Tyr3-Octreotate	n/a	1/12/2009	Treatment of gastro-entero-pancreatic neuroendocrine tumors	BioSynthema, Inc.
1430	[Nle4, D-Phe7]-a-melanocyte stimulating hormone	n/a	7/17/2008	Treatment of erythropoietic porphyrias	Clinuvel Inc.
1431	[met5]-enkephalin	Opioid Growth Factor	1/24/2013	Treatment of pancreatic cancer	TNI BioTech, Inc.
1432	a-Galactosidase A	Plant-Produced Human A-Glactosidase A	1/21/2003	Treatment of Fabry's disease	iBio, Inc.
1433	aaeno-associated viral vector, serotype 2, containing the human choroideremia gene encoding human Rab escort protein 1	n/a	9/12/2013	Treatment of choroideremia due to mutations in the human choroideremia gene (CHM)	Ctr for Cellular & Molecular Therapeutics
1434	abatacept	Orencia	5/30/2013	Treatment of type 1 diabetes mellitus patients with residual beta cell function	Orban Biotech LLC
1435	abeotaxane inhibitor of microtubules	n/a	4/18/2011	Treatment of pediatric neuroblastoma.	Archer Biosciences
1436	abeotaxane inhibitor of microtubules	n/a	10/7/2011	Treatment of gliomas	Archer Biosciences
1437	acadesine	n/a	3/3/2011	Treatment of chronic lymphocytic leukemia	Avanced In Vitro Cell Technologies, S.L.
1438	acadesine	n/a	5/4/2011	Treatment of multiple myeloma	Advancell-Advanced In Vitro Cell Technologies S.A.
1439	acamprosate	n/a	3/25/2013	Treatment of fragile X syndrome	Confluence Pharmaceuticals, LLC

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1440	acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminy-D-cysteinyl-D-arginyl-D-arginyl-D-lysyl-Dasparaginyamide disulfide	n/a	2/18/2011	Treatment of pancreatic cancer.	Genus Oncology, LLC
1441	acetyl-L-carnitine	n/a	7/24/2012	Treatment of Fragile X syndrome	Sigma-Tau Pharmaceuticals, Inc.
1442	acetyl-L-carnitine (ALC)	n/a	3/18/2011	Treatment of Rett syndrome	sigma-tau Pharmaceuticals, Inc.
1443	acetylcysteine	Acetadote	10/19/2001	For the intravenous treatment of moderate to severe acetaminophen overdose	Cumberland Pharmaceuticals, Inc.
1444	acid sphingomyelinase	n/a	8/3/2000	Treatment of acid sphingomyelinase deficiency (Niemann-Pick disease)	Genzyme Corporation
1445	acyclovir	n/a	9/16/2010	Treatment of herpetic keratitis	GlaxoSmithKline
1446	acyclovir	n/a	12/13/2010	Treatment of acute herpetic keratitis caused by Herpes Simplex Virus type 1 and 2.	Fera Pharmaceuticals
1447	adalimumab	Humira	5/11/2011	Treatment of pediatric patients with ulcerative colitis	AbbVie, Inc.
1448	adalimumab	Humira	10/19/2006	Treatment of pediatric Crohn's disease.	AbbVie, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1449	adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs	n/a	5/6/2013	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo type A syndrome)	Lysogene
1450	adeno-associated viral vector containing DNA encoding an RNAi targeting rhodopsin in combination with an adeno-associated viral vector containing DNA encoding a rhodopsin gene	n/a	12/13/2012	treatment of retinitis pigmentosa	Genable Technologies Limited
1451	adeno-associated viral vector containing modified U11 snRNA	n/a	9/15/2010	Treatment of Duchenne muscular dystrophy.	uniQure B.V.
1452	adeno-associated viral vector containing the human NADH Dehydrogenase 4 Gene	n/a	11/20/2013	Treatment of Leber Hereditary Optic Neuropathy	Gen Sight Biologics
1453	adeno-associated viral vector expressing human retinoschisin-1 gene	n/a	5/21/2007	Treatment of X-linked juvenile retinoschisis (XLRS).	Applied Genetic Technologies Corporation
1454	adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene	n/a	12/27/2012	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)	Laboratorios del Dr. Esteve, S.A.
1455	adeno-associated virus transgene of follistatin	n/a	11/19/2012	Treatment of Duchennes and Becker's muscular dystrophy	Milo Biotechnology
1456	adeno-associated virus vector serotype 9 expressing human sulfamidase	n/a	6/1/2011	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A Syndrome).	Laboratorios del Dr. Esteve, S.A.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1457	adenovirus containing a human FAS-c gene	n/a	4/2/2012	Treatment of malignant glioma	Vascular Biogenics Ltd
1458	adult adherent bone marrow-derived multipotent stem cells	Multistem	7/6/2012	Treatment of MPS-1, including Hurler syndrome	Athersys, Inc.
1459	aerosolized beractant	n/a	3/11/2013	Treatment of respiratory distress syndrome	Beena G. Sood, MD, MS
1460	afamelanotide	n/a	12/11/2009	Treatment of solar urticaria	Clinuvel, Inc.
1461	afatinib	Gilotrif	12/3/2012	Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).	Boehringer Ingelheim Pharmaceuticals, Inc.
1462	alemtuzumab	Campath	10/20/1997	Treatment of chronic lymphocytic leukemia.	Genzyme Corporation
1463	alfimeprase	n/a	9/20/2012	Treatment of ST-elevation myocardial infarcted patients who are undergoing primary percutaneous coronary intervention	Niche Therapeutics, LLC
1464	algenpantucel-L	Hyperacute(R)-Pancreatic Cance	10/21/2010	Treatment of pancreatic cancer.	NewLink Genetics Corporation
1465	alicaforsen	n/a	6/24/2008	Treatment of pouchitis.	Atlantic Healthcare Limited
1466	alisertib	n/a	7/12/2013	Treatment of small cell lung cancer	Millennium Pharmaceuticals, Inc.
1467	alisertib	n/a	5/14/2012	Treatment of peripheral T-cell lymphoma	Millennium Pharmaceuticals, Inc.
1468	allantoin	Alwextin	11/21/2002	Treatment of skin blistering and erosions associated with inherited epidermolysis bullosa	Scioderm, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1469	allogeneic ex vivo expanded umbilical cord blood cells	Stemex	2/1/2010	For use as hematopoietic support in patients with chronic myeloid leukemia	Gamida Cell - Teva Joint Venture
1470	allogeneic ex vivo expanded umbilical cord blood cells	Stemex	2/1/2010	For use as hematopoietic support in patients with myelodysplastic syndromes	Gamida Cell - Teva Joint Venture
1471	allogeneic ex-vivo expanded placental adherent stromal cells	n/a	8/22/2011	Treatment of thromboangiitis obliterans (Buerger's disease)	Pluristem Therapeutics, Inc.
1472	allogeneic ex-vivo expanded placental adherent stromal cells	n/a	2/18/2013	Treatment of Aplastic Anemia	Pluristem Therapeutics, Inc.
1473	allogeneic hematopoietic stem cell	Atir(Tm)	2/2/2010	Prevention (reduction) of transplant related mortality (TRM, which is caused by graft versus host disease and/or infections) following mismatched (haploidentical) allogeneic hematopoietic stem cell transplantation.	Kiadis Pharma Netherlands B.V.
1474	allogeneic mesenchymal precursor cells derived from ex vivo healthy donors harvested from iliac crest.	n/a	9/12/2008	Treatment of insufficient hematopoietic stem cell production in patients with hematologic malignancies who have failed treatment with conventional chemotherapy.	Mesoblast, Inc.
1475	allogenic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor	n/a	7/24/2012	Treatment of macular telangiectasia type 2 (MacTel)	Neurotech USA, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1476	allopregnanolone	n/a	7/12/2013	Treatment of Neimann-Pick disease, type C	LaJolla Pharmaceutical
1477	alpha melanotropin	n/a	9/2/2010	Treatment of chronic beryllium disease	mondoBIOTECH Laboratories AG
1478	alpha-1 proteinase inhibitor (human)	Glassia	7/28/2011	Treatment of patients with recent onset (	Kamada, Ltd.
1479	alpha-tocotrienol quinone	n/a	10/21/2010	Treatment of inherited mitochondrial respiratory chain diseases.	Edison pharmaceuticals, Inc.
1480	alpha1 proteinase inhibitor (human)	n/a	1/29/2010	Treatment of emphysema secondary to congenital alpha1-antitrypsin deficiency.	Grifols Therapeutics, Inc.
1481	alpha1-proteinase inhibitor (human)	n/a	4/6/2012	Treatment of cystic fibrosis	Grifols Therapeutics, Inc.
1482	alpha1-proteinase inhibitor (human)	n/a	2/20/2009	Treatment of cystic fibrosis	CSL Behring LLC
1483	alteplase	Activase	1/27/2003	Treatment of intraventricular hemmorage associated with intracerebral hemmorrhage	Daniel F. Hanley, MD
1484	amatuximab	n/a	9/28/2012	Treatment of mesothelioma	Morphotek, Inc.
1485	ambrisentan	Letairis	7/16/2004	Treatment of pulmonary arterial hypertension	Gilead Colorado
1486	ambroxol	n/a	6/29/2011	Treatment of Gaucher disease	ZYWIE, LCC
1487	aminolevulinic acid hydrochloride	Levulan	3/20/2007	Treatment of esophageal dysplasia	DUSA Pharmaceuticals, Inc.
1488	aminosidine	Paromomycin	3/29/2005	Treatment of visceral leishmaniasis	The Institute for One World Health
1489	amitriptyline and ketamine	Epicept(TM) Np-1	1/19/2010	Treatment of postherpetic neuralgia	EpiCept Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1490	ammonium tetrathiomolybdate	n/a	5/5/2008	Treatment of idiopathic pulmonary fibrosis	Pipex Pharmaceuticals, Inc.
1491	amphotericin B	n/a	9/15/2010	Treatment of visceral leishmaniasis.	iCo Therapeutics Inc.
1492	amrubicin	n/a	3/10/2008	Treatment of small cell lung cancer	Celgene Corporation
1493	an adeno-associated viral vector containing a codon-optimised human factor IX gene (AAV5-hFIXco)	n/a	12/22/2011	Treatment of hemophilia B	uniQure, B.V.
1494	anakinra	Kineret	8/19/2010	Treatment of cryopyrin-associated periodic syndromes	Swedish Orphan Biovitrum AB (publ)
1495	angiotensin (1-7)	n/a	8/30/2013	Treatment of patients requiring stem cell transplantation to accelerate the mobilization of hematopoietic stem cells (CD34+) from the bone marrow to the peripheral blood when combined with a granulocyte colony-stimulating factor	US Biotest, Inc.
1496	angiotensin (1-7)[A(1-7)]	n/a	7/25/2013	Treatment of Duchenne muscular dystrophy	US Biotest, Inc.
1497	angiotensin 1-7	n/a	6/17/2010	To accelerate engraftment of hematopoietic cells (treatment of neutropenia, thrombocytopenia, lymphoma, and anemia)in hematopoietic stem cell transplants.	US Biotest, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1498	angiotensin 1-7	n/a	1/29/2010	Treatment of sarcoma.	W. Jeffrey Petty, MD
1499	anthrax immune globulin	n/a	9/3/2009	Treatment of inhalation anthrax disease	Emergent Biosolutions, Inc.
1500	anthrax immune globulin (human)	n/a	7/29/2008	Treatment of toxemia associated with inhalational anthrax.	Cangene Corporation
1501	anti human Nogo-A human monoclonal antibody	n/a	10/20/2008	Treatment of acute spinal cord injury	Novartis Pharmaceuticals
1502	anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion protein	n/a	9/13/2013	Treatment of graft versus host disease	Xenikos BV
1503	anti-CD30 Fc engineered humanized monoclonal antibody	n/a	12/2/2008	Treatment of Hodgkin lymphoma	Xencor, Inc.
1504	anti-Lewis Y humanized monoclonal antibody	n/a	3/9/2012	Treatment of ovarian cancer	Recepta Biopharma S.A.
1505	anti-T-lymphocyte immune globulin, rabbit	n/a	9/12/2008	Prophylaxis of acute allograft rejection in adult recipients in solid organ transplantation	Neovii Biotech NA, Inc.
1506	anti-T-lymphocyte immune globulin, rabbit	Atg-Fresenius(R)	3/26/2010	Prevention of graft versus host disease (GVHD)	Neovii Biotech NA, Inc.
1507	anti-TCR murine monoclonal antibody (MAB, type IgM)	n/a	1/12/2011	Treatment of pediatric multiple sclerosis in patients less than or equal to 16 years of age	Tolera Therapeutics, Inc.
1508	anti-TCR murine monoclonal antibody (MAB, type IgM)	n/a	6/7/2010	Treatment of patients 16 years of age and younger with immune-mediated T1DM and preserved pancreatic beta cell function	Tolera Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1509	anti-inhibitor coagulant complex	Feiba	4/12/2013	Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors	Baxter Healthcare Corporation
1510	anti-insulin-like type 1 receptor immunoglobulin 1	n/a	11/23/2010	Treatment of pancreatic cancer.	Amgen
1511	anti-interferon-gamma Fab from goats	n/a	11/18/2003	For the treatment of immunologic corneal allograft rejection	Advanced Biotherapy, Inc.
1512	anti-nogo-A monoclonal antibody	n/a	7/7/2009	Treatment of amyotrophic lateral sclerosis	GlaxoSmithKline
1513	anti-sense oligonucleotide consisting of 2' deoxyribose RNA with a phosphorothioate backbone	n/a	9/23/2013	Treatment of cystic fibrosis	ProQR therapeutics B.V.
1514	anti-thymocyte globulin [rabbit]	Thymoglobulin	5/25/2010	Prophylaxis of acute organ rejection in patients receiving renal transplants	Genzyme Corporation
1515	antiangiogenic components extracted from marine cartilage	Neovastat (Ae-941)	10/16/2002	Treatment of renal cell carcinoma	AEterna Zentaris, Inc.
1516	antimesothelin-ADC (antibody drug conjugate)	n/a	7/5/2012	Treatment of mesothelioma	Bayer HealthCare Pharmaceuticals, Inc.
1517	antineoplaston A10, antineoplaston AS2-1	n/a	10/30/2008	Treatment of gliomas	Burzynski Research Institute, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1518	antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA]	Gti-2040	3/12/2003	Treatment for renal cell carcinoma	Lorus Therapeutics, Inc
1519	antisense oligonucleotide targeted to human transthyretin (TTR) mRNA	n/a	7/24/2012	Treatment of familial amyloid polyneuropathy	Isis Pharmaceuticals, Inc.
1520	apolipoprotein E mimetic peptide	n/a	12/3/2012	Treatment of homozygous familial hypercholesterolemia	LipimetiX Development, LLC
1521	apremilast	n/a	1/17/2013	Treatment of Behcet's disease	Celgene Corporation
1522	arimoclomol	n/a	3/29/2005	Treatment of amyotrophic lateral sclerosis	CytRx Corporation
1523	aripiprazole	Abilify	1/25/2006	Treatment of Tourette's syndrome	Otsuka Pharmaceutical Development &
1524	arsenic	Trisenox	11/2/2001	Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7	Teva Branded Pharmaceutical Products R&D, Inc.
1525	arsenic trioxide	Trisenox	10/18/2001	Treatment of chronic myeloid leukemia	Teva Branded Pharmaceutical Products R*D, Inc.
1526	arsenic trioxide	Trisenox	6/13/2003	Treatment of liver cancer	Teva Branded Pharmaceutical Products R&D, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1527	arsenic trioxide	Trisenox	7/17/2000	Treatment of myelodysplastic syndrome.	Teva Branded Pharmaceutical Products R&D, Inc.
1528	artemether/lumefantrine	Coartem	8/31/2007	For the treatment of infections due to Plasmodium falciparum or mixed infections including P. falciparum.	Novartis Pharmaceuticals
1529	arylsulfatase A (rhASA)	n/a	2/27/2008	Treatment of metachromatic leukodystrophy	Shire Human Genetic Therapies, Inc.
1530	astuprotimut-R	n/a	5/29/2009	Treatment of MAGE-A3 positive non-small cell lung cancer	GlaxoSmithKline Biologicals, S.A.
1531	astuprotimut-R	n/a	5/29/2009	Treatment of MAGE-A3 positive stages IIb to IV malignant melanoma	GlaxoSmithKline Biologicals, S.A.
1532	ataluren	n/a	3/10/2008	Treatment of spinal muscular atrophy	PTC Therapeutics, Inc.
1533	ataluren	n/a	9/1/2004	For use in the treatment of cystic fibrosis resulting from a nonsense (premature stopcodon) mutation in the cystic fibrosis transmembrane conductance regulatory gene	PTC Therapeutics, Inc.
1534	ataluren	n/a	1/10/2005	Treatment of Muscular Dystrophy resulting from premature stop mutations in the dystrophin gene	PTC Therapeutics, Inc.
1535	auranofin	Ridaura	4/30/2010	Treatment of amebiasis	Ctr for Discovery & Innovation in Parasitic Diseases

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1536	autologous CD34+ hematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA	n/a	4/19/2012	Treatment of adrenoleukodystrophy	bluebird bio, Inc.
1537	autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene	n/a	3/18/2013	Treatment of B-thalassemia major and intermedia	bluebird bio, Inc.
1538	autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene	n/a	2/26/2014	For the treatment of Sickle Cell Disease	bluebird bio Inc.
1539	autologous CD4+CD25hiFoxP3+regulatory T cells	n/a	11/19/2013	Prevention of graft rejection following solid organ transplantation	iREG Medical AB
1540	autologous ex vivo expanded CD4+-enriched leukocytes treated with the demethylating agent 5-aza-2'3'-dideoxycytidine	Alecsat	9/13/2013	Treatment of glioblastoma multiforme	CytoVac A/S
1541	autologous lymphocytes depleted ex vivo of immunoreactive T cells using 4,5	Theralux Photodynamic Therapy	4/3/2008	Treatment of chronic graft versus host disease	Kiadis Pharma Canada, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1542	autologous neo-urinary conduit	n/a	6/7/2011	Treatment of bladder dysfunction requiring incontinent urinary diversion.	Tengion, Inc.
1543	autologous olfactory neural progenitors	Rhinocytes	12/31/2008	Treatment of amyotrophic lateral sclerosis	RhinoCyte, Inc.
1544	autologous tumor-derived gp96 heat shock protein-peptide complex	Oncophage	7/11/2002	Treatment of metastatic melanoma	Agenus, Inc.
1545	autologous tumor-derived gp96 heat shock protein-peptide complex	Oncophage	5/10/2002	Treatment of renal cell carcinoma	Agenus, Inc.
1546	autologous umbilical cord blood	n/a	7/24/2012	Treatment of pediatric (0-16 yrs old inclusive) cerebral palsy due to acquired brain injury	Duke University
1547	autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene	n/a	8/26/2009	Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency.	Glaxo Group Limited
1548	aviptadil	n/a	2/22/2005	Treatment of pulmonary arterial hypertension	Mondobiotech Laboratories AG
1549	azacitidine	Vidaza	12/3/2001	Treatment of myelodysplastic syndromes	Celgene Corporation
1550	aztreonam	Cayston	3/12/2002	Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis	Gilead Sciences (formerly Corus Pharma)

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1551	aztreonam	n/a	5/15/2009	Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.	Gilead Sciences, Inc.
1552	baclofen	n/a	12/2/2003	Treatment of dystonia	Medtronic
1553	baclofen	n/a	12/16/1991	Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.	Infusaid, Inc.
1554	baclofen	Lioresal Intrathecal	11/10/1987	Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy).	Medtronic, Inc.
1555	bacterium Bacteroides thetaiotaomicron	n/a	9/26/2013	Treatment of active Crohn's disease in the pediatric population	GT Biologics Ltd
1556	beclomethasone	n/a	3/4/2009	Treatment of pediatric patients with ulcerative colitis	Aptalis Pharma US, Inc.
1557	beclomethasone 17,21-dipropionate	Orbec(R)	7/24/2009	Treatment of gastrointestinal symptoms with chronic grafted host disease in patients undergoing allogeneic hematopoietic cell transplantation	Soligenix, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1558	beclomethasone 17,21-dipropionate	Bec	8/28/2001	Prevention of gastrointestinal graft-versus-host disease	Soligenix, Inc.
1559	beclomethasone 17,21-dipropionate	n/a	11/19/2012	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	Soligenix, Inc
1560	beclomethasone 17,21-dipropionate	n/a	12/18/2007	Treatment of pediatric patients with Crohn disease.	Soligenix, Inc.
1561	bedaquiline; (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol	Sirturo	1/10/2005	Treatment of active tuberculosis	Janssen Research & Development, LLC
1562	belatacept	Nulojix	2/20/2008	Prophylaxis of organ rejection in renal allograft recipients	Bristol-Myers Squibb Company
1563	beloranib	n/a	1/15/2013	Treatment of Prader-Willi syndrome	Zafgen, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1564	bendamustine hydrochloride	Treanda	11/26/2013	Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)	Cephalon, Inc.
1565	bendamustine hydrochloride with betadex sulfobutyl ether sodium	n/a	9/10/2013	Treatment of chronic lymphocytic leukemia	Supratek Pharma, Inc.
1566	benzoate	n/a	7/6/2012	Treatment of pediatric schizophrenia	SyneuRx International (Taiwan) Corp.
1567	benzoate/phenylacetate	Ammonul	11/22/1993	Treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.	Medicis Pharmaceutical Corp.
1568	beraprost sodium 314d	n/a	12/22/2011	Treatment of pulmonary arterial hypertension	Lung Rx, Inc.
1569	bevacizumab	Avastin	5/26/2006	Treatment of malignant glioma	Genentech, Inc.
1570	bevacizumab	Avastin	2/9/2006	Therapeutic treatment of patients with ovarian cancer	Genentech, Inc.
1571	bevacizumab	Avastin	10/20/2004	Treatment of pancreatic cancer	Genentech, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1572	bevacizumab	Avastin	11/6/2003	Treatment of renal cell carcinoma	Genentech, Inc.
1573	bevacizumab	Avastin	10/13/2009	Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen	Genentech, Inc.
1574	bevacizumab	Avastin	11/23/2010	Treatment of fallopian tube carcinoma.	Genentech, Inc.
1575	bevacizumab	Avastin	11/2/2010	Treatment of primary peritoneal carcinoma.	Genentech, Inc.
1576	bevacizumab	n/a	10/21/2010	Treatment of hereditary hemorrhagic telangiectasia	Terence M. Davidson, MD
1577	bevacizumab	Avastin	11/20/2009	In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.	Genentech, Inc.
1578	bezafibrate	Bezalip	7/24/2013	For therapeutic treatment of Barth syndrome	Barth Syndrome Foundation, Inc.
1579	bi-shRNAfurin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine	Fang	2/17/2012	Treatment of stage IIB to IV melanoma	Gradalis, Inc.
1580	bi-shRNAfurin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine	Fang	4/18/2011	Treatment of ovarian cancer	Gradalis, Inc.
1581	bifidobacterium infantis 35624	n/a	3/24/2008	Treatment of pediatric ulcerative colitis	Alimentary Health Limited
1582	bifidobacterium longum infantis 35624	n/a	1/16/2003	Treatment of pediatric Crohn's disease	Alimentary Health Limited

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1583	binimetinib	n/a	11/19/2013	Treatment Stage IIB-IV melanoma.	Novartis Pharmaceuticals
1584	biocarbonate infusate	Normocarb Hf	8/9/2005	Use in the management of patients undergoing continuous renal replacement therapy with hemofiltration	Dialysis Solutions, Inc.
1585	bisantrene HCl	n/a	2/14/2014	Treatment of acute myeloid leukemia	Update Pharma, Inc.
1586	bispecific antibody (monoclonal antibody)	n/a	8/8/2013	Treatment of HER2-expressing advanced adenocarcinoma of the stomach and gastroesophageal junction	Merrimack Pharmaceuticals, inc.
1587	bispecific antibody (monoclonmal antibody)	n/a	8/8/2013	Treatment of HER2-expressing adenocarcinoma of the esophagus	Merrimack Pharmaceuticals, Inc.
1588	bispecific antibody targeting interleukin 4 (IL-4) and interleukin 13 (IL-13)	n/a	9/14/2011	Treatment of idiopathic pulmonary fibrosis.	Sanofi-Aventis US, Inc.
1589	bivalirudin	Angiomax	11/2/2005	For use as an anticoagulant in patients with or at risk of heparin-induced thrombocytopenia/heparin-induced thrombocytopenia thrombosis syndrome	The Medicines Company
1590	blinatumomab	n/a	5/16/2008	Treatment of prolymphocytic leukemia	Amgen Rockville, Inc.
1591	blinatumomab	n/a	5/16/2008	Treatment of acute lymphocytic leukemia	Amgen Rockville, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1592	blinatumomab	n/a	5/16/2008	Treatment for hairy cell leukemia.	Amgen Rockville, Inc.
1593	bortezomib	Velcade For Injection	4/18/2011	Treatment of mantle cell lymphoma (MCL).	Millennium Pharmaceuticals, Inc.
1594	bortezomib	Velcade	1/15/2003	Treatment of multiple myeloma	Millennium Pharmaceuticals, Inc.
1595	bortezomib	Velcade	1/4/2011	Treatment of follicular non-Hodgkin lymphoma	Millennium Pharmaceuticals, Inc.
1596	bosentan	Tracleer(R)	6/7/2010	Reduction of the number (treatment) of new digital ulcers in patients with systemic sclerosis	Actelion Ltd.
1597	bosutinib	Bosulif	2/24/2009	Treatment of chronic myelogenous leukemia	Wyeth Pharmaceuticals, Inc.
1598	botulism antitoxin heptavalent (A, B, C, D, E, F, G) (Equine)	n/a	6/29/2011	Treatment of botulism.	Cangene Corporation
1599	brentuximab vedotin	Adcetris	10/23/2008	Treatment of anaplastic large cell lymphoma	Seattle Genetics, Inc.
1600	brentuximab vedotin	Adcetris	1/30/2007	Treatment of Hodgkin's lymphoma	Seattle Genetics, Inc.
1601	brentuximab vedotin	Adcetris	9/13/2013	Treatment of patients with angioimmunoblastic T-cell lymphoma	SeattleGenetics, Inc.
1602	brentuximab vedotin	Adcetris(R)	1/31/2014	Treatment of patients with diffuse large B-cell lymphoma.	Seattle Genetics, Inc.
1603	brentuximab vedotin	Adcetris	11/19/2012	Treatment of mycosis fungoides	Seattle Genetics, Inc.
1604	brentuximab vedotin	Adcetris	4/15/2013	Treatment of patients with peripheral T-cell lymphoma, not otherwise specified	Seattle Genetics, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1605	brilliant blue G	Brilliant Peel	12/16/2009	For use in ophthalmic surgery to aid in the removal of the inner limiting membrane of the eye.	Fluron GmbH - Subsidiary of Geuder AG
1606	brivanib alaninate	n/a	3/21/2011	Treatment of hepatocellular carcinoma	Bristol-Myers Squibb
1607	bryostatin-1	n/a	12/3/2001	For use in combination with paclitaxel in the treatment of esophageal cancer	GPC Biotech, Inc.
1608	budesonide	Uceris	5/6/2013	Treat of ulcerative colitis in pediatric patients aged 0 through 16 years.	Santarus, Inc.
1609	budesonide	Nefecon	5/17/2010	To slow the progression of immunoglobulin A nephropathy & delay kidney failure in patients affected by the disease.	Pharmalink AB
1610	bupivacaine	Transdur	6/18/2008	Relief of persistent pain associated with postherpetic neuralgia	Impax Laboratories, Inc.
1611	buprenorphine in combination with naloxone	Suboxone	10/27/1994	Treatment of opiate addiction in opiate users	Reckitt Benckiser Pharmaceuticals, Inc.
1612	busulfan	Partaject	11/25/2002	Preparative therapy for pediatric patients undergoing bone marrow transplantation	SuperGen, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1613	cabozantinib	Cometriq	11/29/2010	Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer.	Exelixis, Inc.
1614	caffeine and sodium benzoate	n/a	8/22/2012	Treatment of seizure prolongation in patients undergoing electroconvulsive therapy	Luitpold Pharmaceuticals, Inc.
1615	calcium benzoate and risperidone	n/a	12/20/2010	Treatment of pediatric patients with schizophrenia	University of California, Los
1616	camostat	n/a	5/18/2011	Treatment of chronic pancreatitis	Stason Pharmaceuticals, Inc.
1617	canakinumab	Ilaris	12/5/2013	Treatment of familial mediterranean fever	Novartis Pharmaceuticals
1618	canakinumab	Ilaris	12/18/2007	Treatment of cryopyrin-associated periodic syndromes	Novartis Pharmaceuticals Corporation
1619	canakinumab	Ilaris	9/30/2008	Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.	Novartis Pharmaceuticals Corporation
1620	canakinumab	Ilaris	12/5/2013	Treatment of hyperimmunoglobulinemia D and periodic fever syndrome	Novartis Pharmaceuticals Corporation
1621	canakinumab	n/a	9/4/2012	Treatment of TNF-receptor associated periodic syndrome (TRAPS)	Novartis Pharmaceuticals Corporation
1622	cannabidiol	n/a	2/27/2014	Treatment of Lennox-Gastaut syndrome	GW Pharma Ltd.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1623	cantharidin	n/a	7/24/2012	Treatment of perforating diseases, including Kyrle's disease, reactive perforating collangenosis, perforating folliculitis and elastosis perforans serpiginosa	Orenova Group, LLC
1624	caprine hyperimmune serum against HIV lysate	n/a	10/28/2009	Treatment of amyotrophic lateral sclerosis	Daval International Limited
1625	caprine hyperimmune serum against HIV lysate	n/a	2/14/2014	Treatment of systemic sclerosis	Daval International Limited
1626	capsaicin	n/a	10/23/2002	Treatment of erythromelgia	Acorda Therapeutics, Inc.
1627	capsaicin	Qutenza	5/2/2003	Treatment of painful HIV-associated neuropathy	NeurogesX, Inc.
1628	capsaicin	Qutenza	5/22/2009	Management of neuropathic pain in patients with postherpetic neuralgia	Acorda Therapeutics, Inc.
1629	carbon monoxide	n/a	9/28/2012	Treatment of sickle cell disease	Hillhurst Biopharmaceuticals,
1630	cardiotrophin-1	n/a	6/24/2008	To protect the liver from ischemia-reperfusion injury inherent to the procedure of transplantation.	Digna Biotech, S.L.
1631	cardiotrophin-1	n/a	9/13/2011	Treatment of acute liver failure.	Digna Biotech S.L.
1632	carfilzomib	Kyprolis	1/18/2008	Treatment of multiple myeloma	Onyx Therapeutics, Inc.
1633	carglumic acid	Carbaglu	1/20/1998	Treatment of N-acetylglutamate synthetase deficiency.	Orphan Europe SARL
1634	carisbamate	n/a	3/16/2012	Management of patients with infantile spasms	SK Life Science, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1635	carlumab	n/a	10/24/2006	Treatment of pancreatic cancer	Centocor, Inc.
1636	catumaxomab	n/a	7/1/2009	Treatment of gastric cancer	Neoviibiotech North America, Inc.
1637	cediranib	n/a	12/13/2010	Treatment of glioblastoma	AstraZeneca
1638	cell based therapeutic composed of allogeneic donor apoptotic cells	Apocell	3/18/2013	Prevention of graft versus host disease	Enlivex Therapeutics Ltd.
1639	cenersen	Aeza	2/27/2008	Treatment of chronic lymphocytic leukemia	Eleos, Inc.
1640	cenersen	Aeza	6/18/2008	Treatment of stage IIB through IV melanoma	Eleos, Inc.
1641	cenersen	n/a	5/8/2006	Treatment of acute myeloid leukemia	Eleos, Inc.
1642	cethromycin	Restanza(Tm)	9/9/2009	Prophylactic treatment of tularemia due to Francisella tularensis.	Advanced Life Sciences, Inc.
1643	cethromycin	n/a	2/28/2007	Prophylactic treatment of patients exposed to inhalation anthrax.	Advanced Life Sciences, Inc.
1644	cethromycin	Restanza(Tm)	9/9/2009	Prophylactic treatment of plague due to Yersinia pestis	Advanced Life Sciences, Inc.
1645	cetuximab	Erbitux	7/3/2000	Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor	ImClone Systems Incorporated
1646	chelmab-y or chelamusab-Y	Oncorad Ov103	4/24/1990	Treatment of ovarian cancer.	Cytogen Corporation
1647	chenodeoxycholic acid	n/a	2/12/2007	Treatment of cerebrotendinous xanthomatosis	Sigma-Tau Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1648	chenodiol	Chenadal	3/22/2010	Treatment of cerebrotendinous xanthomatosis	Manchester Pharmaceuticals, Inc.
1649	chimeric monoclonal antibody 14.18 (ch14.18)	n/a	12/20/2010	Treatment of neuroblastoma	United Therapeutics Corporation
1650	chimeric monoclonal antibody against Claudin 6	n/a	3/18/2013	Treatment of ovarian cancer	Ganymed Pharmaceuticals AG
1651	chimeric monoclonal antibody against claudin-18 splice variant 2	n/a	9/26/2013	Treatment of pancreatic cancer	GANYMED Pharmaceuticals AG
1652	chimeric monoclonal antibody to claudin 18 splice variant 2	n/a	11/20/2012	Treatment of gastric cancer	GANYMED Pharmaceuticals AG
1653	chloropyramine	n/a	10/22/2010	Treatment of pancreatic cancer	CurFAKtor Pharmaceuticals, LLC
1654	chlorotoxin	n/a	12/2/2008	Treatment of stage IIb, IIc, III & IV melanoma	Morphotek, Inc.
1655	cholest-4-en-3-one, oxime	n/a	2/17/2009	Treatment of spinal muscular atrophy.	Trophos SA
1656	cholic acid (3 alpha, 7 alpha, 12 alpha trihydroxy 5-beta cholanoic acid)	Falkochol	7/18/2003	Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism	Asklepion Pharmaceuticals LLC
1657	choline tetrathiomolybdate	n/a	8/25/2011	Treatment of Wilson's disease.	Wilson Therapeutics AB
1658	cinacalcet	Sensipar	5/12/2003	Treatment of hypercalcemia in patients with parathyroid carcinoma	Amgen, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1659	cinacalcet	Sensipar	4/30/2010	Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery	Amgen, Inc.
1660	ciprofloxacin	n/a	6/1/2011	The management of bronchiectasis	Aradigm Corporation
1661	ciprofloxacin DPI	Ciprofloxacin Pulmosphere(R)	2/2/2010	Management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis patients	Bayer HealthCare Pharmaceuticals, Inc.
1662	cis-adamantane-2-spiro-3'-8'-[4'-[2'-(4'-morpholinyl)ethoxy]phenyl]-1',2',4'-trioxaspiro[4.5] decane mesylate	n/a	1/19/2010	Treatment of malaria caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, or Plasmodium malariae	Medicines for Malaria Venture (MMV)
1663	civamide	Zucapsaicin	12/9/2002	Treatment of postherpetic neuralgia of the trigeminal nerve	Winston Laboratories, Inc.
1664	civamide	n/a	2/17/2009	Treatment of postherpetic neuralgia.	Winston Laboratories, Inc.
1665	clarithromycin, rifabutin, clofazimine	n/a	4/26/2011	Treatment of pediatric Crohn's disease.	RedHill Biopharma Ltd.
1666	clobazam	Onfi	12/18/2007	Treatment of Lennox-Gastaut Syndrome	Lundbeck, Inc.
1667	clofarabine	Clofarex	3/14/2002	Treatment of acute myelogenous leukemia	Genzyme Corp (Ilex Products, Inc.)
1668	clofarabine	Clolar	2/7/2002	Treatment of acute lymphoblastic leukemia	Genzyme Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1669	coagulation factor IX (recombinant)	Rixubis	10/31/2012	Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding)	Baxter Healthcare Corporation
1670	coagulation factor XIII A-subunit (recombinant)	Tretten	11/6/2003	Prophylaxis of bleeding associated with congenital factor XIII deficiency	Novo Nordisk, Inc.
1671	cobimetinib	n/a	1/31/2014	Treatment of stage IIb, IIc, III, and IV melanoma with BRAFV600E mutation.	Genentech, Inc.
1672	cobiprostone	n/a	11/14/2002	Treatment of cystic fibrosis	Sucampo Pharma Americas, LLC.
1673	coccidioidin SD Skin Test Antigen	n/a	12/19/2007	For the diagnosis of Coccidioidomycosis	Allermed Laboratories, Inc.
1674	coenzyme Q10 and d-alpha-tocopherol	n/a	3/14/2011	Treatment of Friedreich's Ataxia.	NBI Pharmaceuticals, Inc.
1675	colchicine	Colcrys	9/25/2007	Treatment of familial Mediterranean fever	AR Holding Company, Inc.
1676	collagenase clostridium histolyticum	Xiaflex	3/12/1996	Treatment of Peyronie's disease.	Auxilium Pharmaceuticals, Inc.
1677	collagenase clostridium histolyticum	Xiaflex	5/23/1996	Treatment of advanced (involutional or residual stage) Dupuytren's disease.	Auxilium Pharmaceuticals, Inc.
1678	combretastatin A 1 diphosphate	n/a	11/19/2012	Treatment of acute myelogenous leukemia	OXiGene, Inc.
1679	conjugate of human transferrin and a mutant diphtheria toxin (CRM 107)	Transmid	12/3/2001	Treatment of malignant tumors of the central nervous system	Xenova Biomedix Limited

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1680	conjugated bile acids	Cobartin	7/18/2003	Treatment of steatorrhea in patients with short bowel syndrome	Jarrow Formulas, Inc.
1681	copper histidine	n/a	5/14/2012	Treatment of Menkes disease	Stephen G. Kaler, M.D.
1682	corifungin	n/a	8/22/2011	Treatment of amebic meningoencephalitis.	Ctr for Discovery & Innovation in Parasitic Diseases
1683	corifungin	n/a	7/6/2011	Treatment of visceral leishmaniasis	Sandler Center for Drug Discovery
1684	creatine	Creapure	2/12/2002	Treatment of amyotrophic lateral sclerosis	Avicena Group, Inc.
1685	crenolanib	n/a	10/31/2012	Treatment of acute myelogenous leukemia	AROG Pharmaceuticals, LLC
1686	crenolanib	n/a	3/11/2011	Treatment of soft tissue sarcoma	AROG Pharmaceuticals, LLC
1687	crenolanib	n/a	12/20/2010	Treatment of malignant glioma	AROG Pharmaceuticals, LLC
1688	cridanimod	n/a	1/12/2011	Treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy.	Kevelt Ltd.
1689	crizotinib	Xalkori	10/31/2012	Treatment of neuroblastoma	Pfizer
1690	crizotinib	Xalkori	9/13/2010	Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer	Pfizer, Inc.
1691	crizotinib	Xalkori	9/28/2012	Treatment of anaplastic large cell lymphoma	Pfizer, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1692	cultured, partially T-Cell depleted, allogenic thymic tissue for transplantation	n/a	8/15/2003	As a therapy for primary immune deficiency resulting from athymia associated with complete DiGeorge Syndrome	Duke University Medical Center
1693	cyclic pyranopterin monophosphate (cPMP)	n/a	11/5/2009	Treatment of molybdenum cofactor deficiency type A (MoCD)	Alexion Pharmaceuticals, Inc.
1694	cyclo(-γ-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonyl-L-phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt	n/a	6/24/2013	Treatment of acromegaly	Aspireo Pharmaceuticals Limited
1695	cyclocreatine	n/a	6/18/2012	Treatment of creatine transporter deficiency	Lumos Pharma
1696	cyclophosphamide	Cyrevia(Tm)	6/17/2011	Prevention of graft versus host disease following allogeneic hematopoietic stem cell transplant	Accentia Biopharmaceuticals, Inc.
1697	cyclophosphamide	Cyrevia(Tm)	6/7/2011	Treatment of systemic sclerosis.	Accentia Biopharmaceuticals,
1698	cyclosporine	n/a	2/17/2009	Prophylaxis of graft-versus-host disease	Sigmoid Pharma Limited
1699	cyclosporine	n/a	11/23/2010	Treatment of moderate to severe traumatic brain injury.	NeuroVive Pharmaceutical AB
1700	cyclosporine	n/a	2/17/2009	Treatment of graft-versus-host disease	Sigmoid Pharma Limited
1701	cyclosporine A	Nova22007	4/9/2008	Treatment of herpes simplex virus stromal keratitis	Novagali Pharma S.A.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1702	cyclosporine A	n/a	9/30/2008	Prevention of corneal graft rejection	Novagali Pharma S.A.
1703	cysteamine	n/a	8/6/2008	Treatment of neuronal ceroid lipofuscinoses (Batten disease)	Raptor Pharmaceuticals, Inc.
1704	cysteamine	n/a	5/9/2008	Treatment of Huntington's disease	Raptor Therapeutics
1705	cysteamine	n/a	9/11/2013	Treatment of pancreatic cancer	Raptor Pharmaceuticals, Inc.
1706	cysteamine enteric coated	Procysbi	10/24/2006	Treatment of cystinosis	Raptor Therapeutics,
1707	cytarabine liposome	Depocyt	1/30/2007	Treatment of gliomas	Bruce Frankel, MD
1708	cytochrome C, flavin mononucleotide and thiamin diphosphate	n/a	6/17/2011	Treatment of mitochondrial disorders	NBI Pharmaceuticals, Inc
1709	dabrafenib	Tafinlar	1/12/2011	Treatment BRAF V600 mutation positive Stage IIB through IV melanoma	GlaxoSmithKline, LLC
1710	dacetuzumab	n/a	10/6/2005	Treatment of chronic lymphocytic leukemia	Seattle Genetics, Inc.
1711	dacetuzumab	n/a	8/13/2004	Treatment of multiple myeloma.	Seattle Genetics, Inc.
1712	dalfampridine	Ampyra	6/2/1987	Relief of symptoms of multiple sclerosis	Acorda Therapeutics
1713	dantrolene sodium	n/a	9/25/2012	Treatment of heat stroke	Eagle Pharmaceuticals, Inc.
1714	dantrolene sodium suspension for injection	n/a	8/16/2013	Treatment of malignant hyperthermia syndrome	Eagle Pharmaceuticals, Inc.
1715	daratumumab	Humax(R)-Cd38	5/6/2013	Treatment of multiple myeloma.	Janssen Research & Development, LLC
1716	dasiprotimut-T	Biovaxid	10/28/2009	Treatment of follicular lymphoma	Biovest International, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1717	dasiprotimut-T	Biovax Id	6/17/2010	Treatment of mantle cell lymphoma	Biovest International, Inc.
1718	daunorubicin citrate liposome	Daunoxome	4/15/2013	Treatment of acute myeloid leukemia	Galen Limited
1719	davunetide	n/a	12/7/2009	Treatment of progressive supranuclear palsy.	Allon Therapeutics, Inc.
1720	debrase	Debridase	8/20/2003	Debridement of acute, deep dermal burns in hospitalized patients	MediWound, Ltd.
1721	decitabine	n/a	9/9/2002	Treatment of sickle cell anemia	Eisai, Inc.
1722	deferiprone	n/a	9/1/2011	Treatment of superficial siderosis	ApoPharma, Inc.
1723	deferiprone	n/a	7/31/2008	Treatment of Friedreich's ataxia.	ApoPharma, Inc.
1724	deferiprone	Ferriprox	12/12/2001	Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy	ApoPharma, Inc. A Division of
1725	deferoxamine starch conjugate	n/a	1/28/2005	Treatment of acute iron poisoning	Biomedical Frontiers, Inc.
1726	deferoxamine starch conjugate	n/a	12/21/1998	Treatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia.	Biomedical Frontiers, Inc.
1727	defibrotide	n/a	1/8/2007	For the prevention of hepatic veno-occlusive disease.	Gentium SpA
1728	defibrotide	n/a	5/21/2003	For the treatment of hepatic veno-occlusive disease	Gentium SpA

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1729	deflazacort	Calcort	9/16/2010	Treatment of Duchenne muscular dystrophy	University of Rochester Medical
1730	deflazacort	n/a	8/16/2013	Treatment of Duchenne muscular dystrophy	Marathon Pharmaceuticals, LLC
1731	dehydrated alcohol	n/a	3/16/2012	Treatment of trigeminal neuralgia	Luitpold Pharmaceuticals, Inc.
1732	dehydrated alcohol	Ablysinol	9/11/2013	Treatment of hypertrophic obstructive cardiomyopathy	Belcher Pharmaceuticals, LLC
1733	delta-1,4,9(11)-pregnatriene-17-alpha,21-dihydroxy-16-alpha-methyl-3,20-dione	n/a	12/2/2011	Treatment of Duchenne muscular dystrophy.	ReveraGen Biopharma
1734	dendritic cells pulsed with synthetic peptides derived from antigens MAGE1, HER-2, AIM-2,TRP-2, gp100 and interleukin-13 receptor alpha	n/a	6/7/2010	Treatment of glioblastoma or brain stem glioma	ImmunoCellular Therapeutics Ltd.
1735	dendritic hybrid cell vaccine	Neuroblaxin	9/23/2011	Treatment of neuroblastoma	Orbis Health Solutions, LLC
1736	denileukin diftitox	n/a	7/12/2013	Treatment of cutaneous T-cell lymphoma	Eisai Inc.
1737	denileukin diftitox	Ontak	4/30/2010	Treatment of peripheral T-cell lymphoma	Eisai, Inc.
1738	denileukin diftitox	n/a	6/29/2011	Treatment of peripheral T-cell lymphoma (PTCL)	Eisai, Inc.
1739	denileukin diftitox	Ontak	8/21/1996	Treatment of patients with cutaneous T-cell lymphoma	Eisai, Inc.
1740	denosumab	Xgeva	12/20/2010	Treatment of patients with giant cell tumor of bone	Amgen, Inc.
1741	denosumab	Xgeva	9/11/2013	Treatment of hypercalcemia of malignancy	Amgen, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1742	dexamethasone intravitreal implant	Ozurdex	9/11/1998	Treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis	Allergan
1743	dexamethasone phosphate	n/a	12/2/2008	Treatment of corneal graft rejection.	EyeGate Pharmaceuticals, Inc.
1744	dexamethasone sodium phosphate encapsulated in autologous erythrocytes	n/a	7/24/2012	Treatment of ataxia-telangiectasia	EryDel S.p.A.
1745	dexanabinol	n/a	8/11/2004	For the attenuation or amelioration of the long-term neurological sequelae associated with moderate and severe traumatic brain injury	Pharmos Corporation
1746	dexpramipexole	n/a	10/11/2007	Treatment of amyotrophic lateral sclerosis	Biogen Idec, Inc.
1747	dexrazoxane	Totect(R)	3/25/2004	Treatment of anthracycline extravasation during chemotherapy	Biocodex
1748	dextran 1	n/a	3/21/2003	Treatment of cystic fibrosis	BCY LifeSciences Inc.
1749	diannexin	n/a	10/28/2009	Prevention of ischemia-reperfusion injury in solid organ transplants	Astellas Pharma Global Development, Inc.
1750	diazepam (intranasal)	n/a	7/31/2012	Management of patients with acute repetitive seizures	Acorda Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1751	diazepam auto-injector	n/a	5/30/2013	Management of selected, refractory patients with epilepsy on stable regimens of antiepileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity	Meridian Medical Technologies-a Pfizer subsidiary
1752	diazoxide	n/a	12/3/2012	Treatment of Prader Willi Syndrome	S. Cotter
1753	dichlorphenamide	n/a	9/2/2010	Treatment of primary periodic paralyses	Taro Pharmaceuticals
1754	diethylenetriaminepentaacetate (DPTA)	n/a	4/14/2004	For treatment of patients with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination.	CIS-US
1755	diferuloylmethane	n/a	6/13/2003	Treatment of cystic fibrosis	Allertein Therapeutics, LLC
1756	difluprednate	Durezol	9/30/2008	Treatment of endogenous and traumatic anterior uveitis and panuveitis.	Alcon Pharmaceuticals. Ltd.
1757	digitoxin	n/a	11/2/2001	Treatment of ovarian cancer	PrimeCyte, Inc.
1758	digitoxin	n/a	5/27/2005	Treatment of cystic fibrosis	Bette S. Pollard, LLC
1759	digitoxin	n/a	10/18/2001	Treatment of soft tissue sarcomas	PrimeCyte, Inc.
1760	digoxin immune fab (ovine)	n/a	2/3/2012	Treatment of severe preeclampsia and eclampsia	Glenveigh Medical, LLC

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1761	dihydroartemisinin and piperazine	Eurartesim	1/8/2007	Treatment of uncomplicated malaria caused by "Plasmodium falciparum," Plasmodium vivax," Plasmodium malariae," or "Plasmodium ovale."	Sigma-Tau Pharmaceuticals, Inc.
1762	dimebon	n/a	5/12/2009	Treatment of Huntington's Disease.	Medivation, Inc.
1763	dimethyl fumarate	n/a	9/11/2013	Treatment of Friedreich's Ataxia	Gino Cortopassi
1764	dimethyl sulfoxide	n/a	5/9/2008	For use in combination with antimicrobial drugs for the treatment of drug resistant tuberculosis	Abela Pharmaceuticals, Inc.
1765	dinaciclib	n/a	8/25/2011	Treatment of chronic lymphocytic leukemia.	Merck Sharp & Dohme Ltd.
1766	diphenylcyclopentenone	n/a	6/13/2003	Treatment of chronic severe forms of alopecia areata (Alopecia Totalis [AT]/Alopecia Universalis [AU])	Lloyd E. King, Jr.
1767	docosahexanoic acid-paclitaxel	Taxoprexin	3/5/2001	Treatment of hormone-refractory prostate cancer.	Luitpold Pharmaceuticals, Inc.
1768	domperidone	n/a	9/2/2011	Treatment of hypoprolactinemia in breastfeeding mothers, and in some hypoprolactinemic conditions following the use of cabergoline or bromocriptine in mothers who wish to initiate or return to breastfeeding	Thomas W. Hale, RPh, PhD

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1769	dovitinib	n/a	9/26/2013	Treatment of adenoid cystic carcinoma	Novartis Pharmaceuticals
1770	doxofylline	n/a	2/14/2014	Treatment of bronchiectasis	Alitair Pharmaceuticals, Inc.
1771	doxorubicin	n/a	8/25/2009	Treatment of hepatocellular carcinoma.	Delcath Systems, Inc.
1772	doxorubicin HCL liposome injection	Doxil	12/29/2004	Treatment of multiple myeloma	Johnson & Johnson Pharmaceutical Research & Dev.
1773	doxorubicin PIHCA nanoparticles	Doxorubicin Transdrug	3/14/2005	Treatment of hepatocellular carcinoma	BioAlliance Pharma
1774	doxorubicin with pluronics F-127 and L-61	n/a	2/20/2008	Treatment of gastric cancer	Supratek Pharma, Inc.
1775	droxidopa	Northera	1/17/2007	Treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy.	Chelsea Therapeutics, Inc.
1776	duvoglustat hydrochloride	n/a	6/18/2007	Treatment of Pompe disease	Amicus Therapeutics,
1777	ecallantide	Kalbitor	2/4/2003	Treatment of angioedema	Dyax Corp
1778	ecopipam hydrochloride	n/a	7/21/2009	Symptomatic treatment of self injurious behaviors in patients with Lesch-Nyhan disease.	Psyadon Pharmaceuticals, Inc.
1779	ecopipam hydrochloride	n/a	9/29/2010	Treatment of Tourette's syndrome in children 0-16 years old.	Psyadon Pharmaceuticals, Inc.
1780	eculizumab	Soliris	1/10/2014	Prevention of delayed graft function after renal transplantation	Alexion Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1781	eculizumab	Soliris	8/20/2003	Treatment of paroxysmal nocturnal hemoglobinuria	Alexion Pharmaceuticals, Inc.
1782	eculizumab	Soliris	6/24/2013	Treatment of neuromyelitis optica	Alexion Pharmaceuticals, Inc.
1783	eculizumab	Soliris	4/29/2009	Treatment of atypical hemolytic uremic syndrome	Alexion Pharmaceuticals, Inc.
1784	eculizumab	Soliris	10/18/2011	Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome	Alexion Pharmaceuticals, Inc.
1785	eculizumab	n/a	3/5/2001	Treatment of idiopathic membranous glomerular nephropathy	Alexion Pharmaceuticals, Inc.
1786	efaproxiral	n/a	7/28/2004	Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer	Allos Therapeutics, Inc.
1787	eflornithine	n/a	2/4/2011	Treatment of Familial Adenomatous Polyposis	Cancer Prevention Pharmaceuticals
1788	eflornithine	n/a	11/23/2010	Treatment of neuroblastoma	Cancer Prevention Pharmaceutical, Inc.
1789	eflornithine plus sulindac	n/a	1/22/2013	Treatment of familial adenomatous polyposis	Cancer Prevention Pharmaceuticals, Inc.
1790	eicosapentaenoic acid	n/a	3/8/2011	Treatment of familial adenomatous polyposis	S.L.A. Pharma Ltd. (UK)
1791	elacytarabine	n/a	6/18/2008	Treatment of acute myeloid leukemia (AML)	Clavis Pharma ASA
1792	elafin	n/a	12/28/2012	Treatment of pulmonary arterial hypertension	Proteo Biotech AG
1793	eliglustat	n/a	9/17/2008	Treatment of Gaucher disease	Genzyme Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1794	elosulfase alfa	Vimizim	5/15/2009	Use in the treatment of mucopolysaccharidosis (MPS) Type IV A (Morquio A syndrome)	BioMarin Pharmaceutical Inc.
1795	elotuzumab	n/a	9/1/2011	Treatment of multiple myeloma	Bristol-Myers Squibb Company
1796	eltrombopag	Promacta	11/8/2013	Treatment of aplastic anemia	GlaxoSmithKline LLC
1797	eltrombopag	Promacta	5/5/2008	Treatment of idiopathic thrombocytopenia purpura	GlaxoSmithKline
1798	emricasan	n/a	11/20/2013	Treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease	Conatus Pharmaceuticals Inc.
1799	enalapril maleate (powder for oral solution)	Epaned	1/30/2013	Treatment of hypertension in pediatric patients	Silvergate Pharmaceuticals, Inc.
1800	enchochleate amphotericin B	n/a	1/10/2014	Treatment of visceral leishmaniasis	Aquarius Biotechnologies, Inc.
1801	encorafenib	n/a	11/19/2013	Treatment of Stage IIB-IV melanoma positive for BRAF mutation	Novartis Pharmaceuticals Corporation
1802	encorafenib + binimetinib	n/a	11/19/2013	Treatment in Stage IIB-IV melanoma positive for the BRAF mutation.	Novartis Pharmaceuticalues Corporation
1803	eniluracil	n/a	12/15/2005	Treatment of hepatocellular carcinoma.	Adherex Technologies, Inc.
1804	ensituximab	n/a	10/21/2010	Treatment of pancreatic cancer.	Neogenix Oncology, Inc.
1805	enzastaurin	n/a	3/4/2009	Treatment of diffuse large B-cell lymphoma	Eli Lilly and Company

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1806	epoprostenol	Flolan	3/22/1999	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	GlaxoSmithKline
1807	epratuzumab	n/a	9/30/2008	Treatment of acute lymphoblastic leukemia	Immunomedics, Inc.
1808	epratuzumab	Lymphocide	7/13/1998	Treatment of non-Hodgkin's lymphoma	Immunomedics, Inc.
1809	eptifibatide and iloprost	n/a	4/20/2012	Treatment of purpura fulminans	Thrombologic
1810	erdosteine	n/a	12/20/2013	Treatment bronchiectasis	Alitair Pharmaceuticals, Inc.
1811	eribulin mesylate	Halaven(R)	5/14/2012	Treatment of advanced soft tissue sarcoma	Eisai, Inc.
1812	etanercept	Enbrel	10/27/1998	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	Immunex Corporation
1813	etarfolatide	n/a	2/16/2000	For the identification of ovarian carcinomas	Endocyte, Inc.
1814	eteplirsen	n/a	10/23/2007	Treatment of Duchenne Muscular Dystrophy.	Sarepta Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1815	ethanolamine	Ethamolin	1/17/2014	Prophylactic use in pediatric patients (age 0 through 16 years) with esophageal varices that are at risk of bleeding to obliterate varices and to prevent bleeding	QOL Medical, LLC
1816	ethiodized oil injection	n/a	9/26/2013	Diagnostic for the management of patients with hepatocellular carcinoma	Guerbet LLC
1817	etirinotecan pegol	n/a	4/18/2011	Treatment of ovarian cancer.	Nektar Therapeutics
1818	everolimus	Afinitor	9/16/2010	Treatment of Waldenstrom macroglobulinemia (also known as lymphoplasmacytic lymphoma)	Novartis Pharmaceuticals Corporation
1819	everolimus	Afinitor	5/24/2011	Treatment of gastric cancer	Novartis Pharmaceuticals
1820	everolimus	Afinitor(R)	7/23/2012	Treatment of hepatocellular carcinoma	Novartis Pharmaceuticals
1821	everolimus	Afinitor	2/14/2008	Treatment of neuroendocrine tumors	Novartis Pharmaceuticals
1822	everolimus	Afinitor	6/8/2009	Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangiomyomatosis (LAM)	Novartis Pharmaceuticals Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1823	ex-vivo cultered adult human mesenchymal stem cells	Prochymal(R)	4/30/2010	Treatment of Type 1 diabetes patients with residual beta cell function	Mesoblast, Inc.
1824	ex-vivo expanded autologous bone marrow-derived mesenchymal stem cells	n/a	12/20/2010	Treatment of Amyotrophic Lateral Sclerosis	TCA Cellular Therapy, LLC
1825	exendin-(9-39)	n/a	6/1/2011	Treatment of congenial hyperinsulinemic hypoglycemia and other causes of hyperinsulinemic hypoglycemia in adults and children.	The Children's Hospital of Philadelphia
1826	exon 53 specific phosphorothioate oligonucleotide	n/a	1/23/2013	treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 53	Prosensa Therapeutics B.V.
1827	expanded allogeneic human dermal fibroblasts in hypothermosol(r)-FRS	n/a	8/20/2009	Treatment of Dystrophic Epidermolysis Bullosa.	Intercytex Ltd.
1828	expanded human allogeneic neural retinal progenitor cells extracted from neural retina	n/a	8/22/2013	Treatment of retinitis pigmentosa	ReNeuron Ltd
1829	extract of sorghum bicolor extract	n/a	11/19/2012	Treatment of sickle cell disease	Invenux, LLC
1830	ezatiostat hydrochloride	Telintra	1/9/2013	Treatment of myelodysplastic syndrome	Telik, Inc.
1831	factor VIII mimetic bispecific antibody	n/a	1/10/2014	Treatment of hemophilia A	Chugai Pharma USA, LLC

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1832	factor XIII concentrate (human)	Corifact	1/16/1985	Treatment of congenital factor XIII deficiency	CSL Behring LLC
1833	farletuzumab	n/a	6/16/2006	Treatment of ovarian cancer	Morphotek, Inc.
1834	fenfluramine HCl	Brabafen	12/20/2013	For the Treatment of Dravet Syndrome	Brabant Pharma Limited
1835	fenretinide	n/a	2/1/2007	Treatment of Ewing's sarcoma family of tumors.	Cancer Research UK
1836	fenretinide	n/a	9/4/2013	Treatment of peripheal T-cell lymphoma	CerRx, Inc.
1837	fenretinide	n/a	9/4/2013	Treatment of cutaneous T-cell lymphoma	CerRx, Inc.
1838	ferric hexacyanoferrate (II) "Prussian Blue"	n/a	6/26/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Degussa AG
1839	ferumoxytol	Feraheme	4/29/2011	For use in MR imaging for the mangement of brain tumors	Edward A. Neuwelt, MD
1840	ferumoxytol	n/a	4/6/2012	For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)	ArsNova Partners, LLC
1841	ferumoxytol	n/a	10/7/2011	For use in magnetic resonance imaging in brain metastases	Oregon Health & Science University
1842	fialuridine	n/a	7/24/1992	Adjunctive treatment of chronic active hepatitis B.	Oclassen Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1843	fidaxomicin	Difucid	12/13/2010	Treatment of pediatric Clostridium difficile infection	Optimer Pharmaceuticals, Inc.
1844	fingolimod	n/a	4/30/2010	Treatment of chronic inflammatory demyelinating polyneuropathy	Novartis Pharmaceutical Corporation
1845	firtecan pegol	n/a	4/18/2011	Treatment of neuroblastoma.	Enzon Pharmaceuticals, Inc.
1846	flubendazole	n/a	10/25/2013	Treatment of onchocerciasis caused by Onchocerca volvulus	Janssen Research & Development, LLC
1847	flubendazole	n/a	1/23/2014	Treatment of lymphatic filariasis caused by nematodes of the family Filariodidea, in children and adults.	Janssen Research and Development, LLC
1848	flunarizine hydrochloride	n/a	6/24/2013	Treatment of alternating hemiplegia	Marathon Pharmaceuticals, LLC
1849	fluticasone propionate	n/a	1/19/2011	Treatment of pediatric and adult eosinophilic esophagitis	Aptalis Pharma US, Inc.
1850	fosfomycin/tobramycin	n/a	11/28/2008	Treatment of pulmonary infections associated with cystic fibrosis	Gilead Sciences, Inc.
1851	fresolimumab	n/a	10/21/2010	Treatment of primary focal segmental glomerulosclerosis	Genzyme
1852	fusion protein analog with recombinant human growth hormone (rhGH) at once-a-month dosing	n/a	10/16/2013	Treatment of growth hormone deficiency	Versartis, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1853	gabapentin	Neurontin	7/5/1995	Treatment of amyotrophic lateral sclerosis	Warner-Lambert Company
1854	gabapentin	Gralise	11/8/2010	Management of postherpetic neuralgia	Depomed, Inc.
1855	gabapentin enacarbil	Horizant	6/7/2011	Treatment of postherpetic neuralgia	XenoPort, Inc.
1856	ganciclovir	Zirgan	3/22/2007	Treatment of acute herpetic keratitis (dendritic and geographic ulcers)	Sirion Therapeutics, Inc.
1857	gemcabene	n/a	2/6/2014	Treatment of homozygous familial hypercholesterolemia	Michigan Life Therapeutics, LLC
1858	gene encoding chimeric CD40 ligand	n/a	2/4/2009	Treatment of chronic lymphocytic leukemia	Memgen, LLC
1859	genetically engineered herpes simplex virus (G207)	n/a	4/29/2002	Treatment of malignant glioma	MediGene, Inc.
1860	gevokizumab	n/a	2/21/2014	Treatment of pyoderma gangrenosum	XOMA (US) LLC
1861	gevokizumab	n/a	7/27/2010	Treatment of Behcet's disease	XOMA (US) LLC
1862	gevokizumab	n/a	8/20/2012	Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis	XOMA (US) LLC
1863	givinostat	n/a	4/12/2013	Treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy	Italfarmaco SpA
1864	glatiramer acetate	Copaxone	11/14/2007	Treatment of amyotrophic lateral sclerosis (ALS).	Teva Neurosciences, Inc.
1865	glioma derived cell lysates and irradiated cells	n/a	1/12/2011	Treatment of glioma.	Epitopoietic Research Corp.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1866	glucagon	n/a	12/5/2012	Prevention of hypoglycemia in the congenital hyperinsulinism population	Biodel, Inc.
1867	glucarpidase	Voraxaze	8/19/2003	Treatment of patients at risk of methotrexate toxicity	BTG International Inc.
1868	glufosfamide	n/a	9/18/2006	For treatment of pancreatic cancer.	Eleison Pharmaceuticals LLC
1869	glycyl-L-phenylalanine	n/a	8/22/2008	Prevention of delayed graft function after solid organ transplantation	ProtAffin Biotechnologie AG
1870	glycerol phenylbutyrate	Ravicti	4/27/2009	Maintenance treatment of patients with deficiencies in enzymes of the urea cycle	Hyperion Therapeutics, Inc.
1871	glycopyrrolate	Cuvposa	6/9/2006	Treatment of pathologic (chronic moderate to severe) drooling in pediatric patients	Shionogi, Inc.
1872	glycopyrrolate 2%	n/a	6/17/2010	Treatment of Frey's syndrome	Wellesley Therapeutics, Inc.
1873	glycosylated recombinant human interleukin-7	n/a	9/27/2012	Treatment of progressive multifocal leukoencephalopathy	Cytheris, Inc.
1874	glycyl-L-2-methylprolyl-L-glutamic Acid	n/a	10/23/2013	Treatment of Fragile X Syndrome	Neuren Pharmaceuticals, Ltd.
1875	golimumab	Simponi	3/16/2012	Treatment of pediatric ulcerative colitis	Janssen Biotech, Inc.
1876	golimumab	Simponi Aria	5/21/2012	Treatment of sarcoidosis	Janssen Biotech, Inc.
1877	golnerminogene pradenovec	Tnferade(TM) Biologic	10/28/2009	Treatment of pancreatic cancer.	GenVec, Inc.
1878	granulocyte macrophage colony stimulating factor	n/a	8/27/2008	Treatment of cystic fibrosis	DrugRecure Aps

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1879	granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus, Ad5/3-D24-GMCSF	n/a	7/24/2013	Treatment of soft tissue sarcoma	Oncos Therapeutics Ltd
1880	guanfacine	Tenex	8/5/1999	Treatment of fragile X syndrome.	Watson Laboratories, Inc.
1881	gusperimus trihydrochloride	n/a	6/29/2011	Treatment of Wegener's granulomatosis	Nordic Group B.V.
1882	glyceryl tri (4-pheynlybutyrate)	n/a	9/3/2009	For intermittent or chronic treatment of patients with cirrhosis and any grade hepatic encephalopathy.	Hyperion Therapeutics, Inc.
1883	hRS7-SN-38 IgG Conjugate	n/a	11/27/2013	Treatment of small cell lung cancer	Immunomedics, INc.
1884	halofuginone hydrobromide	n/a	10/13/2011	Treatment of Duchenne Muscular Dystrophy	Halo Theraeputics, LLC
1885	heat killed Mycobacterium w immunomodulator	Cadi Mw	9/3/2004	Active tuberculosis	Cadila Pharmaceuticals
1886	heat killed mycobacterium w immunomodulator	Cadi Mw	11/21/2002	Adjuvant to multi-drug therapy in the management of multibacillary leprosy	CPL, Inc.
1887	heat killed mycobacterium w immunomodulator	Cadi-Mw	7/31/2012	Treatment of non-small cell lung cancers that express desmocollin-3	Cadila Pharmaceuticals Limited
1888	heparin activated recombinant human fibroblast growth factor 1 (FGF1)in combination with a surgically implanted biodegradable device	n/a	10/24/2011	Treatment of patients with a confirmed traumatic complete spinal cord injury where no motor or sensory function is preserved below the injury(Scale A)	BioArctic Neuroscience AB

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1889	hepatitis B immune globulin (human)	Hepagam	3/24/2008	Prevention of hepatitis B recurrence following orthotopic liver transplant	Cangene Corporation
1890	hepatitis B virus neutralizing human monoclonal antibody	Hepabig Gene	5/6/2013	Prevention of hepatitis B recurrence following liver transplantation	Green Cross Corp.
1891	herpes simplex Type-1 virus encoded with human granulocyte-	Oncovexgm-Csf	3/14/2011	Treatment of stage IIb-stage IV melanoma	BioVex, Inc.
1892	heterologous human adult liver derived progenitor cells (HHALPC)	n/a	1/13/2012	Treatment of urea cycle disorders	Promethera Biosciences
1893	heterologous human liver derived progenitor cells	n/a	3/9/2012	Treatment of Crigler-Najjar syndrome	Promethera Biosciences
1894	hexasodium phytate	n/a	12/2/2012	Treatment of calciphylaxis	Laboratoris Sanifit,
1895	homoharringtonine	n/a	2/8/2002	Treatment for chronic myelogenous leukemia	American BioScience, Inc.
1896	human Hepatocarcinoma-Intestine-pancreas/pancreatitis associated protein	n/a	5/11/2011	Treatment of acute liver failure	Alfact Innovation SAS
1897	human IgG1k monoclonal antibody	n/a	10/16/2013	Treatment of systemic sclerosis	MedImmune
1898	human MHC non-restricted cytotoxic T-cell line	n/a	7/6/2012	Treatment of ovarian cancer	Galileo Research srl
1899	human allogeneic bone marrow derived osteoblastic cells	Allob	1/10/2014	Treatment of osteonecrosis	Bone Therapeutics SA
1900	human anti-CD4 monoclonal antibody	Humax-Cd4	8/13/2004	Treatment of mycosis fungoides	Emergent Product Development Seattle,

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1901	human anti-cellular adhesion molecule-1 monoclonal antibody	n/a	7/29/2008	Treatment of multiple myeloma	BioInvent International AB
1902	human anti-integrin receptor avb3/avb5 monoclonal antibody	n/a	12/1/2004	Treatment of patients with high-risk stage II, stage III, and stage IV malignant melanoma	Janssen Research & Development, LLC
1903	human anti-transforming growth factor-B1,2,3	n/a	7/9/2004	Treatment of idiopathic pulmonary fibrosis	Genzyme Corporation
1904	human coagulation factor VIII	Octanate	12/3/2012	Immune tolerance induction in hemophilia A patients with inhibitors	OCTAPHARMA USA, Inc.
1905	human coagulation factor XI	Hemoleven	11/8/2007	Treatment of severe congenital Factor XI deficiency.	Laboratoire francais du Fractionnement et des Biot
1906	human fibrinogen concentrate, pasteurized	Riastap	3/13/2008	Treatment of fibrinogen deficient patients	CSL Behring, LLC
1907	human gammaglobulin	Oralgam	11/14/2003	Treatment of idiopathic inflammatory myopathies	Latona Life Sciences, Inc.
1908	human gammaglobulin	Oralgam	5/25/2001	Treatment for juvenile rheumatoid arthritis	Latona Life Sciences, Inc.
1909	human gammaglobulin	Oralgam	9/16/2002	Treatment of gastrointestinal disturbances (to include constipation, diarrhea, and abdominal pain) associated with regression-onset autism in pediatric patients.	Latona Life Sciences, Inc.
1910	human glial restricted progenitor cells and their progeny	Q-Cells(R)	9/11/2013	Treatment of amyotrophic lateral sclerosis	Q Therapeutics, Inc.
1911	human haptoglobin	n/a	11/19/2013	Treatment of sickle cell disease	BioProducts Laboratory Limited

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1912	human heterologous liver cells	n/a	2/14/2011	Treatment of urea cycle disorders	Cytonet GmbH & Co. KG
1913	human insulin beta chain peptide with incomplete Freund's adjuvant vaccine	n/a	2/11/2013	Treatment of Type 1 diabetes patients with residual beta cell function	Orban Biotech, LLC
1914	human interleukin-3 genetically conjugated to diphtheria toxin protein	n/a	2/18/2011	Treatment of acute myeloid leukemia.	Stemline Therapeutics, Inc.
1915	human interleukin-3 genetically conjugated to diphtheria toxin protein	n/a	6/6/2013	Treatment of blastic plasmacytoid dendritic cell neoplasm	Stemline Therapeutics, Inc.
1916	human laminin-111	n/a	9/23/2011	Treatment of merosin (laminin-alpha2) deficient congenital muscular dystrophy type 1A.	Prothelia, Inc.
1917	human leukocyte-derived cytokine mixture	n/a	7/7/2005	Neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck	IRX Therapeutics, Inc.
1918	human lysosomal acid lipase, recombinant, transgenic gallus	n/a	7/1/2010	Treatment of lysosomal acid lipase deficiency	Synageva BioPharma Corp.
1919	human monoclonal IgG2 to human proprotein convertase subtilisin/kexin type 9	n/a	9/12/2013	Treatment of homozygous familial hypercholesterolemia	Amgen Inc.
1920	human monoclonal anti-PA antibody	n/a	10/21/2010	For post-exposure prophylaxis and treatment of inhalation anthrax.	Emergent Product Development Gaithersburg, Inc.
1921	human monoclonal antibody against human interleukin 13 (IL-13)	n/a	10/15/2013	Treatment of eosinophilic esophagitis	Novartis Pharmaceuticals Corporaton

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1922	human monoclonal antibody directed against active plasma kallikrein	n/a	11/16/2013	Treatment of hereditary angioedema (HAE)	Dyax Corporation
1923	human monoclonal antibody directed against serotype O1 Pseudomonas aeruginosa	n/a	1/6/2010	Treatment of pneumonia caused by serotype O1 positive Pseudomonas aeruginosa	Kenta Biotech Limited
1924	human plasminogen	n/a	6/7/2010	Treatment of ligneous conjunctivitis	Kedrion, S.p.A.
1925	human platelet antigen-1a immunoglobulin (anti-HPA-1a)	Tromplate	6/27/2013	Prevention of fetal and neonatal alloimmune thrombocytopenia	Prophylis Pharma AS
1926	human recombinant DNA-derived, IgG1 kappa monoclonal anti-body to connective growth factor	n/a	7/6/2012	Treatment of idiopathic pulmonary fibrosis	FibroGen, Inc.
1927	human retinal progenitor cells	n/a	7/23/2012	Treatment of retinitis pigmentosa	jCyte, Inc.
1928	human spinal cord derived neural stem cells	n/a	2/4/2011	Treatment of amyotrophic lateral sclerosis.	Neuralstem, Inc.
1929	human tumor necrosis factor coupled to the C terminus of CNGRCG peptide	n/a	10/1/2009	Treatment of liver cancer	Molecular Medicine S.p.A. (Molmed)
1930	human umbilical cord blood-derived mesenchymal stem cells	Pneumostem	11/26/2013	Prevention of bronchopulmonary dysplasia	MEDIPOST America, Inc.
1931	humanized IgG1 anti-serum amyloid A monoclonal antibody	n/a	2/17/2012	Treatment of AA amyloidosis and AL amyloidosis	Onclave Therapeutics Limited

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1932	humanized IgG1 monoclonal anti-CD20 antibody	n/a	5/26/2011	Treatment of follicular lymphoma	MENTRIK Biotech, LLC
1933	humanized IgG2 antibody	n/a	7/22/2008	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	Selexys Pharmaceuticals Corp.
1934	humanized IgG4 monoclonal antibody	n/a	12/12/2011	Prevention of ischemia/reperfusion injury associated with solid organ transplantation	Opsona Therapeutics
1935	humanized anti programmed cell death 1 monoclonal IgG4 antibody	n/a	11/19/2012	Treatment of Stage IIB through IV malignant melanoma	Merck, Sharp & Dohme Corp.
1936	humanized monoclonal antibody against human integrin alphaVbeta6	n/a	8/5/2010	Treatment of idiopathic pulmonary fibrosis	Stromedix, Inc.
1937	humanized monoclonal antibody to tissue factor	n/a	4/26/2011	Treatment of pancreatic cancer.	Morphotek, Inc.
1938	humanized monoclonal antibody against human integrin alphaVbeta6	n/a	6/18/2008	Treatment of fibrosis-associated chronic allograft nephropathy in kidney transplant patients.	Stromedix, Inc.
1939	humanized single chain monoclonal antibody(scFV: IgG1 hinge: IgG1 CH2 and CH3 domains)	n/a	11/17/2011	Treatment of chronic lymphocytic leukemia	Emergent Product Development Seattle, LLC
1940	humanized, afucosylated IgG1 kappa monoclonal antibody	n/a	12/3/2009	Treatment of scleroderma	MedImmune
1941	hyaluronic acid	n/a	3/19/2002	Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency	CoTherix

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1942	hydralazine - magnesium valproate	Transkrip(R)	3/17/2011	Treatment of cutaneous T-cell lymphoma.	Neolpharma S.A.DE C.V.
1943	hydralazine - magnesium valproate	Transkrip(R)	3/17/2011	Treatment of myelodysplastic syndrome	Neolpharma S.A. de C.V.
1944	hydrocortisone modified release tabs	Duocort	6/18/2008	Treatment of adrenal insufficiency	ViroPharma, Inc.
1945	hydroxycarbamide (hydroxyurea)	Siklos(R)	7/24/2013	Treatment of sickle cell disease in patients under 18 years of age	addmedica Laboratories
1946	hydroxyprogesterone caproate	Makena	1/25/2007	Prevention of preterm birth in singleton pregnancies	KV Pharmaceutical Company
1947	hydroxyurea	n/a	4/15/2005	Treatment of pediatric patients with sickle cell anemia.	UPM Pharmaceuticals, Inc.
1948	ibritumomab tiuxetan	Zevalin	9/6/1994	Treatment of B-cell non-Hodgkin's lymphoma.	Spectrum Pharmaceuticals, Inc.
1949	ibrutinib	n/a	10/23/2013	Treatment of diffuse large B-cell lymphoma	Pharmacyclics, Inc.
1950	ibrutinib	Imbruvica	4/6/2012	Treatment of chronic lymphocytic leukemia (CLL)	Pharmacyclics, Inc.
1951	ibrutinib	Imbruvica	12/3/2012	Treatment of mantle cell lymphoma.	Pharmacyclics, Inc.
1952	ibrutinib	n/a	5/16/2013	Treatment of multiple myeloma	Pharmacyclics, Inc.
1953	ibrutinib	n/a	5/30/2013	Treatment of small lymphocytic lymphoma	Pharmacyclics, Inc.
1954	ibrutinib	n/a	10/15/2013	Treatment of Waldenstrom's macroglobulinemia	Pharmacyclics, Inc.
1955	icatibant	Firazyr	11/25/2003	Treatment of angioedema	Shire Orphan
1956	idebenone	n/a	2/16/2007	Treatment of Duchenne muscular dystrophy	Santhera Pharmaceuticals

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1957	idebenone	n/a	5/22/2009	Treatment of mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes syndrome (MELAS)	Santhera Pharmaceuticals Limited
1958	idebenone	n/a	3/25/2004	Treatment of Friedreich's ataxia	Santhera Pharmaceuticals LLC
1959	idebenone	n/a	10/31/2006	Treatment of Leber's hereditary optic neuropathy.	Santhera Pharmaceuticals
1960	idelalisib	n/a	10/15/2013	Treatment of extranodal marginal zone lymphoma	Gilead Sciences, Inc.
1961	idelalisib	n/a	9/26/2013	Treatment of follicular lymphoma	Gilead Sciences, Inc.
1962	idelalisib	n/a	10/15/2013	Treatment of splenic marginal zone lymphoma	Gilead Sciences, Inc.
1963	idelalisib	n/a	10/15/2013	Treatment of nodal marginal zone lymphoma.	Gilead Sciences, Inc.
1964	idelalisib	n/a	10/15/2013	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Gilead Sciences, Inc
1965	idelalisib	n/a	9/26/2013	Treatment of lymphoplasmacytic lymphoma with or without Walenstom's macroglobulinemia	Gilead Sciences, Inc.
1966	idelalisib	n/a	8/25/2011	Treatment of chronic lymphocytic leukemia	Gilead Sciences, Inc.
1967	idursulfase	Elaprase	11/28/2001	Long term enzyme replacement therapy for patients with mucopolysaccharidosis II (Hunter Syndrome)	Shire Human Genetic Therapies, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1968	idursulfase IT	n/a	9/3/2009	For treatment of neurocognitive symptoms associated with Hunter Syndrome	Shire Human Genetic Therapies
1969	idursulfase beta	n/a	2/11/2013	Treatment of Hunter Syndrome (mucopolysaccharidoses)	Green Cross Corp.
1970	iduvec	n/a	1/21/2011	Treatment of Mucopolysaccharidosis Type I	Zebraic Corporation
1971	iferanserin (S-MPEC)	n/a	12/13/2010	For use in pulmonary arterial hypertension.	Sam Amer & Company, Inc.
1972	iloprost	n/a	4/6/2012	Treatment of pulmonary arterial hypertension	Algorithm Sciences, LLC
1973	ilorasertib	n/a	3/16/2012	Treatment of ovarian cancer	AbbVie, Inc.
1974	imatinib	Gleevec	10/11/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Novartis Pharmaceuticals Corporation
1975	imatinib mesylate	Gleevec	12/19/2005	Treatment of dermatofibrosarcoma protuberans	Novartis Pharmaceuticals Corporation
1976	imatinib mesylate	Gleevec	11/1/2001	Treatment of gastrointestinal stromal tumors	Novartis Pharmaceuticals
1977	imexon	Amplimexon	8/12/2005	Treatment of ovarian cancer.	AmpliMed
1978	immune globulin (human)	n/a	3/2/2010	Treatment of Guillain-Barre syndrome	Octapharma USA, Inc.
1979	immune globulin infusion (human)	Gammagard Liquid	7/20/2006	Treatment of multifocal motor neuropathy	Baxter Healthcare Corporation
1980	immune globulin intravenous (human)	Gammaplex	4/29/2011	Treatment of idiopathic thrombocytopenic purpura (also known as primary immune thrombocytopenia)	Bio Products Laboratory

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1981	infliximab	Remicade	10/23/2002	Treatment of juvenile rheumatoid arthritis	Centocor, Inc.
1982	infliximab	Remicade	11/12/2003	Treatment of pediatric (0 to 16 years of age) ulcerative colitis	Janssen Biotech Inc.
1983	infliximab	Remicade	11/14/1995	Treatment of Crohn's disease	Centocor, Inc.
1984	inhibitor of microRNA-451	n/a	2/4/2011	Treatment of polycythemia vera	miRagen Therapeutics, Inc.
1985	inolimomab	Leukotac	10/23/2002	Treatment of graft versus host disease	Jazz Pharmaceuticals
1986	inotuzumab ozogamicin	n/a	3/25/2013	Treatment of B-cell acute lymphoblastic leukemia	Pfizer, Inc.
1987	insecticidal toxin derived from Bacillus thuringiensis	n/a	9/5/2008	Treatment of soil transmitted helminth infection strongyloidiasis	University of California, San Diego
1988	interferon gamma	n/a	11/4/2011	Treatment of Friedreich's ataxia	Roberto Testi, MD
1989	interferon-alpha secreting autologous micro-organ tissue converting into a biopump	Infradure Biopump	6/14/2012	Treatment of chronic hepatitis D	Medgenics, Inc.
1990	intravenous carbamazepine	n/a	6/27/2013	Treatment of epilepsy patients who cannot take anything by mouth (NPO)	Lundbeck, LLC
1991	iobenguane I 131	n/a	7/5/2007	Treatment of neuroendocrine tumors	Jubilant DraxImage, Inc.
1992	iobenguane sulfate I-123	Omaclear	10/21/2005	For the detection, localization, and staging of pheochromocytomas.	Brogan Pharmaceuticals, Inc.
1993	ipilimumab	Yervoy	6/3/2004	Treatment of high risk Stage II, Stage III, and Stage IV melanoma	Bristol-Myers Squibb Pharmaceutical Research Insti

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
1994	irofulven	n/a	7/27/1999	Treatment of renal cell carcinoma.	Eisai, Inc.
1995	irofulven	n/a	7/6/1999	Treatment of ovarian cancer.	Eisai, Inc.
1996	iron(III)-hexacyanoferrate(II)	Radiogardase	5/1/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Heyl Chemisch-Pharmzeitische Fabrik GMBH & Co, KG
1997	isavuconazonium sulfate	n/a	5/6/2013	Treatment of invasive aspergillosis.	Astellas
1998	isavuconazonium sulfate	n/a	10/25/2013	Treatment of zygomycosis	Astellas
1999	isofagomine tartrate	n/a	1/10/2006	Treatment of Gaucher disease	Amicus Therapeutics, Inc.
2000	ivacaftor	Kalydeco	12/20/2006	Treatment of patients with cystic fibrosis	Vertex Pharmaceuticals, Inc.
2001	ixazomib citrate	n/a	2/18/2011	Treatment of multiple myeloma	Millennium Pharmaceuticals
2002	lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococci)	n/a	1/15/2002	Treatment of active chronic pouchitis	VSL Pharmaceuticals, Inc.
2003	lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)	n/a	1/15/2002	Prevention of disease relapse in patients with chronic pouchitis	VSL Pharmaceuticals, Inc.
2004	lactobacillus brevis CD2	n/a	10/4/2011	Treatment Behcet's disease	VSL Pharmaceuticals,
2005	laminin-111 (human)	n/a	7/21/2011	Treatment of Duchenne Muscular Dystrophy	Prothelia, Inc.
2006	lanreotide acetate	n/a	9/8/2011	Treatment of symptoms associated with carcinoid syndrome	Ipsen Biopharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2007	lanreotide acetate	n/a	8/25/2011	Treatment of neuroendocrine tumors.	Ipsen Biopharmaceuticals,
2008	lapatinib	Tykerb	5/29/2009	Treatment of ErbB2 positive gastric cancer	GlaxoSmithKline
2009	lapatinib ditosylate hydrochloride	Tykerb	5/29/2009	Treatment of ErbB2 positive esophageal cancer	GlaxoSmithKline
2010	laromustine	Onrigin	10/21/2004	Treatment of acute myelogenous leukemia	Vion Pharmaceuticals, Inc.
2011	laronidase	Aldurazyme	9/24/1997	Treatment of patients with mucopolysaccharidosis-I.	BioMarin Pharmaceutical, Inc.
2012	late stage human motor neuron progenitors	Motorgraft(Tm)	11/25/2009	Treatment of spinal muscular atrophy	California Stem Cell, Inc.
2013	lenalidomide	Revlimid	1/17/2007	Treatment of chronic lymphocytic leukemia	Celgene Corporation
2014	lenalidomide	Revlimid	3/28/2011	Treatment of diffuse large B-cell lymphoma	Celgene Corporation
2015	lenalidomide	Revlimid	1/29/2004	Treatment of myelodysplastic syndromes	Celgene Corporation
2016	lenalidomide	Revlimid	4/27/2009	Treatment of mantle cell lymphoma	Celgene Corporation
2017	lenalidomide	Revlimid	9/20/2001	Treatment for multiple myeloma	Celgene Corporation
2018	lenalidomide	Revlimid	9/13/2013	Treatment of follicular lymphoma	Celgene Corporation
2019	lenvatinib	n/a	12/27/2012	Treatment of follicular, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer	Eisai, Inc.
2020	lestaurtinib	n/a	9/3/2009	Treatment of Philadelphia-negative classic myeloproliferative disorders	Teva Branded Pharmaceutical Products R&D, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2021	letermovir	n/a	12/12/2011	Prevention of human cytomegalovirus viremia and disease in at risk populations	Merck Sharpe & Dhome Corporation
2022	leukocyte interleukin	Multikine	5/4/2007	Neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck	CEL-SCI Corporation
2023	levetiracetam	Keppra	4/30/2010	Treatment of neonatal seizures	University of California
2024	levoleucovorin	Fusilev	12/18/1990	For use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum	Spectrum Pharmaceuticals, Inc.
2025	levothyroxine sodium	n/a	4/26/2011	The preservation of organ function in brain-dead organ donors.	Fera Pharmaceuticals, LLC
2026	liarozole	n/a	6/18/2004	Treatment of congenital ichthyosis	Stiefel Laboratories, Inc.
2027	liposomal amikacin	Arikace	3/25/2013	Treatment infections caused by non-tuberculous mycobacteria	Insmed Incorporated
2028	liposomal amikacin	Arikace	8/25/2009	Treatment of bronchiectasis in patients with Pseudomonas aeruginosa or other susceptible microbial pathogens	Insmed, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2029	liposomal busulfan	Busulipo	6/24/2013	For use as a conditioning regimen for patients with malignancies undergoing autologous or allogenic hematopoietic stem cell transplantation	Pharmalink AB
2030	liposomal ciprofloxacin plus ciprofloxacin	n/a	6/1/2012	For the management of cystic fibrosis	Aradigm Corporation
2031	liposomal cyclosporine	n/a	5/11/2009	Treatment of bronchiolitis obliterans	PARI Pharma GmbH
2032	liposomal cyclosporine for inhalation	n/a	6/24/2008	Prevention of bronchiolitis obliterans.	PARI Pharma GmbH
2033	liposomal gadodiamide	n/a	11/12/2008	Treatment of glioma.	MedGenesis Therapeutix, Inc.
2034	liposomal irinotecan	n/a	7/21/2011	Treatment of pancreatic cancer	Merrimack Pharmaceuticals, Inc.
2035	liposomal p-ethoxy growth receptor bound protein-2 antisense product	n/a	12/5/2003	Treatment of chronic myelogenous leukemia	Bio-Path, Inc.
2036	liposomal topotecan hydrochloride	n/a	10/30/2008	Treatment of gliomas	MedGenesis Therapeutix, Inc.
2037	liposomal $\alpha$ -galactosylceramide	Lip. Alpha Galactosylceramide	9/28/2012	Prevention of graft-versus-host disease	REGiMMUNE Corporation
2038	listeria monocytogenes	n/a	9/5/2013	Treatment of pancreatic cancer	Aduro BioTech, Inc.
2039	lisuride	n/a	1/17/2013	Treatment of pulmonary arterial hypertension	Sinoxa Pharma
2040	lithium citrate tetrahydrate (in reverse micelle formulation)	n/a	12/13/2010	Treatment of Huntington's disease.	Medesis Pharma

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2041	live attenuated E. Coli expressing Beta catenin shRNA	n/a	12/20/2010	Treatment of Familial Adenomatous Polyposis	Marina Biotech
2042	live attenuated bioengineered Listeria monocytogenes immunotherapy	n/a	11/4/2013	Treatment of human papilloma virus-associated head and neck cancer	Advaxis, Inc.
2043	lomitapide	Juxtapid	10/23/2007	Treatment of homozygous familial hypercholesterolemia	Aegerion Pharmaceuticals, Inc.
2044	lomitapide	n/a	3/3/2011	Treatment of Familial Chylomicronemia	Aegerion Pharmaceuticals, Inc.
2045	lonafarnib	n/a	4/18/2011	Treatment of Hutchinson-Gilford progeria syndrome	The Progeria Research Foundation,
2046	long acting recombinantFactor VIIa-CTP3	n/a	2/27/2014	Treatment and prophylaxis of bleeding episodes in patients with hemophilia A or B with inhibitors to factor VIII or factor IX	PROLOR Biotech, Ltd
2047	losartan	n/a	12/12/2011	Treatment of Marfan Syndrome	National Marfan Foundation
2048	low molecular weight dextran sulfate	Ibsolvmir(R)	7/6/2011	Treatment to mobilize progenitor cells prior to stem cell transplantation	TikoMed AB
2049	low molecular weight dextran sulfate	Ibsolvmir	10/20/2009	Prevention of graft rejection during pancreatic islet transplantation	TikoMed AB
2050	lurbinectedin	n/a	8/20/2012	Treatment of ovarian cancer	Pharma Mar USA Inc.
2051	lyso-thermosensitive liposomal doxorubicin	Thermodox (R)	3/17/2009	Treatment of hepatocellular carcinoma	Celsion Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2052	lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase	n/a	9/10/2008	Treatment of mucopolysaccharidosis Type IVA (Morquio Syndrome)	Vivendy Therapeutics LTD
2053	mPEG-r-crisantaspase	Asparec(Tm)	2/1/2010	Treatment of acute lymphoblastic leukemia.	Jazz Pharmaceuticals, Inc.
2054	mTOR kinase inhibitor (CC-223)	n/a	10/16/2013	Treatment of hepatocellular carcinoma	Celgene Corporation
2055	macitentan	Opsumit	9/3/2009	Treatment of pulmonary arterial hypertension	Actelion Pharmaceuticals Ltd
2056	manganese (II) chloride tetrahydrate (with L-alanine and vitamin D3 as promoters of absorption)	n/a	9/26/2013	Use as a targeted contrast agent for diagnostic MRI for the detection and localization of focal liver lesions in patients where gadolinium based contrast agents are contraindicated or cannot be administered	CMC Contrast AB
2057	mannopentaose phosphate sulfate	n/a	4/27/2004	Treatment of high-risk Stage II, Stage III, and Stage IV melanoma	Medigen Biotechnology Corp.
2058	maribavir	n/a	6/7/2011	Treatment of clinically significant cytomegalovirus viremia and disease in at-risk patients.	ViroPharma, Inc.
2059	maribavir	n/a	2/1/2007	Prevention of cytomegalovirus viremia and disease in the populations at risk.	ViroPharma Inc.
2060	masitinib	n/a	7/21/2009	Treatment of patients with pancreatic cancer	AB Science

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2061	masitinib	n/a	4/20/2005	Treatment of malignant gastrointestinal stromal tumors	AB Science
2062	maytansinoid DM1-conjugated humanized monoclonal antibody N901	n/a	3/2/2010	Treatment of Merkel cell carcinoma	ImmunoGen, Inc.
2063	maytansinoid DM1-conjugated humanized monoclonal antibody N901	n/a	11/29/2010	Treatment of multiple myeloma.	ImmunoGen, Inc.
2064	mecasermin	lplex	12/3/2007	Treatment of myotonic dystrophy	Insmmed, Inc.
2065	mecasermin rinfabate	n/a	9/20/2012	Prevention of retinopathy of prematurity in premature infants born at risk for the disease	Premacure AB
2066	mecasermin rinfabate	lplex	5/17/2002	Treatment of growth hormone insensitivity syndrome (GHIS)	Insmmed, Inc.
2067	mecasermin rinfabate	lplex	7/23/2012	Treatment of amyotrophic lateral sclerosis	PCUT BioPartners, Inc.
2068	meclorethamine	Valchlor	8/17/2004	Treatment of mycosis fungoides	Actelion Pharmaceuticals Ltd.
2069	mefloquine HCL	Lariam	4/13/1988	For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs	Hoffmann-La Roche, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2070	melarsoprol-hydroxypropylbetadex	n/a	9/13/2013	Treatment of human African trypanosomiasis (sleeping sickness)	Peter Kennedy, CBE, MD, PhD, DSc, FRCP FMedSci,
2071	melatonin	n/a	4/12/2013	Treatment of neonatal hypoxic ischemic encephalopathy	Scharper S.p.A.
2072	meloxicam	Mobic	11/22/2002	Treatment of juvenile rheumatoid arthritis	Boehringer Ingelheim Pharmaceuticals, Inc.
2073	melphalan	n/a	11/19/2012	Treatment of retinoblastoma	Icon Bioscience, Inc.
2074	melphalan	n/a	11/24/2008	High dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation	Spectrum Pharmaceuticals, INC.
2075	melphalan	n/a	11/19/2012	Treatment of Stage IIB through IV melanoma	OncoTx, LLC
2076	melphalan hydrochloride	n/a	11/12/2008	Treatment of patients with ocular (uveal) melanoma.	Delcath Systems, Inc.
2077	melphalan hydrochloride	n/a	9/26/2013	Treatment of patients with hepatocellular carcinoma	Delcath Systems, Inc.
2078	melphalan hydrochloride	n/a	11/12/2008	Treatment of patients with cutaneous melanoma.	Delcath Systems, Inc.
2079	melphalan hydrochloride	n/a	5/22/2009	Treatment of neuroendocrine tumors	Delcath Systems, Inc.
2080	menaquinone	Menaquinonegold	9/4/2012	Treatment of calciphylaxis	Nu Science Trading,
2081	menatetrenone	Mk4	3/17/2011	Treatment of acute myeloid leukemia	NBI Pharmaceuticals, Inc.
2082	menatetrenone	Mk4(R)	11/2/2010	Treatment of hepatocellular carcinoma (HCC).	NBI Pharmaceuticals, Inc.
2083	menatetrenone	Mk4(R)	2/4/2011	Treatment of myelodysplastic syndrome.	NBI Pharmaceuticals, Inc.
2084	menatetrenone	Mk4(R)	11/2/2010	Treatment of acute promyelocytic leukemia.	NBI Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2085	menatetrenone and Vitamin D3	n/a	8/22/2011	Treatment of myelodysplastic syndrome	NBI Pharmaceuticals, Inc.
2086	mepivacaine	n/a	1/8/2007	Treatment of postherpetic neuralgia	Cinergen, LLC
2087	mepolizumab	n/a	7/14/2011	Treatment of Churg-Strauss Syndrome.	GlaxoSmithKline LLC
2088	mepolizumab	n/a	5/28/2004	For first-line treatment in patients with hypereosinophilic syndrome	GlaxoSmithKline LLC
2089	mercaptopurine	n/a	8/20/2012	Treatment of acute lymphoblastic leukemia in pediatric patients	Nova Laboratories Limited
2090	mesalamine	Canasa	1/19/2010	Treatment of pediatric ulcerative colitis	Aptalis Pharma US, Inc.
2091	mesalamine and N-acetylcysteine	n/a	9/10/2009	Treatment of pediatric patients with ulcerative colitis (inclusive through age 16 years)	Altheus Therapeutics, Inc.
2092	mesalamine; 5-aminosalicylic acid	Lialda	2/27/2008	Treatment of ulcerative colitis in pediatric patients (revised indication 10/21/2010).	Shire
2093	mesenchymal stromal cells secreting neurotrophic factors	Nurown	2/4/2011	Treatment of Amyotrophic Lateral Sclerosis	BrainStorm Cell Therapeutics Ltd.
2094	met-enkephalin; Met-N	n/a	2/18/2011	Treatment of pancreatic cancer.	NBI Pharmaceuticals, Inc.
2095	metadoxine	n/a	12/16/2013	Treatment of Fragile X Syndrome	Alcobra, Inc.
2096	methotrexate	n/a	8/20/2009	Treatment of acute lymphoblastic leukemia	Only for Children Pharmaceuticals

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2097	methylene blue	n/a	7/24/2012	Treatment of methemoglobinemia	Fera Pharmaceuticals, LLC
2098	methylene blue injection	n/a	8/11/2012	Treatment of congenital and acquired methemoglobinemia	Luitpold Pharmaceuticals, Inc.
2099	methylene blue0.5%	n/a	12/18/2012	Treatment of hereditary and acquired methemoglobinemia	Provepharm SAS
2100	methylparaben suberohydroxamic acid phenyl ester	n/a	4/15/2013	Treatment of cutaneous T-cell lymphoma	Shape Pharmaceuticals, Inc.
2101	metreleptin	n/a	8/22/2001	Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy	Amylin Pharmaceuticals LLC
2102	metreleptin	Myalept	8/22/2001	Treatment of metabolic disorders secondary to lipodystrophy	Amylin Pharmaceuticals, LLC
2103	metronidazole	n/a	9/17/2008	Treatment of pouchitis	Formac Pharmaceuticals, NV
2104	metronidazole	n/a	4/26/2011	Treatment of pouchitis.	S.L.A. Pharma Limited (UK)
2105	metyrapone	n/a	9/25/2012	Treatment of Cushing's syndrome	Laboratoire HRA Pharma
2106	metyrosine	Demser	7/25/2008	Treatment of velocardiofacial syndrome associated psychosis.	Cerberus Princeton, LLC
2107	mexiletine	n/a	9/2/2010	Treatment of nondystrophic myotonia	University of Rochester Medical
2108	mibefradil	n/a	10/16/2008	Treatment of pancreatic cancer.	Tau Therapeutics, LLC

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2109	mibefradil	n/a	8/25/2009	Treatment of glioblastoma multiforme.	Tau Therapeutics, LLC
2110	mibefradil	n/a	6/15/2007	Treatment of ovarian cancer	Tau Therapeutics, LLC
2111	midazolam	n/a	7/24/2012	Treatment of nerve agent-induced seizures	Meridian Medical Technologies, Inc.
2112	midazolam	n/a	10/20/2009	Rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity (e.g. acute repetitive seizures, seizure clusters)	Upsher-Smith Laboratories, Inc.
2113	midazolam	n/a	5/8/2006	Treatment of bouts of increased seizure activity in selected refractory patients with epilepsy who are on stable regimens of anti-epileptic drugs and who require intermittent use of midazolam	UCB, Inc
2114	mifamuritide	Junovan	6/5/2001	Treatment of osteosarcoma	Millennium Pharmaceuticals, Inc.
2115	mifepristone	Korlym	7/5/2007	Treatment of the clinical manifestations of endogenous Cushing's syndrome	Corcept Therapeutics, Inc.
2116	migalastat hydrochloride	n/a	2/25/2004	Treatment of Fabry Disease	Amicus Therapeutics,
2117	miglustat	Zavesca (R)	11/12/2008	Treatment of the neurological manifestations of Niemann-Pick disease, type C.	Actelion Pharmaceuticals Ltd
2118	miglustat	Zavesca	5/29/1998	Treatment of Gaucher disease.	Actelion Pharmaceuticals Ltd

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2119	milatuzumab	n/a	6/24/2008	Treatment of chronic lymphocytic leukemia.	Immunomedics, Inc.
2120	milatuzumab	n/a	3/10/2008	Treatment of multiple myeloma	Immunomedics, Inc.
2121	milciclib maleate	n/a	9/20/2012	Treatment of thymic epithelial tumors.	Nerviano Medical Sciences S.r.l.
2122	miltefosine	Miltex/Impavido	3/18/2009	Topical treatment of cutaneous lymphoma encompassing cutaneous manifestations of T-cell lymphoma and B-cell lymphoma	ExperGen Drug Development GmbH
2123	miltefosine	Impavido	10/10/2006	Treatment of leishmaniasis.	Paladin Therapeutics,
2124	mipomersen	Kynamro	5/23/2006	Treatment of homozygous familial hypercholesterolemia	Genzyme Corporation
2125	misoprostol	Gymiso	1/10/2005	Treatment of intrauterine fetal death not accompanied by complete expulsion of the products of conception in the second and third trimesters of pregnancy.	Gynuity Health Projects, LLC
2126	mitomycin	n/a	1/13/2011	Prevention of recurrence of pterygium after its surgical excision.	Mobius Therapeutics, LLC
2127	mitomycin	n/a	6/1/2011	Prevention of corneal sub-epithelial haze formation following surface ablation laser keratectomy	Mobius Therapeutics, LLC
2128	mitomycin-C	Mitosol	1/8/2008	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	Mobius Therapeutics, LLC

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2129	modified recombinant human C-type natriuretic peptide (CNP)	n/a	1/17/2013	Treatment of achondroplasia	BioMarin Pharmaceutical, Inc.
2130	modified recombinant human Factor VIIa (rFVIIa) molecule	n/a	5/30/2013	Treatment of bleeding episodes in hemophilia A or B subjects with inhibitors	Bayer HealthCare Pharmaceuticals, Inc.
2131	modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain	n/a	8/20/2012	Treatment of inherited mitochondrial respiratory chain disease	Gencia Corporation
2132	mogamulizumab	n/a	11/2/2010	Treatment of peripheral T-cell lymphoma.	Kyowa Hakko Kirin Pharma, Inc.
2133	mogamulizumab	n/a	7/14/2011	Treatment of adult T-cell leukemia/lymphoma (ATLL).	Kyowa Hakko Kirin Pharma, Inc.
2134	mogamulizumab	n/a	11/2/2010	Treatment of patients with cutaneous T-cell lymphoma.	Kyowa Kakko Kirin Pharma, Inc.
2135	monarsen	n/a	11/14/2003	Treatment of myasthenia gravis	Bioline Rx, Ltd.
2136	monoclonal antibody	n/a	1/21/2011	Prevention of congenital cytomegalovirus (CMV)infection following primary CMV infection in pregnant women.	Theraclone Sciences
2137	monoclonal antibody 11-1F4	n/a	12/11/2009	For use as a therapeutic agent for patients AL amyloidosis.	Alan Solomon, M.D.
2138	monoclonal antibody 11-1F4	n/a	12/7/2009	For use as a radioimaging agent in amyloidosis	Alan Solomon, M.D.
2139	monoclonal antibody 3F8	n/a	10/16/2008	Treatment of neuroblastoma	United Therapeutics Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2140	monoclonal antibody Hu3F8	n/a	1/10/2014	Treatment of osteosarcoma	Memorial Sloan-Kettering Cancer
2141	monoclonal antibody directed at hepatitis C virus E2 glycoprotein	n/a	11/4/2013	Prevention of Hepatitis C recurrence in patients receiving liver transplantation	MassBiologics-University of MA Medical School
2142	motexafin gadolinium	Xcytrin	1/27/2003	For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors	Pharmacyclics, Inc.
2143	mouse-human chimeric monoclonal anti-GD2 IgG1 antibody	n/a	9/20/2012	Treatment of neuroblastoma.	APEIRON Biologics AG
2144	moxetumomab pasudotox	n/a	11/15/2007	Treatment of CD22-positive chronic lymphocytic leukemia	MedImmune, LLC
2145	moxetumomab pasudotox	n/a	11/15/2007	Treatment of hairy cell leukemia	MedImmune, LLC
2146	moxetumomab pasudotox	n/a	6/28/2013	Treatment of acute lymphoblastic leukemia	MedImmune, LLC
2147	moxidectin	n/a	9/29/2010	Treatment of onchocerciasis volvulus in children and adults.	World Health Organization (WHO)
2148	multi-vitamin infusion without vitamin K	M.V.I.-12	3/8/2004	Prevention of vitamin deficiency and thromboembolic complications in people receiving home parenteral nutrition and warfarin-type anticoagulant therapy	Mayne Pharma (USA) Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2149	murine monoclonal antibody against CD26	Begedina	2/18/2011	Treatment of graft versus host disease	Adienne S.r.l.
2150	mycobacterium vaccae	n/a	8/6/2010	Treatment of pancreatic cancer	Immodulon Therapeutics Ltd.
2151	mycobacterium vaccae	n/a	8/20/2010	Treatment of tuberculosis	Immodulon Therapeutics Ltd
2152	myo-inositol	n/a	4/7/2005	Prevention of retinopathy of prematurity in preterm infants at risk for developing retinopathy of prematurity	Abbott Nutrition
2153	nabumetone	n/a	5/5/2008	Treatment of pediatric juvenile rheumatoid arthritis	Cook Pharma
2154	naloxone	n/a	11/23/2010	Topical treatment of pruritus associated with mycosis fungoides	Elorac, Inc.
2155	naltrexone	n/a	1/19/2010	Treatment of Crohn's disease in pediatric patients	TNI BioTech, Inc.
2156	natural human lymphoblastoid interferon-alpha	n/a	11/18/2002	Treatment of polycythemia vera	Amarillo Biosciences, Inc.
2157	nelarabine	Arranon	8/10/2004	Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma	GlaxoSmithKline LLC
2158	nelarabine	n/a	9/2/1999	Treatment of chronic lymphocytic leukemia.	GlaxoSmithKline LLC
2159	neostigmine	n/a	3/18/2013	Treatment of acute colonic pseudo-obstruction	Luitpold Pharmaceuticals, Inc.
2160	neostigmine methylsulfate	n/a	2/17/2012	Treatment of Myasthenia Gravis	Luitpold Pharmaceuticals, Inc.
2161	neridronate	n/a	3/25/2013	Treatment of complex regional pain syndrome (CRPS-1, CRPS-II, CRPS-NOS)	Grunenthal USA, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2162	nevirapine	n/a	11/25/2009	Prevention of HIV infection in pediatric patients under the age of 16 years	Auritec Pharmaceuticals
2163	nifurtimox	n/a	12/31/2013	Treatment of Chagas disease	MetronomX Therapeutics, LLC
2164	nifurtimox	Lampit	8/5/2010	Treatment of Chagas disease (American Typanosomiasis)caused by T. cruzi	Bayer HealthCare Pharmaceuticals, Inc.
2165	nilotinib	Tasigna	4/27/2006	Treatment of chronic myelogenous leukemia	Novartis Pharmaceutical
2166	nimodipine	Nymalize	9/16/2011	Treatment of subarachnoid hemorrhage.	Arbor Pharmaceuticals, Inc.
2167	nintedanib	n/a	6/29/2011	Treatment of patients with idiopathic pulmonary fibrosis.	Boehringer Ingelheim
2168	niprisan	Hemoxin	8/15/2003	Treatment of sickle cell disease	Xechem International, Inc.
2169	nitazoxanide	Alinia	2/14/2002	Treatment of intestinal giardiasis	Romark Laboratories, L.C.
2170	nitazoxanide	Cryptaz	10/23/2001	Treatment for intestinal amebiasis	Romark Laboratories, L.C.
2171	nitric oxide	Inomax (R)	9/5/2008	Use in combination with a drug delivery device for acute treatment of sickle cell vaso-occlusive crisis (pain crises)	INO Therapeutics
2172	nitric oxide	Inomax	12/28/2011	Treatment of pulmonary arterial hypertension	INO Therapeutics
2173	nitric oxide	n/a	6/18/2012	Treatment of persistent pulmonary hypertension in newborns	GeNO, LLC

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2174	nivolumab	n/a	1/23/2013	Treatment of Stage IIb to IV melanoma	Bristol-Myers Squibb Co.
2175	obeticholic acid	n/a	4/9/2008	Treatment of primary biliary cirrhosis	Intercept Pharmaceuticals, Inc.
2176	obinutuzumab	Gazyva	2/17/2012	Treatment of chronic lymphocytic leukemia	Genentech, Inc.
2177	obinutuzumab	n/a	2/17/2012	Treatment of diffuse large B cell lymphoma	Genentech, Inc.
2178	oblimersen	Genasense	8/28/2001	Treatment of chronic lymphocytic leukemia	Genta, Inc,
2179	oblimersen	Genasense	8/28/2001	Treatment of multiple myeloma	Genta, Inc.
2180	oblimersen	Genasense	8/28/2001	Treatment of acute myelocytic leukemia	Genta Inc.
2181	oblimersen	Genasense	7/31/2000	Treatment of advanced malignant melanoma (Stages II,III, IV).	Genta, Inc.
2182	octreotide	Sandostatin Lar	8/5/2010	Treatment of neuroendocrine tumors	Novartis Pharmaceuticals
2183	octreotide (oral)	Octreolin(Tm)	6/17/2010	For the oral treatment of acromegaly	Chiasma, Inc.
2184	octreotide acetate subcutaneous implant	n/a	12/7/2009	Treatment of acromegaly	Endo Pharmaceuticals Solutions, Inc.
2185	ofatumumab	Arzerra	3/10/2009	Treatment of chronic lymphocytic leukemia	GlaxoSmithKline
2186	ogluflanide disodium	n/a	9/24/2001	Treatment of ovarian cancer	Implicit Bioscience Pty Ltd
2187	olaparib	n/a	10/16/2013	Treatment of ovarian cancer	AstraZeneca Pharmaceuticals LP
2188	oleylphosphocholine	n/a	10/25/2013	Treatment of leishmaniasis	Dafra Pharma International nv

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2189	oligopeptide containing 6 amino acids (H-Phe-Ser-Arg-Tyr-Ala-Arg-OH)	n/a	2/27/2014	Treatment of amyotrophic lateral sclerosis	Genervon Biopharmaceuticals, LLC
2190	omacetaine mepesuccinate	n/a	1/12/2009	Treatment of myelodysplastic syndromes	IVAX International GmbH
2191	omacetaxine mepesuccinate	Synribo	3/10/2006	Treatment of chronic myelogenous leukemia	IVAX International GmbH
2192	ombrabulin; N-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]phenyl}-L-serinamide hydrochloride	n/a	3/3/2011	Treatment of soft tissue sarcoma	Sanofi-Aventis U.S., Inc.
2193	omigapil	n/a	6/24/2008	Treatment of congenital muscular dystrophy.	Santhera Pharmaceuticals
2194	onartuzumab	n/a	1/23/2013	Treatment of gastric cancer including gastroesophageal cancer	Genentech, Inc.
2195	onartuzumab (MetMab)	n/a	12/16/2013	Treatment of hepatocellular carcinoma	Genentech, Inc.
2196	oncophage	n/a	4/14/2009	Treatment of glioma	Agenus, Inc.
2197	opioid growth factor	n/a	4/16/2013	Treatment of liver and intrahepatic bile duct cancer	Primocure Pharma, Inc.
2198	opium tincture	n/a	12/2/2011	Treatment of chronic diarrhea in short bowel syndrome patients with an inadequate response to anti-diarrheal treatment	Marathon Pharmaceuticals, LLC
2199	optically pure phenylalanine derivative	n/a	8/20/2012	Treatment of narcolepsy	Jazz Pharmaceuticals International III
2200	oral unfractionated heparin	n/a	1/29/2004	Treatment of sickle cell disease	TRF Technologies, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2201	otelixizumab	n/a	2/6/2006	Treatment of new-onset type I diabetes mellitus	GlaxoSmithKline
2202	oxaloacetate	n/a	7/24/2012	Treatment of gliomas	Terra Biological LLC
2203	oxybate	Xyrem	11/7/1994	Treatment of narcolepsy.	Jazz Pharmaceuticals
2204	p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt	n/a	3/7/2001	For the treatment of cystic fibrosis	Inspire Pharmaceuticals, Inc.
2205	paclitaxel	n/a	5/1/2009	Treatment of pancreatic cancer	MediGene AG
2206	paclitaxel aqueous gel	Oncogel (Tm)	12/23/2008	Treatment of brain cancer.	BTG International, Inc
2207	paclitaxel aqueous gel	Oncogel(Tm)	2/1/2008	Treatment of esophageal cancer	BTG International, Inc.
2208	paclitaxel nanoparticles	n/a	1/3/2013	Treatment of pancreatic cancer	CIRJ Co., Ltd.
2209	paclitaxel poliglumex	Opaxio	9/20/2012	Treatment of glioblastoma multiforme	Cell Therapeutics, Inc.
2210	paclitaxel protein-bound particles	Abraxane	9/3/2009	Treatment of pancreatic cancer.	Abraxis BioScience, LLC
2211	paclitaxel, micellar	Paclical	4/3/2009	Treatment of ovarian cancer	Oasmia Pharmaceutical AB
2212	pacritinib	n/a	3/13/2008	Treatment of myeloproliferative disorders with the JAK2 V617F mutation	Cell Therapeutics, Inc..
2213	pafuramidine maleate	n/a	11/17/2006	Treatment of pneumocystis jiroveci pneumonia	Immtech Pharmaceuticals, Inc.
2214	panobinostat	Farydak	8/20/2012	Treatment of multiple myeloma	Novartis Pharmaceuticals
2215	paquinimod	n/a	1/17/2014	Treatment of systemic sclerosis	Active Biotech AB

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2216	parathyroid hormone	n/a	8/31/2007	Treatment of hypoparathyroidism	NPS Pharmaceuticals, Inc.
2217	paromomycin sulfate/gentamicin sulfate	n/a	1/18/2008	Treatment of all uncomplicated cutaneous leishmaniasis (both New World and Old World)	Office of the Surgeon General
2218	pasireotide	n/a	8/25/2009	Treatment of acromegaly	Novartis Pharmaceuticals
2219	pasireotide	Signifor	7/24/2009	Treatment of Cushing's disease	Novartis Pharmaceuticals
2220	pazopanib	Votrient	10/20/2009	Treatment of soft tissue sarcomas	GlaxoSmithKline
2221	pazopanib	n/a	5/6/2013	Treatment of ovarian cancer.	Glaxo Wellcome Mfg Pte Ltd
2222	peginterferon alfa-2b	Sylatron	4/9/2008	Treatment of malignant melanoma stages IIb through IV.	Schering-Plough Corporation
2223	pegloticase	Krystexxa	2/21/2001	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	Savient Pharmaceuticals, Inc.
2224	pegsitacase	Uricase-Peg 20	12/3/2009	Treatment of Lesch-Nyhan syndrome.	EnzymeRx, LLC
2225	pegylated arginine deiminase	Hepacid	3/26/1999	Treatment of hepatocellular carcinoma	Polaris Pharmaceuticals, Inc.
2226	pegylated carboxyhemoglobin	n/a	10/21/2010	Treatment of acute painful sickling crises in patients with sickle cell disease	Sangart, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2227	pegylated proline-interferon alpha-2b; PEG-P-IFNa-2b	n/a	4/2/2012	Treatment of polycythemia vera	PharmaEssentia Corporation
2228	pemetrexed disodium	Alimta	8/28/2001	Treatment of malignant pleural mesothelioma	Eli Lilly and Company
2229	pentagastrin	n/a	5/29/2009	To aid in the diagnosis of medullary thyroid carcinoma	Medical Defense Technologies, LLC
2230	pentamidine	n/a	8/12/2013	Treatment of liver and intrahepatic bile duct cancer	Oncozyme Pharma, Inc.
2231	pentamidine	n/a	9/13/2010	Treatment of pancreatic cancer.	Oncozyme Pharma, Inc.
2232	pentamidine	n/a	8/12/2013	Treatment of ovarian cancer	Oncozyme Pharma,
2233	pentetate trisodium	Diethylenetriaminepentaaacetate	4/12/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium.	Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG
2234	pentosan polysulfate sodium	n/a	11/21/2008	Treatment of sickle cell disease.	TRF Pharma, Inc.
2235	pentosan polysulfate sodium	n/a	9/16/2011	Treatment of sickle cell disease.	Vanguard Therapeutics, Inc.
2236	pentoxifylline	n/a	6/14/2012	Treatment of Behcet's disease	Keck Graduate Institute of Applied
2237	peptide YY	n/a	4/18/2011	Treatment of hepatocellular carcinoma.	mondoBIOTECH Laboratories AG
2238	peptide-based vaccine targeting telomerase reverse transcriptase	n/a	2/20/2009	Treatment of telomerase reverse transcriptase (TERT) positive non-small cell lung cancer in HLA-A*0201 positive patients	VAXON-Biotech

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2239	peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO)	n/a	9/3/2009	Treatment of Duchenne muscular dystrophy in patients with a deletion, duplication or frame shift mutation correctable by skipping of exon 50 of the dystrophin gene to allow restoration of the reading frame (including mutations within exons 51, 51-53, or 51-55).	Sarepta Therapeutics, Inc.
2240	peptides mimicking antigen receptors on autoimmune B cells and autoimmune T cells associated with myasthenia gravis	n/a	2/4/2011	Treatment of myasthenia gravis	CuraVac Europe SPRL
2241	perampanel	Fycompa	12/7/2012	Treatment of Lennox-Gastaut Syndrome	Eisai, Inc.
2242	peretinoin	n/a	9/23/2011	Treatment of hepatocellular carcinoma.	Kowa Pharmaceutical Europe Co. Ltd.
2243	perhexiline maleate	n/a	6/14/2012	Treatment of moderate to severe symptomatic (NYHA class III or IV) hypertrophic cardiomyopathy	Heart Metabolics, Ltd.
2244	perifosine	n/a	7/9/2010	Treatment of neuroblastoma	Aeterna Zentaris
2245	perillyl alcohol	n/a	4/18/2011	Treatment of glioma.	NeOnc Technologies,
2246	pertuzumab	n/a	7/12/2013	Treatment of gastric cancer	Genentech, Inc.
2247	pertuzumab	n/a	6/8/2009	Treatment of ovarian cancer	Genentech, Inc.
2248	pexastimogene devacirepvec	n/a	5/6/2013	Treatment of hepatocellular carcinoma	Jennerex, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2249	phenobarbital sodium injection	n/a	10/23/2013	Treatment of hypoxic-ischemic encephalopathy to prevent seizures in neonates	Fera Pharmaceuticals, LLC
2250	phenylephrine	n/a	2/14/2002	Treatment of ileal pouch anal anastomosis related fecal incontinence	S.L.A. Pharma
2251	phenylephrine	n/a	1/31/2012	Treatment of Tetralogy of Fallot	Luitpold Pharmaceuticals, Inc.
2252	phosphorothioate antisense oligonucleotide against EWS-Fli-1	n/a	9/22/2008	Treatment of Ewing's sarcoma	The Cure Our Children Foundation
2253	phoxilium	n/a	2/14/2014	For use as a replacement solution in patients undergoing continuous renal replacement therapy	Gambro Renal Products, Inc.
2254	picibanil	n/a	3/17/2011	Treatment of lymphatic malformations	Richard Smith, M.D.
2255	picibanil	n/a	5/15/2009	Treatment of patients with lymphatic malformations	Royds Pharmaceuticals, Inc.
2256	pirfenidone	n/a	11/19/2013	Treatment of systemic sclerosis (including the associated interstitial lung disease)	InterMune, Inc.
2257	plasmin (human)	n/a	3/30/2009	Treatment of acute peripheral arterial occlusion	Grifols Therapeutics, Inc.
2258	plasminogen (human)	n/a	3/5/2013	Treatment of hypoplasminogenemia, or type I plasminogen deficiency	ProMetic Biotherapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2259	plerixafor	Mozobil (R)	7/10/2003	For use to improve the yield of progenitor cells in the apheresis product for subsequent stem cell transplantation following myelosuppressive or myeloablative chemotherapy	Genzyme Corporation
2260	polifeprosan 20 with carmustine	Gliadel	12/13/1989	Treatment of malignant glioma	Guilford Pharmaceuticals, Inc.
2261	polifeprosan 20 with carmustine	Gliadel	12/13/1989	Treatment of malignant glioma.	Guilford Pharmaceuticals, Inc.
2262	poloxamer 188 (purified)	n/a	6/27/1989	Treatment of sickle cell disease (this includes the treatment and prevention of complications of sickle cell disease)	Mast Therapeutics Inc.
2263	poloxamer-188 NF	n/a	1/19/2010	Treatment of Duchenne muscular dystrophy	Phrixus Pharmaceuticals, Inc.
2264	poly(lactide-co-glycolide) carboxylated microparticle	n/a	10/25/2013	Treatment of acute encephalitis syndrome	Cour Pharmaceutical Development Company, Inc.
2265	polyinosinic-polycytidilic acid	Poly-IcIc	8/2/2002	As an adjuvant to smallpox vaccination	Oncovir
2266	polyinosinic-polycytidilic acid	Poly-IcIc	3/3/2003	Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses	Oncovir

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2267	polyinosinic-polycytidilic acid (Poly-ICLC)	Hiltonol	11/19/2002	Treatment for orthopox virus infections	Oncovir
2268	polyphenon E	n/a	7/17/2008	Treatment of chronic lymphocytic leukemia	Mitsui Norin Co., Ltd
2269	pomalidomide	n/a	9/21/2010	Treatment of persons with myeloproliferative neoplasm-associated myelofibrosis and anemia who are red blood cell tranfusion dependent.	Celgene Corporation
2270	pomalidomide	n/a	8/22/2013	Treatment of systemic sclerosis	Celgene Corporation
2271	pomalidomide	Pomalyst	1/15/2003	Treatment of multiple myeloma	Celgene Corporation
2272	ponatinib	Iclusig	11/20/2009	Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)	ARIAD Pharmaceuticals Inc.
2273	ponatinib	Iclusig	11/20/2009	Treatment of chronic myeloid leukemia	ARIAD Pharmaceuticals Inc.
2274	porcine GM1 ganglioside	n/a	12/3/2012	Treatment of acute spinal cord injury	TRB Chemedica International S.A.
2275	porfimer	Photofrin	10/19/2001	For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy	Axcan Scandipharm Inc.
2276	potassium sodium aluminosilicate	n/a	1/8/2007	For treatment of poisoning by or exposure to cesium.	Framework Therapeutics, LLC
2277	pracinostat	n/a	2/27/2014	Treatment of acute myeloid leulemia	MEI Pharma Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2278	pralatrexate	n/a	5/3/2010	Treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder	Allos Therapeutics, Inc.
2279	pralatrexate	n/a	10/20/2008	Treatment of diffuse large B-cell lymphoma	Allos Therapeutics, Inc.
2280	pralatrexate	n/a	10/20/2008	Treatment of follicular lymphoma	Allos Therapeutics, Inc.
2281	pralatrexate	Folotyn	7/20/2006	Treatment of T-cell lymphoma	Allos Therapeutics, Inc.
2282	pralmorelin hydrochloride	n/a	10/18/2012	As a diagnostic agent for the detection of growth hormone deficiency	Sella Pharmaceuticals, Inc.
2283	pramipexole	Mirapex	1/31/2008	Treatment of Tourette's syndrome in pediatric patients	Boehringer-Ingelheim Pharmaceuticals, Inc.
2284	profimer sodium	Photofrin	12/2/2011	Treatment of malignant mesothelioma	Pinnacle Biologics, Inc.
2285	progesterone	n/a	12/22/1994	Establishment and maintenance of pregnancy in women undergoing in vitro fertilization or embryo transfer procedures.	Watson Laboratories, Inc.
2286	progesterone	n/a	9/3/2009	For early intervention in the treatment of moderate to severe closed-head traumatic brain injury	BHR Pharma, LLC
2287	prolactin receptor antagonist	Prolanta	4/15/2013	Treatment of ovarian cancer	Oncolix, Inc.
2288	propranolol	n/a	9/5/2008	Treatment of proliferating infantile hemangiomas requiring systemic therapy	Pierre Fabre Dermatologie

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2289	prothrombin complex concentrate (human)	Kcentra	12/27/2012	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	CSL Behring
2290	purified bovine type collagen	n/a	4/27/2009	Treatment of idiopathic pulmonary fibrosis	ImmuneWorks, Inc.
2291	pyridoxine; vitamin B6	n/a	3/3/2011	Treatment of pyridoxine dependent seizures.	NBI Pharmaceuticals, Inc.
2292	pyrimethamine	n/a	8/16/2011	Treatment of GM-2 gangliosidoses (Tay-Sachs disease and Sandhoff disease).	ExSAR Corporation
2293	quinacrine	n/a	9/28/2012	Treatment of hepatocellular carcinoma	Cleveland BioLabs, Inc & Incuron, LLC Joint
2294	quinine Sulfate	n/a	6/3/2004	Treatment of malaria	AR Holding Company,
2295	quinine sulfate	n/a	12/2/2008	Treatment of malaria excluding Plasmodium faliparum	Zyodus Pharmaceuticals, Inc.
2296	rAAV2-CB-hRPE65	n/a	2/11/2005	Treatment of type II Leber's Congenital Amaurosis	Applied Genetic Technologies Corp.
2297	rSP-C lung surfactant	Venticute	4/3/2000	Treatment of adult respiratory distress syndrome.	Byk Gulden Pharmaceuticals
2298	rSP-C surfactant	Venticute	9/18/2006	For use in patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygen impairment	Altana Pharma

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2299	rVIIa-FP	n/a	12/22/2011	Treatment and prophylaxis of bleeding episodes in patients with congenital hemophilia and inhibitors to coagulation factor VIII or IX	CSL Behring
2300	radiolabeled somastatin analog	Galiomedix(Tm)	12/31/2013	Diagnostic for the management of neuroendocrine tumors	RadioMedix, Inc.
2301	raloxifene hydrochloride	Evista	8/20/2010	Treatment of hereditary hemorrhagic telangiectasia	Consejo Superior de Investigaciones Cientificas
2302	ramucirumab	n/a	2/16/2012	Treatment of gastric cancer	ImClone Systems LLC
2303	ranagengliotucel-L	Glionix(Tm)	5/29/2009	Treatment of astrocytic tumors	NovaRx Corporation
2304	ranprinase	Onconase	1/25/2007	Treatment of malignant mesothelioma	Alfacell Corporation
2305	rasburicase	Elitek	10/11/2000	Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research
2306	raxibacumab	Abthraxtm	11/12/2003	Treatment of anthrax	Human Genome Sciences, Inc.
2307	recombinant DNA plasmid	n/a	1/31/2014	Treatment of stage IIb, IIc, III and IV melanoma.	Scancell Ltd.
2308	recombinant IgA protease of bacterium Heamophilus influenzae	n/a	4/18/2011	Treatment of immunoglobulin A nephropathy (IgAN, Berger's disease).	Shire Human Genetics Therapies
2309	recombinant adeno-associated virus vector AAV2/rh8 expressing human B-hexosaminidase A and B subunits	n/a	3/25/2013	For the treatment of Sandhoff disease	Nat'l Tay-Sachs & Allied Diseases Association

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2310	recombinant adeno-associated virus alpha 1-antitrypsin vector	Raav-Aat	1/27/2003	Treatment of alpha1-antitrypsin deficiency	Applied Genetic Technologies Corp.
2311	recombinant adeno-associated virus encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP)	n/a	8/25/2009	Treatment of Huntington's disease.	Neurologix, Inc.
2312	recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel beta subunit (rAAV-CNGB3)	n/a	2/4/2011	Treatment of achromatopsia caused by mutations in the CNGB3 gene.	Applied Genetic Technologies Corporation
2313	recombinant adenovirus vector AAV2/rh8 expressing human B-hexosaminidase A & B subunits	n/a	3/25/2013	Treatment of Tay-Sachs disease	Na't Tay-Sachs & Allied Diseases Association
2314	recombinant chimeric monoclonal antibody to anthrax	Anthim	6/9/2006	Treatment of exposure to B. anthracis spores	Elusys Therapeutics, Inc.
2315	recombinant elafin	n/a	3/18/2013	Prevention of inflammatory complications of transthoracic esophagectomy	Proteo Biotech AG
2316	recombinant fusion protein consisting of a modified form of extracellular domain of human Activin receptor IIB	n/a	3/18/2013	Treatment of myelodysplastic syndrome	Acceleron Pharma, Inc

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2317	recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB (ActRIIB) linked to a human IgG1 Fc domain	n/a	3/11/2013	Treatment of B-thalassemia	Accelaron Pharma, Inc.
2318	recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)	n/a	4/27/2012	Treatment of patients with congenital factor IX deficiency (hemophilia B).	CSL Behring, LLC
2319	recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)	n/a	5/6/2013	Treatment of congenital factor VII deficiency which includes treatment and prophylaxis of bleeding episodes in patients with congenital factor VII deficiency	CSL Behring
2320	recombinant fusion protein with a truncated form of the cytotoxic protein Pseudomonas exotoxin	Proxinium	1/28/2005	Treatment of Ep-CAM-positive squamous cell carcinoma of the head and neck	Viventia Biotech, Inc.
2321	recombinant glycosylated independent lysosomal targeting (GILT) tagged human acid alpha glucosidase	n/a	8/20/2010	Treatment of Pompe disease.	BioMarin Pharmaceutical, Inc.
2322	recombinant human GM-CSF, molgramostim	n/a	10/31/2012	Treatment of pulmonary alveolar proteinosis	Serendex ApS

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2323	recombinant human IgG1 monoclonal antibody	n/a	12/14/2009	Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets)	Kyowa Hakko Kirin Pharma, Inc. (KKP)
2324	recombinant human Naglu-insulin-like growth factor II	n/a	3/5/2013	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B)	Shire Human Genetic Therapies, Inc.
2325	recombinant human Pentraxin-2; recombinant human Serum Amyloid P	n/a	2/17/2012	Treatment of idiopathic pulmonary fibrosis.	Promedior, Inc.
2326	recombinant human acid ceramidase	Plexcerase(Tm)	12/24/2013	Treatment of Farber disease	Plexcera Therapeutics, LLC
2327	recombinant human alpha 1-antitrypsin (rAAT)	n/a	11/20/2001	Treatment of cystic fibrosis	AiroMedica LLC
2328	recombinant human alpha-1 antitrypsin	n/a	3/6/1998	Treatment of cystic fibrosis.	PPL Therapeutics (Scotland) Limited
2329	recombinant human alpha-1 antitrypsin (rAAT)	n/a	8/28/2001	To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis	AiroMedica LLC
2330	recombinant human alpha-N-acetylglucosaminidase	n/a	4/15/2013	Treatment of mucopolysaccharidosis IIIB (Sanfilippo B syndrome)	Synageva BioPharma Corp.
2331	recombinant human alpha-glucosidase conjugated with synthetic bis-mannose-6-phosphate-Man6 glycan	n/a	11/19/2013	Treatment of Pompe Disease	Genzyme, a Sanofi Company

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2332	recombinant human anti-GDF-8 monoclonal antibody	n/a	7/24/2012	Treatment of Duchenne Muscular Dystrophy.	Pfizer, Inc.
2333	recombinant human antithrombin	Atryn	12/7/2007	Treatment of congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures	GTC Biotherapeutics, Inc.
2334	recombinant human beta-glucuronidase	n/a	2/16/2012	Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)	Ultragenyx Pharmaceutical, Inc.
2335	recombinant human coagulation factor IX fusion protein	n/a	10/30/2008	For the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease)	Biogen Idec
2336	recombinant human coagulation factor VIII Fc fusion protein	n/a	11/23/2010	Treatment of hemophilia A	Biogen Idec Hemophilia, Inc.
2337	recombinant human endostatin protein	n/a	2/21/2002	Treatment of metastatic melanoma	EntreMed, Inc.
2338	recombinant human erythropoietin (rHuEPO)	n/a	5/26/2011	Treatment of multiple myeloma	XTL Biopharmaceuticals,
2339	recombinant human galactocerebrosidase (rhGALC);	Galaczym	12/12/2011	Treatment of globoid cell leukodystrophy (Krabbe Disease)	ACE BioSciences A/S

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2340	recombinant human growth hormone in an ocular delivery system	n/a	12/3/2012	Treatment of persistent corneal epithelial defects	Jade Therapeutics LLC
2341	recombinant human histone H1.3; recombinant human N-bis-met-histone H1.3	Oncohist	10/20/2008	Treatment of acute myeloid leukemia	Xenetic Biosciences Plc
2342	recombinant human lecithin:cholesterol acyltransferase (rhLCAT)	n/a	9/2/2010	Treatment of LCAT deficiency syndromes	AlphaCore Pharma, LLC
2343	recombinant human minibody against complement component	n/a	6/7/2011	Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system.	Adienne S.r.l
2344	recombinant human minibody against complement component C5	Mubodina	2/4/2009	Treatment of primary membranoproliferative glomerulonephritis	Adienne S.r.1.
2345	recombinant human minibody against complement component C5 fused with RGD-motif	n/a	2/4/2009	Prevention of ischemia/reperfusion injury associated with solid organ transplantation.	Adienne S.r.1.
2346	recombinant human monoclonal IgM antibody targeting glucose regulated protein 78	n/a	10/25/2013	Treatment of multiple myeloma	Patrys Ltd.
2347	recombinant human monoclonal antibody against activin receptors type II	n/a	6/18/2012	Treatment of inclusion body myositis	Novartis Pharmaceuticals Corp.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2348	recombinant human monoclonal antibody to hsp90	Mycograb	9/16/2002	Treatment of invasive candidiasis	Novartis Pharmaceuticals Corp.
2349	recombinant human nerve growth factor	n/a	8/8/2013	Treatment of retinitis pigmentosa	Dompe s.p.a.
2350	recombinant human neutrophil inhibitor (hNE)	n/a	12/9/2003	Treatment of cystic fibrosis	Dyax Corporation
2351	recombinant human platelet derived growth factor-BB	n/a	8/6/2010	Treatment of osteochondritis dissecans	Biomimetic Therapeutics, Inc.
2352	recombinant human porphobilinogen deaminase	Porphozyme	9/9/2002	Treatment of acute intermittent porphyria attacks	Zymenex A/S
2353	recombinant human porphobilinogen deaminase, erythropoetic form	n/a	7/11/2002	Treatment of acute intermittent porphyria preventing attacks	ZymenexA/S
2354	recombinant human proinsulin (Including rhPI-Methionine)	n/a	12/10/2008	Treatment of retinitis pigmentosa	ProRetina Therapeutics, S.L.
2355	recombinant human rod-derived cone viability factor	n/a	1/7/2008	Treatment of retinitis pigmentosa	Fovea Pharmaceuticals
2356	recombinant human tripeptidyl-peptidase 1 (rhTPP1)	n/a	4/1/2013	Treatment of neuronal ceroid lipofuscinosis type 2	BioMarin Pharmaceutical, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2357	recombinant human type I pancreatic elastase	n/a	4/3/2009	Prevention of arteriovenous fistula maturation and arteriovenous graft failure in patients with end stage renal disease who are receiving hemodialysis or preparing for hemodialysis	Proteon Therapeutics, Inc.
2358	recombinant human type VII collagen	n/a	6/18/2008	Treatment of hereditary dystrophic epidermolysis bullosa (DEB)	David T. Woodley, MD and Mei Chen, MD
2359	recombinant human vascular endothelial growth factor	n/a	6/7/2010	Treatment of amyotrophic lateral sclerosis	NeuroNova AB
2360	recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR)	n/a	4/12/2013	Treatment of sickle cell disease	NKT Therapeutics, Inc.
2361	recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)	n/a	5/17/2011	Treatment of pancreatic cancer.	Gilead Sciences, Inc.
2362	recombinant kallikrein inhibitor	n/a	11/23/2010	Treatment of Netherton Syndrome.	Dermadis SA
2363	recombinant ovine interferon tau	Tauferon	1/25/2005	Treatment of pediatric multiple sclerosis	PEPGEN Corporation
2364	recombinant thymidine phosphorylase encapsulated with autologous erythrocytes	n/a	12/13/2010	Treatment of mitochondrial neurogastrointestinal encephalomyopathy due to thymidine phosphorylase deficiency.	St. George's University of London
2365	recombinant von Willebrand factor (rhVWF)	n/a	11/23/2010	Treatment of von Willebrand disease.	Baxter Healthcare Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2366	refanalin	n/a	5/25/2010	To improve renal function and prevent delayed graft function following renal transplantation	Angion Biomedica Corporation
2367	regorafenib	Stivarga	1/12/2011	Treatment gastrointestinal stromal tumors	Bayer HealthCare Pharmaceuticals, Inc.
2368	reparixin	n/a	1/27/2003	Prevention of delayed graft function in solid organ transplant	Dompe S.p.A.
2369	reparixin	n/a	9/25/2012	Prevention of graft loss in pancreatic islet transplantation	Dompe S.p.A.
2370	replication-deficient recombinant serotype 2 adeno-associated viral vector containing hAQP1 cDNA	n/a	5/3/2013	Treatment of symptoms of Grade 2 and Grade 3 late xerostomia from parotid gland hypofunction caused by radiotherapy for cancer of the oral cavity.	John A. Chiorini, PhD
2371	repository corticotropin injection	H.P. Acthar Gel	6/28/2013	Treatment of amyotrophic lateral sclerosis	Questor Pharmaceuticals, Inc.
2372	repository corticotropin or adrenocorticotrophic hormone	H.P. Acthar Gel	5/21/2003	Treatment of infantile spasms	Questcor Pharmaceuticals, Inc.
2373	resiniferatoxin	n/a	5/13/2003	Treatment of intractable pain at end-stage disease	NIH/NIDCR
2374	reslizumab	Cinquil	1/12/2011	Treatment of hypereosinophilic syndrome	Teva Pharmaceuticals, Inc.
2375	reslizumab	n/a	12/19/2007	Treatment of children with eosinophilic esophagitis	Cephalon, Inc.
2376	resminostat	n/a	9/16/2011	Treatment of Hodgkin's lymphoma.	4SC AG

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2377	resminostat	n/a	6/29/2011	Treatment of hepatocellular carcinoma	4SC AG
2378	retroviral gamma-c cDNA containing vector	n/a	4/29/2002	Treatment of X linked severe combined immune deficiency disease	AVAX technologies, Inc.
2379	rh-microplasmin, ocriplasmin	Jetrea	3/16/2004	Adjunct to surgery in cases of pediatric vitrectomy	ThromboGenics Inc.
2380	rhIGF-I/rhIGFBP-3	Somatokine	12/9/2003	Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)	Insmmed, Inc.
2381	ribavirin	Rebetol	4/4/2003	Treatment of chronic hepatitis C in pediatric patients	Schering Corporation
2382	ribavirin	Virazole	4/12/1991	Treatment of hemorrhagic fever with renal syndrome	Valeant Pharmaceuticals
2383	ribavirin elaidate	n/a	9/2/2011	Treatment of follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer	Translational Therapeutics, Inc.
2384	riboflavin ophthalmic solution & ultraviolet A	n/a	9/2/2011	Treatment of keratoconus	Avedro, Inc.
2385	riboflavin ophthalmic solution ultraviolet-A (UVA) irradiation	n/a	12/2/2011	Treatment of corneal ectasia following refractive surgery	Avedro, Inc.
2386	ricin vaccine	Rivax(R)	1/7/2011	Prevention of ricin intoxication.	Soligenix, Inc.
2387	rifaximin	Normix	2/10/1998	Treatment of hepatic encephalopathy	Salix Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2388	rigisertib	n/a	3/18/2011	Treatment of pancreatic cancer.	Onconova Therapeutics, Inc
2389	rigisertib	n/a	9/3/2009	Treatment of myelodysplastic syndromes	Onconova Therapeutics, Inc.
2390	rigosertib	n/a	3/16/2012	Treatment of ovarian cancer	Onconova Therapeutics, Inc.
2391	rilonacept	Arcalyst	1/9/2013	Treatment of familial Mediterranean fever	Philip J Hashkes, MD, MSc.
2392	rilotumumab	n/a	6/18/2012	Treatment of gastric cancer including gastroesophageal junction adenocarcinoma	Amgen, Inc.
2393	rindopepimut	n/a	11/19/2007	Treatment of EGFRvIII-expressing glioblastoma multiforme	Celldex Therapeutics, Inc.
2394	riociguat	Adempas	9/19/2013	Treatment of pulmonary arterial hypertension.	Bayer HealthCare Pharmaceuticals, Inc.
2395	riociguat	Adempas	9/19/2013	Treatment of chronic thromboembolic pulmonary hypertension	Bayer HealthCare Pharmaceuticals, Inc.
2396	risedronate sodium	Actonel	12/18/2006	Treatment of patients with osteogenesis imperfecta.	Warner Chilcott Pharmaceuticals
2397	rituximab	Rituxan	2/14/2006	Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)	Genentech, Inc.
2398	rituximab	Rituxan	3/12/2002	Treatment of immune thrombocytopenic purpura	Genentech, Inc.
2399	rituximab	Rituxan	6/13/1994	Treatment of non-Hodgkin's B-cell lymphoma	Genentech, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2400	rituximab	Rituxan	1/29/2004	Treatment of chronic lymphocytic leukemia	Genentech, Inc.
2401	rofecoxib	Vioxx	3/16/2004	Treatment of juvenile rheumatoid arthritis	MERCK & Co., Inc.
2402	romidepsin	Istodax	9/30/2004	Treatment of non-Hodgkin T-cell lymphomas	Celgene Corporation
2403	romiplostim	n/a	10/31/2007	Treatment of thrombocytopenia associated with myelodysplasia syndrome	Amgen Inc.
2404	romiplostim	Nplate	3/27/2003	Treatment of immune thrombocytopenic purpura	Amgen, Inc.
2405	rosuvastatin	Crestor	2/14/2014	For the treatment of pediatric homozygous familial hypercholesterolemia	AstraZeneca Pharmaceuticals LP
2406	rozrolimupab	n/a	9/13/2010	Treatment of primary immune thrombocytopenia.	Symphogen A/S
2407	rsATP7A cDNA	n/a	1/10/2014	Treatment of Menkes disease	Stephen G. Kaler, MD
2408	rubitecan	n/a	7/17/2002	Treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome	SuperGen, Inc.
2409	rucaparib	n/a	7/31/2012	Treatment of ovarian cancer	Clovis Oncology, Inc.
2410	rufinamide	Banzel	10/8/2004	Treatment of Lennox-Gastaut Syndrome.	Eisai, Inc.
2411	ruxolitinib	Jakafi	8/16/2013	Treatment of pancreatic cancer	Incyte Corporation
2412	ruxolitinib phosphate	Jakafi	3/26/2010	Treatment of polycythemia vera	Incyte Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2413	ruxolitinib phosphate	Jakafi	9/5/2008	Treatment of myelofibrosis	Incyte Corporation
2414	ruxolitinib phosphate	Jakafi	3/22/2010	Treatment of essential thrombocythemia	Incyte Corporation
2415	salicylic acid 6%	n/a	2/17/2012	Treatment of rare congenital ichthyoses.	Orenova Group, LLC
2416	salirasib	n/a	12/18/2006	Treatment of pancreatic cancer.	Kadmon Corporation, LLC
2417	salmeterol xinafoate/fluticasone propionate	n/a	10/29/2009	Treatment of symptomatic exophthalmos associated with thyroid related eye disease.	Lithera, Inc.
2418	sapropterin	Kuvan	1/29/2004	Treatment of hyperphenylalaninemia	Biomarin Pharmaceutical Inc.
2419	sarcosine	n/a	10/12/2011	Treatment of obsessive compulsive disorder in pediatric patients (0 to 16 years of age)	Guochuan Emil Tsai, MD, PhD
2420	sdTD-K6a.513a.12; small interfering RNA composed of 2 strands of hybridized RNAs	n/a	4/15/2013	Treatment of pachyonychia congenita	TransDerm, Inc.
2421	secukinumab	n/a	3/26/2010	Adjunctive treatment of chronic non-infectious uveitis requiring systemic immunosuppression	Novartis Pharmaceutical Corporation
2422	selective antagonist of the chemokine receptor type 4	n/a	9/5/2013	Treatment of acute myeloid leukemia	BioLineRx, Ltd.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2423	selective deacylglycerol acyltransferase 1 inhibitor	n/a	3/28/2011	Treatment of hypertriglyceridemia in te setting of Type I hyperlipoproteinemia, also known as Familial Chylomicronema Syndrome	Novartis Pharmaceuticals Corporation
2424	self-complimentary adeno-associated virus vector, serotype 9, packaging the full lenght GAN gene in the viral capsid	n/a	9/27/2013	Treatment of Giant Axonal Neuropathy	Hannah's Hope Fund
2425	selisistat	n/a	12/7/2009	Treatment of Huntington's disease	Siena Biotech SpA
2426	sialic acid	n/a	9/23/2011	Treatment of hereditary inclusion body myopathy.	Ultragenyx Pharmaceutical, Inc.
2427	sildenafil	Revatio	7/28/2011	Treatment of pediatic (defined as children less than 17 years of age) pulmonary arterial hypertension	Pfizer, Inc.
2428	siltuximab	n/a	5/26/2006	Treatment of Castleman's disease	Janssen Research & Development, LLC
2429	siltuximab	n/a	10/11/2005	Treatment of multiple myeloma	Janssen Research & Development, LLC
2430	sirolimus	n/a	3/18/2013	Treatment of pachyonychia congenita	TransDerm, Inc.
2431	sirolimus	Rapamune(R)	10/31/2012	Treatment of lymphangioleiomyomatosis	Pfizer, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2432	sirolimus	n/a	11/4/2011	Treatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and non-infectious, uveitis affecting the posterior of the eye (NICUPS).	Santen Inc.
2433	sirolimus in an implantable collagen matrix	Coll-R, Sirogen	5/10/2012	Prevention of arteriovenous(AV) fistula or AV graft failure in patients with end stage renal disease, receiving hemodialysis or preparing for hemodialysis	Vascular Therapies, LLC
2434	sitimagene ceradenovec	Cerepro	7/31/2001	Use with gancyclovir in the treatment of malignant glioma	Ark Therapeutics Ltd
2435	skin tissue	Stratagraft	5/21/2012	Treatment of hospitalized patients with complex skin defects resulting from partial and full thickness skin burns requiring excision and grafting	Stratatech Corporation
2436	small molecule inhibitor of histone methyltransferase DOT1L	n/a	8/8/2013	Treatment of acute lymphoblastic leukemia (ALL)	Epizyme Inc.
2437	small molecule inhibitor of phosphodiesterase 10	n/a	9/26/2013	Treatment of Huntington's disease	Omeros Corporation
2438	smilagenin	Cogane	7/21/2011	Treatment of amyotrophic lateral sclerosis	Junaxo, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2439	sobetirome	n/a	4/29/2011	Treatment of X-linked adrenoleukodystrophy	EndoChem, Inc.
2440	sodium 2, 2 dimethylbutyrate	n/a	7/25/2008	Treatment of sickle cell disease.	HemaQuest Pharmaceuticals, Inc.
2441	sodium 4-phenylbutyrate	n/a	10/18/2011	Treatment of spinal muscular atrophy	GMP-Orphan SAS
2442	sodium 4-{ [9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-d] [2] benzazepin-2-yl]-2-methoxybenzoate	n/a	4/3/2009	Treatment of ovarian cancer	Millennium Pharmaceuticals, Inc.
2443	sodium ascorbate and menadione sodium bisulfite	n/a	4/15/2013	Treatment of autosomal dominant polycystic liver disease	IC-Medtech Corporation
2444	sodium ascorbate and menadione sodium bisulfite	Apatone	4/15/2013	Treatment of autosomal dominant polycystic kidney disease	IC-MedTech Corporation
2445	sodium benzoate and clozapine	n/a	12/22/2011	Treatment of treatment-resistant schizophrenia	Guochuan Emil Tsai, MD, PhD
2446	sodium chlorite	n/a	8/22/2011	For slowing the progression of amyotrophic lateral sclerosis.	Neuraltus Pharmaceuticals, Inc.
2447	sodium dichloroacetate	n/a	7/3/2003	Use as an antidote in the management of systemic monochloroacetic acid poisoning	EBD Group
2448	sodium dichloroacetate	n/a	11/29/2010	For pulmonary arterial hypertension.	Peter W. Stackpoole, PhD, MD
2449	sodium fusidate	n/a	10/23/2013	Treatment of patients with prosthetic joint infections	Cempra Pharmaceuticals, Inc.
2450	sodium nitrate	n/a	1/9/2012	Treatment of chlorine gas poisoning	Hope Pharmaceuticals

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2451	sodium nitrite	n/a	9/3/2009	Prevention of ischemia reperfusion injury to donor organ tissue associated with solid organ transplantation	Hope Pharmaceuticals
2452	sodium nitrite	n/a	7/8/2008	Treatment of pulmonary arterial hypertension	Aires Pharmaceuticals, Inc.
2453	sodium nitrite and sodium thiosulfate	Nithiodote	4/9/2008	Treatment of known or suspected cyanide poisoning	Hope Pharmaceuticals
2454	sodium phenylbutyrate	n/a	7/2/1992	Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy, and S-thalassemia hemoglobinopathy.	Medicis Pharmaceutical Corp.
2455	sodium phenylbutyrate	Buphenyl	11/22/1993	Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency.	Medicis Pharmaceutical Corp.
2456	sodium phenylbutyrate	n/a	1/19/2010	Treatment of urea cycle disorder.	Navinta LLC
2457	sodium phenylbutyrate	Pheburane	6/6/2013	Treatment of urea cycle disorders	Lucane Pharma SA
2458	sodium stibogluconate	n/a	10/28/2009	Treatment of cutaneous leishmaniasis	Surgeon General of the US Army
2459	sodium sulfate, potassium sulfate, and magnesium sulfate	Suprep	10/31/2012	For cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in children and adolescents	Braintree Laboratories, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2460	sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride	Suclear	9/4/2013	For use in cleansing of the colon in preparation for colonoscopy in children and adolescents	Braintree Laboratories, Inc.
2461	sodium thiosulfate	n/a	11/19/2012	Treatment of calciphylaxis	Edinburg BioQuarter
2462	sodium thiosulfate	n/a	12/2/2010	Treatment of extravasation of meclorethamine hydrochloride into subcutaneous tissues.	Hope Pharmaceuticals
2463	sodium thiosulfate	n/a	3/3/2011	Treatment of sulfur mustard poisoning	Hope Pharmaceuticals
2464	sodium thiosulfate	n/a	10/13/2011	Prevention of platinum-induced ototoxicity in pediatric patients	Hope Pharmaceuticals
2465	sodium thiosulfate	n/a	11/9/2011	Treatment of uremic and non-uremic calciphylaxis	Hope Pharmaceuticals
2466	solvent/detergent treated non-blood-group specific human coagulation active plasma	Uniplas	12/12/2005	Treatment of thrombotic thrombocytopenic purpura	Octapharma USA, Inc.
2467	somatorelin	Somatrel	8/8/1989	Diagnostic measure of the capacity of the pituitary gland to release growth hormone.	Ferring Laboratories, Inc.
2468	somatropin [rDNA]	Genotropin	12/27/2000	Treatment of growth failure in children who were born small for gestational age.	Pharmacia and Upjohn Company

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2469	sorafenib	Nexavar	12/12/2011	Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer	Bayer HealthCare Pharmaceuticals, Inc.
2470	sotalol (IV)	So-Aqueous	7/25/2008	For ventricular tachycardia, ventricular fibrillation, or the maintenance of sinus rhythm in patients converted from atrial fibrillation or atrial flutter when oral administration is not possible.	Academic Pharmaceuticals
2471	sotalol hydrochloride	n/a	2/10/2014	Treatment of life-threatening ventricular arrhythmias in pediatric patients	Arbor Pharmaceuticals, LLC
2472	sotatercept	n/a	12/5/2013	Treatment of beta-thalassemia intermedia and major	Celgene Corporation
2473	spherical carbon adsorbent	n/a	12/19/2007	Treatment of chronic pouchitis	Ocera Therapeutics, Inc.
2474	squalamine lactate	n/a	5/11/2001	Treatment of ovarian cancer refractory or resistant to standard chemotherapy	Genaera Corporation
2475	stiripentol	Diacomit	10/30/2008	Treatment of Dravet syndrome	Biocodex
2476	sulfamidase	n/a	5/22/2008	For treatment of Sanfilippo Syndrome (MPS IIIA)	Shire Human Genetic Therapies, Inc.
2477	sulfonated monophosphorylated mannose oligosaccharide	n/a	2/17/2012	Treatment of hepatocellular carcinoma	Medigen Biotechnology Corporation

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2478	sulthiame	n/a	7/25/2013	Treatment of patients with benign epilepsy of childhood with centrotemporal spikes (BECTS) also known as rolandic epilepsy	Marathon Pharmaceuticals, LLC
2479	superoxide dismutase, gliadin	Etr019	4/30/2010	Treatment of amyotrophic lateral sclerosis	Verius Limited
2480	synthetic double-stranded siRNA oligonucleotide against antithrombin (AT) mRNA	n/a	8/16/2013	Treatment of hemophilia A	Alnylam Pharmaceuticals
2481	synthetic double-stranded siRNA oligonucleotide against antithrombin mRNA	n/a	8/12/2013	Treatment of hemophilia B	Alnylam Pharmaceuticals
2482	synthetic double-stranded siRNA oligonucleotide against p53 mRNA	n/a	12/23/2009	Prophylaxis of delayed graft function in renal transplant patients	Quark Pharmaceuticals, Inc.
2483	synthetic double-stranded siRNA oligonucleotide against transthyretin (TTR) mRNA	n/a	6/14/2012	Treatment of familial amyloidotic polyneuropathy	Alnylam Pharmaceuticals, Inc.
2484	synthetic peptide H-D-Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-D-Ala-OH	n/a	10/12/2011	Treatment of necrotizing soft tissue infections (NSTI)	Atox Bio, Inc.
2485	synthetic peptide; cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-ALA-Lys-Pro-Trp-Tyr-Cys	n/a	1/15/2013	Treatment of high altitude pulmonary edema	Apeptico Forschung und Entwicklung GmbH

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2486	synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue	n/a	3/16/2012	Treatment of preterm neonatal respiratory distress syndrome	Chiesi Pharmaceuticals, Inc.
2487	tabalumab	n/a	11/19/2012	Treatment of multiple myeloma	Eli Lilly and Company
2488	taberminogene vadenovec	Trinam	10/24/2000	Prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.	Ark Therapeutics Ltd.
2489	tacrolimus	n/a	7/6/2012	Treatment of hemorrhagic cystitis	Lipella Pharmaceuticals Inc.
2490	tadalafil	Adcirca	12/18/2006	Treatment of pulmonary arterial hypertension	Eli Lilly and Company
2491	tafamidis	n/a	5/23/2006	Treatment of familial amyloid polyneuropathy	Pfizer, Inc.
2492	tafamidis meglumine	n/a	2/17/2012	Treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy.	Pfizer, Inc.
2493	tafenoquine	n/a	1/15/2013	Treatment of malaria	Glaxo Group Limited, England
2494	talactoferrin alfa	n/a	8/20/2003	For the prevention of graft-versus-host disease	Agennix, Inc.
2495	talactoferrin alfa	n/a	8/20/2003	For the treatment of graft versus host disease	Agennix, Inc.
2496	talarazole	n/a	3/16/2012	Treatment of congenital ichthyosis	Stiefel Laboratories, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2497	tasimelteon	n/a	4/30/2010	Treatment of sleep-wake disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion	Vanda Pharmaceuticals, Inc.
2498	tasimelteon	Hetlioz	1/19/2010	Non-24-hour sleepwake disorder in blind individuals without light perception	Vanda Pharmaceuticals, Inc.
2499	taurine	n/a	3/22/2010	Treatment of cystathionine beta-synthase deficient homocystinuria	Johan L. Van Hove, MD, PhD
2500	tecovirimat	n/a	9/29/2010	Treatment of orthopoxvirus infections.	SIGA Technologies, Inc.
2501	tecovirimat	n/a	12/18/2006	post exposure prophylaxis against smallpox	SIGA Technologies, Inc.
2502	tecovirimat	n/a	12/27/2006	Treatment of smallpox.	SIGA Technologies,
2503	teduglutide [rDNA origin]	Gattex	6/29/2000	Treatment of short bowel syndrome.	NPS Pharmaceuticals, Inc.
2504	telatinib	n/a	5/17/2010	Treatment of gastric cancer	ACT Biotech Inc.
2505	temocillin sodium	Negaban	4/21/2004	Treatment of pulmonary infections caused by Burkholderia cepacia	Belpharma S.A.
2506	temozolomide	Temodar	10/5/1998	Treatment of recurrent malignant glioma.	Schering-Plough Research Institute
2507	tenofovir	Viread	3/17/2009	Treatment of pediatric HIV infection.	Gilead Sciences, Inc.
2508	teprotumumab	n/a	5/6/2013	Treatment of active (dynamic) phase Grave's orbitopathy	River Vision, Inc.
2509	terguride	Mysalfon, Teluron	5/17/2013	Treatment of systemic sclerosis	Serodapharm UG
2510	terlipressin	n/a	10/29/2004	Treatment of Hepatorenal Syndrome	Ikaria (INO Therapeutics)

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2511	tesetaxel	n/a	11/21/2008	Treatment of stages IIB, IIC, III, and stage IV melanoma	Genta, Inc.
2512	tesetaxel	n/a	12/22/2008	Treatment of gastric cancer	Genta Inc.
2513	testosterone undecanoate (oral)	n/a	2/13/2013	Treatment of constitutional delay in growth and puberty in adolescent boys (14-17 yrs of age)	SOV Therapeutics, Inc.
2514	tetra substituted prophyrin derivative containing manganese (III)	n/a	1/17/2014	For use in patients exposed to radiation following a nuclear accident or detonation in order to treat or mitigate acute radiation syndrome.	Aeolus Pharmaceuticals, Inc.
2515	tetrabenazine	n/a	7/1/2009	Treatment of Tourette's Syndrome in school-age children, ages 5-16	Valeant International (Barbados) SRL
2516	tetracosactide hexaacetate (beta 1-24-corticotrophin)	Synacthen Depot, S. Retard	10/31/2012	Treatment of infantile spasms	Cerium Pharmaceuticals, Inc.
2517	thymopentin	n/a	2/4/2011	Treatment of sarcoidosis.	mondoBIOTECH Laboratories, AG
2518	thymosin beta 4	n/a	12/31/2013	Treatment of patients with neurotrophic keratopathy	RegeneRx Biopharmaceuticals,
2519	tigecycline	n/a	10/23/2013	Treatment of acute myeloid leukemia.	Stem Cell Therapeutics
2520	tin ethyl etiopurpurin	n/a	11/4/2003	Prevention of access graft disease in hemodialysis patients	Miravant Medical Technologies
2521	tinidazole	Tindamax	4/18/2002	Treatment of giardiasis	Presutti Laboratories,
2522	tiptorelin pamoate	n/a	8/20/2012	Treatment of central precocious puberty	Debiopharm
2523	tirapazamine	n/a	10/23/2002	Treatment of head and neck cancer	Sanofi-Aventis US, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2524	tivantinib	n/a	10/16/2013	Treatment of hepatocelular carcinoma	Daiichi Sankyo Pharma Development
2525	tocilizumab	Actemra	4/17/2013	Treatment of systemic sclerosis	Genentech, Inc.
2526	tocilizumab	Actemra	7/31/2012	Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis	Genentech, Inc.
2527	tolvaptan	Samsca	4/6/2012	Treatment of autosomal dominant polycystic kidney disease	Otsuka Pharmaceuticals Co., Ltd.
2528	topiramate injection	n/a	7/24/2013	Treatment of partial onset or primary generalized tonic-clonic seizures for hospitalized epilepsy patients or epilepsy patients being treted in an emergency care setting who are unable to take oral topiramate	Ligand Pharmaceuticals, Inc.
2529	trabectedin	Yondelis	3/29/2005	Treatment of patients with ovarian cancer	Janssen Research & Development, LLC
2530	trabectedin	Yondelis	9/30/2004	Treatment of soft tissue sarcoma.	Janssen Research & Development, LLC
2531	trabedersen	n/a	8/22/2011	Treatment of Stage IIB through Stage IV malignant melanoma.	Isarna Therapeutics GmbH
2532	trabedersen	Oncomun	6/5/2002	Treatment of malignant glioma	Antisense Pharma GmbH
2533	trabedersen	n/a	7/21/2009	Treatment of pancreatic cancer.	Antisense Pharma GmbH

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2534	tralokinumab (recombinant human and anti-interleukin-13 monoclonal antibody)	n/a	7/24/2012	Treatment of idiopathic pulmonary fibrosis	MedImmune Ltd.
2535	trametinib	Mekinist	12/20/2010	Treatment of Stage IIb through Stage IV melanoma	GlaxoSmithKline, LLC
2536	trametinib and dabrafenib	Mekinist And Tafinlar	9/20/2012	Treatment of Stage IIb through IV melanoma.	GlaxoSmithKline, LLC
2537	tranilast	Rizaben	12/23/2010	Prevention of scarring following glaucoma filtration surgery	Altacor Ltd
2538	trans sodium crocetinate	n/a	12/3/2012	Treatment of brain metastasis	Diffusion Pharmaceuticals, LLC
2539	trans sodium crocetinate	n/a	7/21/2011	Treatment of glioblastoma in conjunction with radiotherapy	Diffusion Pharmaceuticals, LLC
2540	transforming growth factor-beta receptor 1 kinase inhibitor	n/a	3/11/2013	Treatment of glioma	Eli Lilly and Company
2541	transforming growth factor-beta receptor 1 kinase inhibitor	n/a	4/1/2013	Treatment of hepatocellular carcinoma	Eli Lilly and Company
2542	trastuzumab	Herceptin	10/13/2009	Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction	Genentech, Inc.
2543	trastuzumab	Herceptin	12/14/1999	Treatment of patients with pancreatic cancer that overexpress p185HER2.	Genentech, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014**  
**Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2544	trastuzumab emtansine	Kadcyla	10/25/2013	For the treatment of gastric cancer including gastroesophageal junction cancer.	Genethech, Inc.
2545	trebananib	n/a	8/30/2013	Treatment of ovarian cancer	Amgen, Inc.
2546	trehalose	Cabaletta	10/25/2013	Treatment of oculopharyngeal muscular dystrophy	BIOBLAST PHARMA LTD.
2547	tremelimumab	n/a	9/18/2006	Treatment of stage IIb to stage IV metastatic melanoma	MedImmune
2548	treprostinil	Remodulin	6/4/1997	Treatment of pulmonary arterial hypertension.	United Therapeutics Corp.
2549	treprostinil (inhalational)	Tyvaso	6/17/2010	Treatment of pulmonary arterial hypertension	LungRx, Inc.
2550	tri-antennary glycotriptide derivative of 5-fluorodeoxyuridine monophosphate	n/a	11/23/2001	Treatment for hepatocellular carcinoma	Cell Works Inc.
2551	tricitabine	n/a	2/1/2008	Treatment of multiple myeloma	VioQuest Pharmaceuticals, Inc.
2552	trientine hydrochloride	Syprine(R)	11/2/2010	Treatment of manganism.	Cerberus Princeton,
2553	tryptophan hydroxylase (TPH) inhibitor	n/a	3/9/2012	Management of symptoms of carcinoid syndrome associated with carcinoid tumor	Lexicon Pharmaceuticals, Inc.
2554	tyrosine kinase inhibitor	n/a	9/14/2005	Treatment of mastocytosis	AB Science
2555	ublituximab	n/a	9/5/2013	Treatment of Nodal marginal zone lymphoma	TG Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2556	ublrituximab	n/a	9/5/2013	Treatment of Extranodal marginal zone lymphoma (mucosa-associated lymphatic tissue, MALT)	TG Therapeutics, Inc.
2557	ublrituximab	n/a	8/6/2010	Treatment of chronic lymphocytic leukemia	TG Therapeutics, Inc.
2558	unoprostone isopropyl	Rescula	9/16/2010	Treatment of retinitis pigmentosa	Sucampo Pharma Americas, LLC
2559	urea	n/a	11/7/2011	Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosiform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis).	Orenova Group, LLC
2560	uridine triacetate	n/a	5/1/2009	An antidote in the treatment of 5-fluorouracil poisoning	Wellstat Therapeutics Corp.
2561	uridine triacetate	n/a	8/9/2013	Treatment of hereditary orotic aciduria	Wellstat Therapeutics, Inc.
2562	uridine triacetate	n/a	9/3/2009	Treatment of mitochondrial disease	Wellstat Therapeutics Corporation
2563	ursodiol	Ursofalk Suspension	10/23/2007	Treatment of cystic fibrosis liver disease	Asklepion Pharmaceuticals, LLC

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2564	ustekinumab	Stelara	12/28/2011	Treatment of chronic sarcoidosis	Janssen Biotech, Inc.
2565	ustekinumab	Stelara	11/29/2010	Treatment of type 1 diabetes mellitus patients with residual beta-cell function.	Johnson & Johnson Pharmaceutical & Development LLC
2566	ustekinumab; human monoclonal antibody to interkeukin 12p40	Stelara	12/22/2011	Treatment of primary biliary cirrhosis	Janssen Biotech, Inc.
2567	valine-valine-ganciclovir	n/a	5/21/2007	Treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HSV1 and HSV2.	Verenta Pharmaceuticals, Inc.
2568	vancomycin	n/a	12/27/2012	Treatment of endophthalmitis	Fera Pharmaceuticals, LLC
2569	vancomycin hydrochloride (inhalational)	n/a	9/20/2012	Treatment of persistent methicillin-resistant S. aureus lung infection in patients with cystic fibrosis	Savara Pharmaceuticals, Inc.
2570	vandetanib	Caprelsa(R)	10/21/2005	Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma	AstraZeneca Pharmaceutical LP
2571	vapreotide	Sanvar	1/10/2000	Treatment of esophageal variceal hemorrhage patients with portal hypertension.	Debiovision, Inc.
2572	vapreotide	Octastatin	1/10/2000	Treatment of gastrointestinal and pancreatic fistulas.	Debiopharm S.A.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2573	vapreotide	Octastatin	3/6/2000	Prevention of early postoperative complications following pancreatic resection.	Debiopharm S.A.
2574	vapreotide	Sanvar	11/4/2003	Treatment of acromegaly	H3 Pharma, Inc.
2575	vascular endothelial growth factor 165b	n/a	6/24/2008	Treatment of advanced melanoma stages IIb through IV.	PhiloGene, Inc.
2576	vatiquinone	Vincerinone	1/31/2014	Treatment of Friedreich's ataxia	Edison Pharmaceuticals, Inc.
2577	velaglucerase-alfa	Vpriv	6/8/2009	Treatment of Gaucher disease	Shire Human Genetics Therapies, Inc.
2578	veliparib	n/a	11/20/2009	Treatment of hepatocellular carcinoma in combination with DNA-damaging agents	AbbVie, Inc.
2579	veliparib	n/a	5/9/2008	Treatment of glioblastoma multiforme when used in combination with DNA-damaging agents	AbbVie, Inc.
2580	veltuzumab	n/a	8/28/2008	Treatment of chronic lymphocytic leukemia	Immunomedics, Inc.
2581	vemurafenib	Zelboraf	12/20/2010	Treatment of patients with IIb to Stage IV melanoma positive for the BRAF(v600) mutation	Hoffmann-La Roche, Inc.
2582	verteporfin	Visudyne(R)	3/9/2012	Treatment of chronic or recurrent central serous chorioretinopathy	Valeant Pharmaceuticals North America LLC
2583	vibriolysin	Vibrilase	6/16/2006	Debridement of severe, deep dermal burns in hospitalized patients	BioMarin Pharmaceutical Inc.

**Orphan Drug Designations and Approvals List as of 03-03-2014  
Governs April 1, 2014 - Jun 30, 2014**

<b>Row Num</b>	<b>Generic Name</b>	<b>Trade Name</b>	<b>Designation Date</b>	<b>Designation</b>	<b>Contact Company/Sponsor</b>
2584	vigabatrin	Sabril	6/12/2000	Treatment of infantile spasms.	H. Lundbeck A/S
2585	vinCRISTine sulfate LIPOSOME injection	Marqibo	1/8/2007	Treatment of acute lymphoblastic leukemia	Talon Therapeutics, Inc.
2586	vincristine sulfate liposomes	Marqibo	6/24/2008	Treatment of metastatic uveal melanoma.	Talon Therapeutics
2587	vintafolide	n/a	12/16/2013	Treatment of ovarian cancer	Merck Sharp & Dohme Corp.
2588	vorinostat	Zolinza	3/16/2004	Treatment of T-cell non-Hodgkin's lymphoma	Merck & Co., Inc.
2589	vosaroxin	n/a	10/28/2009	Treatment of acute myeloid leukemia	Sunesis Pharmaceuticals, Inc.
2590	zidovudine	Retrovir	7/17/1985	Treatment of AIDS	Glaxo Wellcome Inc.
2591	zoledronic acid	Zometa, Reclast, Aclasta	5/6/2013	Treatment of complex regional pain syndrome (CRPS).	Axsome Therapeutics, Inc.